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Crosstalk between HGF and TGF-β signaling 
pathways in adult liver progenitor cells and 
hepatocellular carcinoma cells 
Introduction 
Chronic liver diseases (CLDs) are associated with fibrosis, which eventually 
progress to cirrhosis and ultimately to hepatocellular carcinoma (HCC) 
development, constituting a major global health problem. In the context of 
chronic liver injury where the proliferative capacity of adult hepatic cells is 
impaired, the population of adult hepatic progenitor cells (HPCs), also known as 
oval cells in rodents, takes over the regenerative process. Upon activation, 
HPCs/oval cells expand, proliferate and migrate into liver parenchyma and due 
to their bipotential nature differentiate into hepatocytes and cholangiocytes 
compensating the cellular loss and maintaining liver functionality. However, 
some authors give HPCs/oval cells a pro-fibrotic role, establishing a direct 
relationship between the HPCs/oval cell expansion and the severity of the 
fibrosis. They could also be the cells of origin of a subset of HCC. It is therefore 
evident that the signals and mechanisms regulating HPC/oval cell biology and 
function need to be clarified not only because of their potential utility in 
regenerative medicine, but also because of their still uncertain role in the 
aforementioned diseases.  
TGF-β signaling plays important roles in the sequence of events leading to 
fibrosis and HCC development. EMT induction is among the mechanisms 
through which TGF-β exerts its pro-fibrotic and pro-carcinogenic role. HPCs/oval 
cells can undergo EMT in response to TGF-β. However, it is unclear if TGF-β-
induced EMT in HPCs/oval cells somehow affects their pro-regenerative or pro-
fibrotic/pro-tumoral potential.  
HGF/Met signaling axis is crucial for an efficient liver regenerative response, 
both hepatocyte- and HPCs/oval cell-mediated, but its aberrant activation is also 
involved in the development and progression of hepatocarcinogenesis. 
HGF/Met and TGF-β often trigger opposite activities during liver damage. In fact, 
experimental evidence indicates that HGF/Met opposes to TGF-β pro-fibrotic 
activity. Nevertheless, whether HGF/Met signaling could modulate oval cell 
response to TGF-β during liver damage is not known. Likewise, a potential 
crosstalk between these two pathways for the regulation of liver tumor cells has 
not yet been explored. 
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Aims 
TGF-β and HGF/Met pathways are important mediators during liver 
regeneration, fibrosis and hepatocarcinogenesis and play roles on different 
liver cell populations. Taking this into consideration, the general objective of 
this work was to analyze the relevance of the crosstalk between TGF-β and 
HGF/Met pathways in oval cell biology and fate in a context of chronic liver 
injury as well as to explore if such crosstalk could play a role during 
hepatocarcinogenesis.    
To achieve this general objective, we propose three specific objectives: 
Objective 1: To characterize the TGF-β-induced EMT response in oval cells 
in vitro and to evaluate the effects on oval cell fate upon transplantation into a 
fibrotic liver. 
Objective 2: To elucidate the HGF/Met signaling-mediated regulation on 
the EMT response induced by TGF-β and its contribution to oval cell properties. 
Objective 3: To analyze the TGF-β pathway in liver tumor cells from Met-
overexpressing livers and how affects tumor cell growth and survival 
properties. 
 
Results 
Our results show that oval cells suffer a partial EMT in response to chronic 
TGF-β treatment. After EMT, oval cells display profound changes in their 
phenotype and properties. Besides the loss of some epithelial markers and gain 
of mesenchymal markers, cells acquire proliferative, survival and invasive 
advantages. However, these changes are not associated with stemness but 
rather with induction of differentiation along the hepatic lineage. Importantly, 
these changes confer oval cells a greater in vivo regenerative capacity being able 
to attenuate liver damage when transplanted into mice submitted to CCl4-
induced liver fibrosis. Moreover, our results reveal that HGF/Met signaling 
pathway is essential to allow oval cell expansion after TGF-β-induced EMT. In 
the absence of Met tyrosine kinase activity oval cells enter into a senescence 
process concomitant with an exacerbated oxidative stress. In this respect, we 
have uncovered a novel role for Twist as a downstream mediator of HGF/Met 
antioxidant activity against TGF-β-induced oxidative stress in oval cells. 
Additionally, HGF/Met signaling pathway contributes to the phenotypic and 
functional properties of oval cells after EMT, counterbalancing the 
mesenchymal switch while promoting proliferation, survival and invasion.  
On the other hand, we provide preliminary evidence on the activation of the 
TGF-β pathway in livers with moderate Met overexpression and in subsequently 
developed tumors. We also provide preliminary evidence on reciprocal 
regulatory interactions between HGF/Met and TGF-β signaling pathways in 
tumor cell lines derived from these livers. Thus, high levels of Met lead to 
constitutive Met activation and a decrease in TGF-β-triggered Smad activation, 
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whereas TGF-β decreases Met phosphorylation in Met-low overexpressing HCC 
cells. Notably, this signaling interplay affects tumor cell properties. In fact, our 
results suggest that Met kinase activity is critical for tumor cell survival and 
protection against TGF-β-induced apoptosis. 
 
Conclusions 
1. Chronic treatment of oval cells with TGF-β leads to a stable and partial 
EMT phenotype. 
 
2. TGF-β-induced EMT in oval cells does not increase stemness but rather 
promotes differentiation along the hepatic lineage, while conferring 
proliferation, survival and invasion advantages in vitro. 
 
3. Oval cells chronically treated with TGF-β attenuate CCl4-induced liver 
damage and fibrosis upon transplantation. 
 
4. HGF/Met signaling activation is required to overcome the oxidative stress-
induced senescence and allow oval cell expansion after TGF-β-induced 
EMT. 
 
5. Twist is a downstream target of HGF/Met in oval cells that mediates the 
antioxidant activity driven by HGF/Met signaling and prevents cell 
senescence. 
 
6. HGF/Met signaling modulates TGF-β-induced EMT phenotype in oval cells 
contributing to cell proliferation, survival and invasive advantages while 
counterbalancing the mesenchymal phenotypic switching. 
 
7. HCC cell lines derived from Alb-R26Met mice show negative regulatory 
circuits between HGF and TGF-β signaling pathways. Thus, HCC cells with 
high levels of Met show an attenuation of TGF-β-triggered Smad signaling, 
whereas TGF-β is able to decrease Met phosphorylation but only in HCC 
cells with low overexpression of levels of Met. 
 
8. HCC cell lines derived from Alb-R26Met mice show dependence on Met 
signaling for cell survival and protection against TGF-β. 
 
 
 
 
 
 
  
  
 
 
 
 
  
  
 
 
  
2. Resumen 
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Interacción entre las vías de HGF y TGF-β 
en células progenitoras adultas hepáticas y 
células de hepatocarcinoma 
Introducción 
Las enfermedades hepáticas crónicas (CLD) están asociadas con fibrosis, que 
eventualmente progresa a cirrosis, y en último término al desarrollo de un 
carcinoma hepatocelular (HCC), y constituyen un importante problema de salud 
global. En este contexto de daño hepático crónico en el que la capacidad 
regenerativa de las células maduras hepáticas se ve comprometida, es la 
población de células progenitoras adultas (HPCs), también conocidas como 
células ovales en modelos murinos, la que va a tomar las riendas del proceso de 
regeneración hepática. Tras su activación, las HPCs/células ovales se expanden, 
proliferan y migran en el parénquima hepático y gracias a su naturaleza 
bipotencial se diferencian a hepatocitos y colangiocitos, compensando así la 
pérdida de masa hepática y manteniendo la funcionalidad hepática. Sin 
embargo, algunos autores dotan a las HPCs/células ovales de un papel pro-
fibrótico, estableciendo una relación directa entre su expansión y la severidad 
de la fibrosis. Estas células también pueden ser el origen celular de algunos 
subtipos de HCC. Resulta por tanto evidente la necesidad de estudiar las señales 
y mecanismos que regulan la biología y la función de estas células, no solo por 
su potencial utilidad en medicina regenerativa sino también por su papel aún no 
claro en las ya mencionadas enfermedades hepáticas. 
La vía de señalización del TGF-β es clave en los distintos eventos que 
conducen a un proceso fibrótico y al desarrollo del HCC. La inducción de EMT es 
uno de los mecanismos a través de los cuales el TGF-β lleva a cabo su papel pro-
fibrótico y pro-tumoral. Las HPCs/células ovales pueden sufrir EMT en respuesta 
al TGF-β. Sin embargo, no está claro si esta respuesta influye en su potencial 
pro-regenerativo o pro-fibrótico/pro-tumoral. 
La vía de señalización de HGF/Met es fundamental para una regeneración 
hepática eficiente, tanto la llevada a cabo por las células maduras como la 
mediada por las HPCs/células ovales, aunque una activación aberrante de esta 
vía también está implicada en el desarrollo y la progresión de la carcinogénesis 
hepática. HGF/Met y TGF-β a menudo tienen papeles opuestos en el daño 
hepático crónico. De hecho, las evidencias experimentales indican que HGF/Met 
se opone a los efectos pro-fibróticos de TGF-β. Sin embargo, no se sabe si el 
HGF podría regular la respuesta de las HPCs/células ovales al TGF-β durante el 
daño hepático. Asimismo, tampoco se ha explorado una posible interacción 
entre estas dos vías de señalización en la regulación de las células tumorales 
hepáticas.  
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Objetivos 
El objetivo general de este trabajo ha sido analizar la relevancia de la 
interacción cruzada entre las vías de TGF-β y HGF/Met en la biología y el destino 
de la célula oval en el hígado dañado, así como estudiar si dicha interacción 
podría intervenir en procesos de hepatocarcinogenesis. 
Para conseguir este objetivo proponemos tres objetivos específicos: 
 
Objetivo 1: Caracterizar la respuesta de EMT inducida por TGF-β en las 
células ovales in vitro y evaluar sus efectos en el destino de la célula oval tras su 
trasplante en un hígado fibrótico. 
 
Objetivo 2: Elucidar la regulación medida por la vía de HGF/Met sobre la 
respuesta de EMT inducida por TGF-β y su contribución a las propiedades de la 
célula oval. 
 
Objetivo 3: Analizar la vía de TGF-β en células tumorales hepáticas 
procedentes de hígados con sobre-expresión de Met y cómo esta vía podría 
afectar al crecimiento y supervivencia de la célula tumoral. 
 
Resultados 
Nuestros resultados muestran que las células ovales sufren un proceso de 
EMT parcial en respuesta al tratamiento crónico con TGF-β. Este proceso 
provoca profundos cambios en el fenotipo y las propiedades de las células. 
Además de la pérdida de algunos marcadores epiteliales y la adquisición de 
marcadores mesenquimales, estas células adquieren ventajas proliferativas, de 
supervivencia e invasión. Sin embargo, estos cambios desencadenados por la 
EMT no están asociados con la adquisición de marcadores y propiedades de 
célula madre, sino con la inducción de diferenciación hacia el linaje del 
hepatocito. Es importante destacar que estos cambios confieren a las células 
ovales una mayor capacidad regenerativa in vivo, siendo capaces de atenuar el 
daño hepático cuando son trasplantadas en ratones con un proceso de fibrosis 
hepática inducida por CCl4. Adicionalmente, nuestros resultados revelan que la 
vía de HGF/Met es esencial para permitir la expansión de la /célula oval tras la 
inducción de EMT por TGF-β. En ausencia de la actividad tirosina quinasa de Met 
las células ovales entran en senescencia, proceso que es simultáneo a un estrés 
oxidativo exacerbado. En este sentido, hemos descubierto un nuevo papel para 
Twist como mediador de la actividad antioxidante de HGF/Met frente al estrés 
oxidativo inducido por TGF-β en células ovales. La vía de HGF/Met también 
contribuye a las características fenotípicas y funcionales de las células ovales 
adquiridas después de la EMT, contrarrestando la transición mesenquimal a la 
vez que promueve la proliferación, supervivencia e invasión. 
Por otro lado, con este trabajo mostramos evidencias preliminares de la 
activación de la vía de señalización de TGF-β en hígados de ratón con 
sobreexpresión moderada de Met y en los tumores hepáticos que desarrollan, 
así como de la existencia de interacciones regulatorias recíprocas entre las vías 
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de HGF/Met y TGF-β en líneas de células tumorales derivadas de estos hígados. 
Así, niveles altos de Met conducen a su activación constitutiva y a una 
disminución en la activación de Smads por TGF-β, mientras que el TGF-β 
disminuye la fosforilación de Met en células tumorales con una baja 
sobreexpresión de Met. Esta interacción a nivel de señalización afecta a las 
propiedades de la célula tumoral. De hecho, nuestros resultados sugieren que la 
actividad quinasa de Met es crítica para la supervivencia y la protección de las 
células tumorales frente a la apoptosis inducida por TGF-β.  
 
Conclusiones 
1. El tratamiento crónico con TGF-β induce en las células ovales un 
fenotipo EMT parcial y estable.  
 
2. La inducción de EMT por TGF-β en las células ovales no conlleva un 
incremento en los marcadores y propiedades de célula madre, sino que 
promueve la diferenciación hacía el linaje hepático, confiriendo, 
además, ventajas proliferativas, de supervivencia e invasivas in vitro. 
 
3. El trasplante de las células ovales crónicamente tratadas con TGF-β 
atenúan el daño hepático y la fibrosis inducidos por CCl4. 
 
4. La activación de la vía de HGF/Met es esencial para superar la 
senescencia producida por estrés oxidativo y permitir la expansión de la 
célula oval tras la inducción de EMT por TGF-β. 
 
5. Twist es una diana de la vía de señalización de HGF/Met en las células 
ovales que media la actividad antioxidante ejercida por HGF/Met 
previniendo la senescencia celular. 
 
6. La vía de señalización de HGF/Met modula el fenotipo EMT inducido por 
TGF-β en las células ovales contribuyendo así a las ventajas 
proliferativas, de supervivencia e invasivas a la vez que contrarresta el 
cambio fenotípico mesenquimal. 
 
7. Las células de hepatocarcinoma obtenidas de los ratones Alb-R26Met 
muestran un circuito de regulación negativa entre las vías de 
señalización de HGF y TGF-β. Así, las células de hepatocarcinoma con 
altos niveles de Met muestran una atenuación de la señalización 
desencadenada por TGF-β a través de las Smad, mientras que TGF-β es 
capaz de reducir la fosforilación de Met, pero solo en las células de 
hepatocarcinoma con una baja sobreexpresión de Met. 
 
8. La supervivencia y la protección frente al TGF-β de las células de 
hepatocarcinoma obtenidas de los ratones Alb-R26Met es dependiente 
de la señalización de Met. 
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AFP alpha-Fetoprotein 
AKT AK strain Transforming 
ALB Albumin 
ALK Activin receptor-Like Kinase 
ALT Alanine aminotransferase 
AMH Anti-Mullerian Hormone 
AST Aspartate aminotransferase 
BCL-2 B-Cell Lymphoma 2 
BIM BCL-2-like-11 
BMF BCL-2 Modifying Factor 
BMP Bone Morphogenetic Proteins 
BSA Bovine Serum Albumin 
C-CBL Casitas B-Lineage Lymphoma 
CCL4 Carbon Tetrachloride 
CIEMAT Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas 
CK Cytokeratin 
CKI Cyclin Dependent Kinase Inhibitors 
CLD Chronic Liver Disease 
CO-SMAD Cooperating SMAD 
CRK v-crk sarcoma virus CT10 oncogene homolog 
CTGF Connective Tissue Growth Factor 
CYP Citocrome 
DAPI 4′,6-diamidino-2-phenylindole 
DAP-KINASE Death-Associated Protein Kinase 
DCFH-DA 2′,7′-dichlorofluorescein dihydro diacetate 
DDC 3,5-diethoxycarbonyl-1,4-dihidro-collidine 
DMEM Dulbecco's Modified Eagle Medium 
DMSO Dimethyl Sulfoxide 
DNA Deoxyribonucleic Acid 
DTT Dithiothreitol 
ECAR Extracellular Acidification Rate 
ECM Extracellular Matrix 
EDTA Ethylenediaminetetraacetic Acid 
EGF Epidermal Growth Factor 
EGFR EGF Receptor 
EMT Epithelial to Mesenchymal Transition 
EMT-TF EMT Transcription Factors 
EPCAM Epithelial Cell Adhesion Molecule 
ERK Extracellular Signal-Regulated Kinases 
F.I. Fluorescence Intensity 
FAK Focal Adhesion Kinase 
FASL Fas Ligand 
FBS Foetal Bovine Serum 
FGF Fibroblast Growth Factor  
GAB1 GRB2 Associated Binding Protein 1 
GDP Growth Differentiation Factor 
GFP Green Fluorescence Protein 
GGT gamma-Glutamyltransferase 
3. Abbreviations 
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GRB2 Growth Factor Receptor Bound Protein 2 
H&E Hematoxylin and Eosin  
HCC Hepatocellular Carcinoma 
HCSC Hospital Clínico San Carlos  
HGF Hepatocyte Growth Factor 
HNF Hepatocyte Nuclear Factor 
HPC Hepatic Progenitor Cell 
HSC Hepatic Stellate Cell 
IB Immunoblotting  
ICAM1 Intercellular Adhesion Molecule 1 
IFNα Interferon alfa   
IGF-I Insulin-like Growth Factor I 
IL Interleukin 
IP Immunoprecipitation 
IPT Immunoglobulin-like domains shared by Plexins and Transcriptional factors 
I-SMAD Inhibitory SMAD 
JNK c-Jun N-terminal kinase 
KC Kupffer Cells 
LAP Latency-Associated Peptide 
MAPK Mitogen-Activated Protein Kinase 
MET Mesenchymal to Epithelial Transition 
MFB Myofibroblasts 
miRNA microRNA 
MIS Müllerian Inhibiting Substance 
MMP Matrix Metalloproteinase 
MOI Multiplicity of Infection 
mTOR mammalian Target of Rapamycin 
NADPH Nicotinamide Adenine Dinucleotide Phosphate 
NAFLD Non-Alcoholic Fatty Liver Disease 
N-CAM Neural Cell Adhesion Molecule 
NF-ΚB Factor kappa-Light-chain-enhancer of activated B cells 
NT Non-Targeting 
OC Oval Cell 
OCR Oxygen consumption rate 
PAI1 Plasminogen Activator Inhibitor-1 
PBS Phosphate Buffered Saline 
PCR Polymerase Chain Reaction 
PDGF Platelet Derived Growth Factor 
PFA Paraformaldehyde 
PI Propidium Iodide 
PI3K PhosphatidylInositol 3-kinase 
PLCγ Phospholipase C gamma 
PSI Plexin-Semaphorin-Integrin 
PTP1B Protein Tyrosine Phosphatase 1B 
RB Retinoblastoma Protein 
RNA Ribonucleic Acid 
ROS Reactive Oxygen Species 
R-SMAD Receptor-associated SMAD 
RTK Receptor Tyrosine Kinase 
RT-qPCR quantitative Reverse Transcription-Polymerase Chain Reaction 
S.D. Standard Deviation 
S.E.M. Standard Error Of The Mean 
 15 
 
SAHF Senescence-Associated Heterochromatic Foci 
SASP Senescence-Associated Secretory Phenotype 
SA-β-GAL Senescence-Associated beta-Galactosidase 
SDF1 Stromal cell-Derived Factor 1 
SDS Sodium Dodecyl Sulphate 
SDS-PAGE SDS Polyacrylamide Gel Electrophoresis 
SF Scatter Factor 
SHC SH2 domain-containing transforming protein 
SHP2 Src Homology 2 domain-containing Phosphatase-2 
siRNA Small interference RNA 
STAT Signal Transducers and Activators of Transcription 
TE buffer Tris-EDTA buffer 
TERT Telomerase Reverse Transcriptase 
THY-1 Thymocyte Differentiation Antigen 1 
TIEG1 TGF-β-Inducible Early Response Gene 1 
TIMP Tissue Inhibitors of Metalloproteinase 
TNF-α Tumor Necrosis Factor alfa 
TNF-β Transforming Growth Factor beta 
TPBS Tween 20-PBS 
TTBS Tween 20-Tris-Buffered Saline 
TU Transducing Units 
TWEAK Tumor Necrosis factor-like weak inducer of apoptosis 
TβR TGF-β Receptor 
TβT-OC Oval Cells chronically treated with TGF-β 
VEGF Vascular Endothelial Growth Factor 
ZEB Zinc finger E-box-Binding homeobox 
ZO-1 Zonula Occludens 1 
α-SMA alfa Smooth Muscle Actin 
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Figure 1. Structure of the hepatic lobule. a) 
The portal triad consists of a bile duct, 
hepatic artery and portal vein. Blood from 
the portal vein and hepatic artery flows 
through sinusoids to the central vein. Bile is 
excreted by hepatocytes, and flows through 
canaliculus to the bile ducts formed by 
cholangiocytes. The canal of Hering conducts 
bile from bile canaliculi to terminal bile 
ducts. b) Each hepatic lobule is formed by a 
central vein and 6 portal triads. Adapted 
from Duncan et al., 2009. 
1. Liver damage  
The liver, composed of parenchymal cells (hepatocytes and cholangiocytes) 
and non-parenchymal cells (endothelial cells, Kupffer cells (KC), lymphocytes 
and hepatic stellate cells (HSCs)), is a vital organ with a unique capacity to 
regenerate in response to liver damage (Itoh and Miyajima, 2014).  
The functional unit of the liver is the hepatic lobule. The lobules are 
demarcated by portal triads, which consist of a portal vein, a hepatic artery and 
a bile duct. Blood enters the liver from portal vein and hepatic artery and flows 
through liver sinusoids towards the central vein. Row of hepatocytes is 
delimited by endothelium forming the sinusoids, which facilitate interaction 
between the blood and hepatocyte cell surface. Bile secreted by hepatocytes is 
collected into bile canaliculus, which is finally connected with bile ducts formed 
by cholangiocytes (bile duct epithelial cells) via the canal of Hering (Duncan et 
al., 2009).  
 
A number of insults, including viral activity (chronic hepatitis C virus and 
hepatitis B virus), chemical toxicity and metabolic overload, result in liver 
damage and hepatocyte and cholangiocyte death. Liver injury triggers a cascade 
of molecular and cellular reactions oriented towards damage limitation. Briefly, 
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the initial event of liver damage is liver epithelial cell stress, resulting in necrotic 
and/or apoptotic death. Death-mediated signals induce the activation of an 
inflammatory and wound healing response that might lead to tissue 
regeneration and repair in an acute damage. However, in chronic liver disease 
(CLD), the liver injury continues and the inflammation and wound healing 
become persistent. Finally, tissue remodeling goes awry, becomes inefficient, 
and results in fibrosis and cirrhosis, context in which hepatocellular carcinoma 
(HCC) could develop and deadly hepatic failure could occur. The number of 
patients with CLD is increasing, and CLD is becoming a common and difficult 
clinical challenge (Dooley and ten Dijke, 2012; Weiskirchen and Tacke, 2016). 
 
1.1. Liver fibrosis and cirrhosis 
Liver cirrhosis is the 13th most common cause of death in adults worldwide 
and the 4th among chronic diseases with 1,2 million deaths per year. Globally, 
the main causes of fibrosis and cirrhosis are, in this order, infection with 
hepatitis C virus, infection with hepatitis B virus and alcohol abuse (Rowe, 
2017).  
 
1.1.1. Pathophysiology 
Liver fibrosis is a complex wound healing process characterized by an 
imbalance between extracellular matrix (ECM) synthesis and degradation in 
favor of deposition of ECM proteins. In the first stages of liver damage, liver 
fibrosis tries to encapsulate the injury in an attempt to limit its consequences 
and it is considered a reversible process. If injury is maintained, this process 
ultimately progresses to advanced fibrosis or cirrhosis, which might be 
irreversible, situation that occurs during a CLD (Ebrahimi et al., 2016). Cirrhosis 
is defined as an advanced stage of fibrosis characterized by regenerative 
nodules of liver parenchyma, which are encapsulated in fibrotic septa and 
associated with angioarchitectural changes (Pinzani, 2015). Together with 
chronic activation of the wound healing response, other different pro-fibrogenic 
mechanisms have been identified, including oxidative stress, disarrangement of 
epithelial-mesenchymal interactions, epithelial to mesenchymal transition 
(EMT) of parenchymal cells, hepatocyte loss and chronic inflammation (Czaja, 
2014; Lee et al., 2014; Parola and Pinzani, 2019). 
The principal source of ECM accumulation in the wound healing reaction is 
the activity of myofibroblasts (MFB). Different cell types have been proposed to 
be the origin of MFB, but undoubtedly, the major source of fibrogenic cells are 
portal fibroblasts and HSCs (Iwaisako et al., 2014).  
HSCs are non-parenchymal liver cells that function as a major site of storage 
of vitamin A, constituting the largest reservoir of vitamin A in the body. In 
pathologic conditions, HSCs suffer a trans-differentiation process triggered by 
reactive oxygen species (ROS), pro-inflammatory and mitogenic cytokines and 
growth factors such as tumor necrosis factor alfa (TNF-α), transforming growth 
factor beta (TGF-β) or platelet derived growth factor (PDGF), changing from a 
quiescent phenotype to an activated myofibroblast state. MFB are characterized 
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by the expression of α-smooth muscle actin (α-SMA) protein, loss of lipid and 
retinoid storages, increased proliferation, survival, migration and contraction 
capacities, and secretion of pro-inflammatory cytokines and chemokines 
(Ebrahimi et al., 2016; Mallat and Lotersztajn, 2013). Furthermore, MFB 
contribute to the fibrous scar present in CLD by synthesizing large amounts of 
ECM proteins, specifically type I and type III collagen, and regulating ECM 
degradation. MFB express combinations of matrix metalloproteinases (MMPs) 
and tissue inhibitors of metalloproteinases (TIMPs) that degrade normal liver 
matrix, while inhibiting degradation of the accumulated fibrillary collagen in 
liver fibrosis. Although MMPs and TIMPS expression in MFB are thought to play 
central roles in the development of CLD, it has been suggested that hepatocyte-
derived MMPs are also important mediators of the ECM turnover (Benyon and 
Arthur, 2001; Duarte et al., 2015; Mallat and Lotersztajn, 2013). 
In addition to HSCs and fibroblasts, other cell types can suffer a 
myofibroblastic differentiation and therefore contribute to ECM accumulation 
(Weiskirchen et al., 2018; Wells, 2008). Thus, bone marrow fibrocytes (small 
subset of mononuclear bone marrow cells, that transmigrate to liver through 
the blood stream in response to injury), vascular smooth muscle cells, 
endothelial cells, pericytes and epithelial cells may undergo EMT (Rowe et al., 
2011; Rygiel et al., 2008; Zeisberg et al., 2007), although the epithelial origin of 
MFB is still under debate. 
Apart from the wound healing response, other processes take place during 
CLD. For example, oxidative stress with formation and degradation of ROS is a 
crucial part of fibrosis development and persistence. Intracellular sources of 
ROS include the mitochondrial electron transport chain and extra-mitochondrial 
ROS generating enzymes (Richter and Kietzmann, 2016). Among these, the NOX 
family of nicotinamide adenine dinucleotide phosphate oxidases (NADPH 
oxidases) appears to have a key role during liver fibrosis, being NOX4 the 
isoform with a more critical role in ROS production under pro-fibrogenic 
conditions (Crosas-Molist et al., 2015; De Minicis et al., 2010; Paik et al., 2014). 
ROS production contributes to the fibrotic process directly or indirectly by 
sustaining inflammation and/or increasing the production of chemokines or 
growth factors. At this respect, it is worth mentioning that ROS can activate 
latent TGF-β, which further promotes ROS production and oxidative stress. All 
these mechanisms can in turn increase fibrosis. More specifically, ROS 
contribute to transdifferentiate HSC to MFB. Additionally, ROS may activate 
proliferation, migration and differentiation of fibroblasts, and ROS can induce 
EMT and are responsible for apoptosis of epithelial cells and/or ECM deposition 
(Richter and Kietzmann, 2016). 
Among the cytokines involved in CLD, TGF-β has a major pro-fibrotic role 
and acts as the main orchestrator of the injury. Because of its importance, roles 
of TGF-β during CLD will be discussed in 3.3 section. 
Inflammation is also a central pathogenic mechanism of liver disease. A 
number of signaling molecules and executor cells are involved in this process 
(Dooley and ten Dijke, 2012). Activation of KC, HSCs and MFB, and dying cells, 
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Figure 2. Pathogenesis of hepatic fibrosis. Prolonged liver injury results in fibrosis/cirrhosis 
where HSCs are key mediators. HSCs transdifferentiate to MFB by soluble mediators 
(chemokines/cytokines, ROS, growth factors) released by immune cells (KC, leukocytes) and 
other cell types including damaged hepatocytes and cholangiocytes. The pool of MFB is 
further increased by different cells (resident fibroblasts, hepatocytes, cholangiocytes, bone 
marrow fibrocytes, pericytes and endothelial cells) that acquire pro-fibrotic activities and 
become ECM producers. MFB, positive for α-SMA, display an increased proliferation, survival, 
migration and contraction capacities, and are the predominant source of collagen deposition. 
Moreover, ECM homeostasis is disturbed during fibrotic process through the increase of 
expression of TIMPs, decrease of matrix MMPs or the expression of pro-fibrotic MMPs. 
Adapted from Ralf Weiskirchen et al., 2018. 
like hepatocytes, produce cytokines (TNF-α, interleukin (IL)-1α/β, IL-6, IL-12, IL-
18) and trigger the infiltration of macrophages, lymphocytes and eosinophils 
cells, which are responsible for a persistent inflammatory response 
(Weiskirchen and Tacke, 2016; Zhou et al., 2014). It is worthy to note that KC 
play a key role in the initiation and maintenance of the inflammatory response 
that sustains the fibrotic process. After activation, KC express chemokine 
receptors and secret various cytokines contributing to activate HSCs (Ebrahimi 
et al., 2016).  
 23 
 
 
1.1.2. Diagnosis and therapy 
Defining the disease state is essential in deciding the therapeutic choices 
and predicting prognosis. Liver biopsy is considered the gold standard method 
for assessing liver fibrosis but it has limitations such as invasiveness and 
sampling errors. Liver fibrosis is a heterogeneous process, often the obtained 
tissue does not represent the whole liver pathology and its analysis is subjected 
to observer variability. That is why other non-invasive methods have been 
developed. Imaging diagnostic modalities, including ultrasound-based or 
magnetic resonance imaging, and laboratory tests based on the detection of 
biochemical and hematological serum markers are other alternatives (Cheng 
and Wong, 2017; Ebrahimi et al., 2016). 
Concerning the treatment, patients with fibrosis and cirrhosis caused by 
hepatitis virus infection show regression of liver fibrosis upon anti-viral therapy. 
In the case of non-alcoholic fatty liver disease (NAFLD), controlling metabolic 
risk factors is the option to improve liver fibrosis. Advances in the knowledge of 
the disease mechanisms are allowing the development of new treatments 
focused on HSCs regulation, collagen synthesis inhibition, blocking TGF-β action 
and inflammatory response control. Unfortunately, although some of these 
strategies work well in pre-clinical models, none of them has been translated 
into effective therapies in human so far (Cheng and Wong, 2017; Koyama et al., 
2016).  
 
1.2. Hepatocellular carcinoma (HCC) 
Faery liver cancer association estimates that liver cancer is the second 
largest cause of cancer-related deaths (600,000 deaths each year) worldwide. 
HCC is the most common primary malignancy of the liver (80%-90% of all 
primary liver cancers) and the fourth most common cancer worldwide. Due to 
the asymptomatic nature in the early stages of the disease, the majority of HCC 
cases are detected in advanced stages, leading to incurable disease states 
(https://www.bluefaery.org/statistics). 
Although HCC has a multitude of etiological risk factors, the development of 
HCC is closely related to the presence of CLD. In fact, around 80%-90% of HCC 
cases occur in the setting of underlying cirrhosis secondary to viral hepatitis 
(specifically hepatitis B virus or hepatitis C virus) or other non-viral CLD (Forner 
et al., 2012; Ghouri et al., 2017). 
 
1.2.1. Pathophysiology 
HCC is the result of a long-term process that begins with a pre-malignant 
stage that progresses to a dysplastic stage and ends in a malignant one. 
Hepatocarcinogenesis involves dysregulation of a number of molecular 
pathways as well as genetic alterations that ultimately lead to malignant 
transformation and HCC disease progression (Liu et al., 2014). It can originate 
from various cell types, including mature hepatocytes and stem or progenitor 
cells (Llovet et al., 2016). HCC hallmarks, as for other types of tumours, are 
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sustained cell proliferation, ability to evad growth suppression, resistance to cell 
death, invasion, metastasis, angiogenesis and deregulated energy metabolism 
(Liu et al., 2014).  
HCC is a complex and heterogeneous disease both clinically and 
histopathologically, with a wide array of genetic and epigenetic changes that 
regulate cell proliferation, growth, survival, apoptosis, adhesion and metabolism 
(Liu et al., 2014). Recurrent somatic mutations in specific genes are well 
recognized as potential drivers of carcinogenesis. The most frequent mutations 
found affect telomerase reverse transcriptase (TERT) promoter, p53 (tumor 
suppressor) and Wnt/β-catenin pathways. Additional mutations in HCC have 
been described, such as those affecting members of SWI/SNF chromatin 
remodeling complex and JAK/ signal transducers and activators of transcription 
(STAT) pathways; genes related to oxidative stress, RAS/mitogen-activated 
protein kinase (MAPK) signaling and genes that encode members of the 
ubiquitination process such as ubiquitin ligases (Dhanasekaran et al., 2016; Ding 
et al., 2017; Inokawa et al., 2016; Liu et al., 2014; Llovet et al., 2016).   
In addition to genetic modifications, epigenetic alterations (changes in the 
methylation, hydroxymethylation, acetylation of histone proteins or 
dysregulation of the deoxyribonucleic acid (DNA) methylation) and changes in 
micro ribonucleic acid (miRNA) expression result in an altered expression of key 
proteins involved in HCC, contributing to carcinogenesis by influencing gene 
transcription, chromosomal stability and cell differentiation (Dhanasekaran et 
al., 2016; Inokawa et al., 2016; Llovet et al., 2016).  
Apart from genetic and epigenetic alterations, several specific pathways are 
dysregulated in HCC that include: receptor tyrosine kinases (RTK) signaling 
pathways regulated by insulin-like growth factor (IGF); epidermal growth factor 
(EGF); PDGF and hepatocyte growth factor (HGF). It has also been reported 
alterations in pathways related to cell differentiation (Wnt, Notch, Hedgehog). 
Due to the fact that HCC is a highly vascularized tumor and the angiogenic 
process is a dominant feature, it is not surprising to find changes in angiogenic 
pathways and its ligands, such as vascular endothelial growth factor (VEGF) and 
fibroblast growth factor (FGF). Moreover, the main signaling mediators 
RAS/RAF/MEK/extracellular signal-regulated kinases (ERK) and 
phosphatidylinositol 3-kinase/AK strain transforming/ mammalian target of 
rapamycin (PI3K/AKT/mTOR) cascades are likewise important to liver 
carcinogenesis. Another pathway that has not been mentioned so far is the one 
triggered by TGF-β, which plays a critical role in cancer and will be subject of 
discuss in section 3.3 (Dhanasekaran et al., 2016; Tahmasebi Birgani and Carloni, 
2017; Whittaker et al., 2010). 
It is known that tumor microenvironment is critical for the initiation, growth 
and metastasis of tumor. Fibroblasts, myofibroblast, endothelial cells, perycites, 
adipose cells, ECM and infiltrating immune cells form the typical tumor 
microenvironment. Tumor microenvironment is enriched with diffusible 
cytokines, chemokines or enzymes that are secreted from cancerous or non-
cancerous cells (Tahmasebi Birgani and Carloni, 2017). All of these signals 
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Figure 3. Pathogenesis of hepatocellular carcinoma. Chronic exposure of the liver to injury 
causes repeated hepatocyte damage and sets up a vicious cycle of cell death and regeneration 
which eventually results in cirrhosis. The resultant genomic instability leads to initiation of 
HCC. Accumulation of somatic mutations, epigenetic changes and molecular pathway 
alterations eventually lead to tumor progression and metastasis. Adapted from Dhanasekaran 
et al., 2016. 
determine tumor growth, angiogenesis and immune response, and jointly, 
tumor progression (Liu et al., 2014).   
 
 
 1.2.2. Diagnosis and therapy 
HCC, as described previously, is genetically diverse and heterogeneous and 
is often diagnosed in a late phase because the symptoms appear at an advanced 
stage. These characteristics minimize the possibility to find and develop 
effective treatments against the disease at diagnosis and death is ensured after 
a few months. However, it is worth emphasizing that HCC has a prolonged 
subclinical course, which provides the opportunity for an early detection and 
treatment. Early-stage HCC lesions are small and frequently curable usually by 
minimally invasive methods (Dimitroulis et al., 2017; Llovet et al., 2016).  
Within the different algorithms that have been developed to HCC detection, 
the principal methods for the diagnosis are the imaging studies and laboratory 
tests. For the imaging studies, ultrasonography, computed tomography, 
scanning and magnetic resonance imaging are used. As to laboratory tests, 
alpha-fetoprotein (AFP) is the most widely used serum marker. A part from 
these non-invasive diagnostic methods, liver biopsy is often a critical component 
in establishing the diagnosis of many forms of liver disease (Dimitroulis et al., 
2017; Rockey et al., 2009).  
In 2018, guidelines have been proposed to allow physicians to select the 
correct treatment for each patient. Complete HCC resection, either HCC lesion 
resection or a major hepatectomy is the treatment of choice when possible, 
mostly in patients without cirrhosis. Liver transplantation is the perfect 
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treatment for HCC with an underlying CLD because it eliminates liver disease. 
For early HCC, patients can undergo local ablative therapy (radiofrequency 
ablation, microwave ablation or laser-induced interstitial thermotherapy). An 
alternative to these options is the transarterial chemoembolization (Dimitroulis 
et al., 2017). Despite the existence of these clinical possibilities to deal with the 
tumor, chemotherapy is the most important treatment for advanced HCC even 
though results are still unsatisfactory mainly due to HCC high molecular 
heterogeneity and its resistance to conventional chemotherapy. This may be the 
reason why prognosis of HCC patients is poor. Sorafenib is the first-line therapy 
for patients with advanced HCC. Since its discovery, only one of the numerous 
studied agents, lenvatinib, has shown survival benefit and non-inferiority to 
sorafenib. Recently, immuno-oncologic treatment and other new agents are 
under development or in clinical trials. Individual therapies based on genome 
sequencing might be the solution to improve the treatment in patients with 
advanced HCC (Ikeda et al., 2018; Llovet et al., 2016).  
 
2. Hepatic progenitor cell/oval cell 
regeneration 
2.1. Liver regenerative response 
The liver has a unique capacity to regenerate in response to liver damage. 
Following partial removal of the tissue, the remaining population of 
parenchymal cells starts proliferating to meet replacement demands of cellular 
loss. This process is better defined as a compensatory hyperplasia since the 
expanding liver does not regain its original anatomical structure (Mao et al., 
2014). 
Different animal models have been used to study this phenomenon but the 
most widely studied model is partial hepatectomy in rodents (Higgins et al 
1931). 2/3 of liver mass are surgically removed and the regenerative response is 
complete within 5-7 days after surgery, both in rats and mice. The remaining 
mitotically quiescent hepatocytes undergo cell division entering into S phase 
and consequently, binuclear hepatocytes give rise to two mononuclear cells. 
After two or three cell cycles, remaining liver has enlarged to a mass equivalent 
to the original organ (Mao et al., 2014; Michalopoulos, 2007, 2010, 2014). 
Nevertheless, if the liver injury is persistent or severe and the proliferation 
capacity and function of hepatocytes is impaired or exhausted, such as during 
submassive necrosis, chronic viral hepatitis and NAFLD, the normal renewal 
from mature epithelial cells is overwhelmed. In this context, adult hepatic stem/ 
progenitor cells, called hepatic progenitor cells (HPCs) in humans and oval cells 
in rodents, act as a second line of defense against liver failure (Chen et al., 2017; 
Duncan et al., 2009). 
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2.2. HPC/oval cell generalities 
HPCs have been described in many pathophysiological processes of human 
liver diseases (chronic hepatitis B and C, cirrhosis, alcoholic and nonalcoholic 
liver disease among others) (Bria et al., 2017; Chen et al., 2017; Lowes et al., 
1999). 
In rodents, oval cells were first described by E.Farber in 1956 as 
hepatobiliary reactive cells with approximately 10 μm of diameter, large 
nuclear-cytoplasm ratio and oval-shape nucleus (hence their name). The term 
hepatobiliary refers to their bipotential differentiation capacity towards both 
hepatocytes and cholangiocytes (Fausto and Campbell, 2003).  
The oval cell-mediated regenerative process is referred to as “oval cell 
response” or “ductular reaction” because oval cells organize into ductular 
structures or ductules (Bria et al., 2017). However, ductular reaction is 
associated not only with HPCs/oval cells expansion, but also with other liver 
cells, such as stromal cells, inflammatory cells and infiltrated cells, including 
bone marrow–derived macrophages, and therefore, other liver processes such 
as ECM modifications, inflammatory infiltration and angiogenesis (Roskams et 
al., 2004; Sato et al., 2019). 
Different liver injury protocols have been developed for activation and 
expansion of oval cells in rodents, but one of the most extensively used in mice 
is the administration of a diet containing 0.1% of 3,5-diethoxycarbonyl-1,4-
dihidro-collidine (DDC), a porphyrinogenic hepatotoxin (Preisegger et al., 1999). 
DDC diet causes the inhibition of mitochondrial enzyme ferrochelatase leading 
to accumulation of protoporphyrin. This pigment accumulates in the cytoplasm 
of parenchymal cells and in KC. Due to its hydrophobic nature, the pigment only 
exits the liver through biliary secretion, precipitating and forming crystals in bile 
canaliculi and bile ducts that obstruct the biliary tree. Therefore, the tissue 
responds with a ductular reaction, peri-cholangitis, periductal fibrosis, and 
portal-portal fibrosis after 4–8 weeks that resembles the human cholestatic 
disease primary sclerosing cholangitis (Delire et al., 2015). 
 
2.3. HPC/oval cell markers 
HPCs/oval cells represent a heterogeneous population of cells that include 
different states of differentiation reflected by dynamic phenotype changes. 
Despite this, a number of surface antigens and intracellular proteins 
characteristic of the HPC/oval cell population have been described. Because of 
its bipotential and immature nature, these cells express a diverse set of markers 
that include hepatocyte markers as albumin (ALB), cytokeratins 8 and 18 (CK8, 
CK18) and MET; immature hepatocyte markers as AFP; biliary epithelial markers 
as CK19, A6, OV6 and epithelial cell adhesion molecule (EPCAM); markers 
associated with hematopoietic linages as thymocyte differentiation antigen 
(THY-1) (CD90) and c-KIT; neuroendocrine markers as neural cell adhesion 
molecule (N-CAM); and stem cell markers as CD133, CD44 and nestin (Bria et al., 
2017; Chen et al., 2017).  
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2.4. HPC/oval cell origin 
The cellular origin and location of HPCs/oval cells is still controversial and 
different theories keep emerging. The classical theory supports that HPCs/oval 
cells derive from quiescent stem cells located in the Canal of Hering, which is a 
structure connecting bile canaliculi formed by hepatocyte with bile ducts lined 
by cholangiocytes in the portal triad (Fausto, 2004; Fausto and Campbell, 2003; 
Itoh and Miyajima, 2014). This is still considered the most likely origin of 
HPCs/oval cells. Nevertheless, recent studies have demonstrated the existence 
of other stem cell origins apart from canal of Hering including intralobular bile 
ducts, periductal cells and peribiliary hepatocytes (Kuwahara et al., 2008). 
In contrast with this view, it has been proposed that a liver stem cell 
hierarchy exists with different stages of HPC/oval cell maturation where the 
most mature HPC/oval cell is the one with the bipotential capacity. An 
additional model proposes that there are different precursor cells for 
hepatocytes and cholangiocytes instead of a bipotential progenitor population 
(Duncan et al., 2009). An extrahepatic origin of oval cells, particularly bone 
marrow, has also been proposed. Additional theories hold that HPCs/oval cells 
may come from hepatic stellate cells (Kordes et al., 2014), or from hepatocytes 
or bile epithelial cells (Tarlow et al., 2014), after a dedifferentiation process in 
response to liver damage (Bria et al., 2017; Tarlow et al., 2014). 
2.5. HPC/oval cell response 
Following the classical theory, upon activation of HPC/oval cell precursors at 
periportal niches, HPCs/oval cells expansion occurs, proliferating, migrating into 
liver parenchyma and differentiating into hepatocytes and cholangiocytes. In 
fact, activation, proliferation, migration and differentiation are considered the 
four phases of the HPC/oval cell response (Tanaka et al., 2011).  
These phases, together with HPC/oval cell survival, self-renewal and/or 
maintenance of stemness in HPCs/oval cells, are regulated by the 
microenvironment, which is referred to as HPC/oval cell niche, and is composed 
of different cell types, ECM scaffold, growth factors and cytokines and other 
signals and molecules released by the niche cells. 
The different cell types in the niche can interact and cross-talk with HPCs/ 
oval cells influencing its response. Parenchymal cells, hepatocytes and 
cholangiocytes, which are damaged during liver injury can direct/determine the 
activation and the fate of HPCs/oval cells. Moreover, cooperation with HSCs and 
myofibroblasts plays a critical role in HPC/oval cell expansion and differentiation 
through the release of growth factors and production of ECM. It has been also 
suggested that inflammatory cells stimulate and initiate regenerative responses 
in experimental models and can also remodel the ECM through the production 
of MMPs. ECM and ECM remodeling are essential for survival, activation, 
expansion and differentiation of HPCs/oval cells by binding, and presenting 
growth factors and signals to HPCs/oval cells (Bria et al., 2017; Chen et al., 2017; 
Van Hul et al., 2009; Vestentoft et al., 2013). 
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Figure 4. Classic model of HPC/oval cell origin. Quiescent stem cells are the precursors of 
HPCs/oval cells. The canal of Hering can provide a niche for these precursors of HPCs/oval 
cells. The niche is defined as the microenvironment which regulates HPC/oval cell behavior. 
Different cell types, ECM scaffold, growth factors and cytokines and other signals and 
molecules released by the niche cells form part of the HPC/oval cell niche. Adapted from 
Chen et al., 2017. 
 
The niche is the  microenvironment which regulates oval cell behavior. The niche is 
composed of different cell types, extracellular components, growth factors and cytokines 
and other signals and molecules released by the niche cells.  
regulates stem cell behaviour  Adapted from Chen et al.2017.  
Important signals take part in HPC/oval cell response. Among these signals, 
which can act directly on HPCs/oval cells or indirectly via non-parenchymal cells 
that in turn regulate HPCs/oval cells, are growth factors such as HGF, TGF-β, 
FGF, connective tissue growth factor (CTGF); hormones (insulin, somatoestatin); 
adipokines (leptin); chemokines (SDF1, stromal cell-derived factor 1); and 
neurotransmitt rs (ser tonin, pinephrine or norepinephrine). Besides this 
signaling network, inflammatory response (immune cells and inflammatory 
cytokines, such as interferon alfa (IFNα), TNFα, tumor necrosis factor-like weak 
inducer of apoptosis (TWEAK), IL-6, STAT3, etc) is critical for HPC/oval cell 
regenerative process (Best et al., 2013; Bird et al., 2008; Lukacs-Kornek and 
Lammert, 2017). Additionally, morphogens such as Wnt, Notch and Hedgehod 
are key regulators of HPC/oval cell response (Apte et al., 2008; Chen et al., 2017; 
Darwiche et al., 2011; Yang et al., 2008).  
Due to the large number of signals and molecules that regulate HPCs/oval 
cells, a better understanding of their specific role and relevance in HPC/oval cell 
biology is necessary.  
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Figure 5. HPC/oval cell response. With minor injury, restoration of hepatocyte mass and 
function is mediated by the replication of remaining healthy hepatocytes (and 
cholangiocytes). During major liver insult, this mechanism is overwhelmed and HPCs/oval cells 
compartment is activated in an attempt to restore epithelial cell mass, architecture and 
function. The bipotential HPCs/oval cells upon activation are able to infiltrate along the liver 
parenchyma from the Canals of Hering, proliferate and differentiate into hepatocytes and 
cholangiocytes. This regenerative process is triggered and regulated by a plethora of signals. 
Adapted from Best et al., 2013.  
2.6. HPC/oval cell in therapy 
The bipotential nature of HPCs/oval cells and their ability to restore the 
damaged liver make the scientific community think in this population as an 
interesting target to develop new strategies against CLD. Thus cell 
transplantation alone or combined with drugs to enhance native regeneration 
could be alternative options to liver transplantation, the only effective therapy 
nowadays for patients with end-stage liver disease. 
 Regeneration by liver repopulation with transplanted hepatocytes has been 
explored for patients with liver-based inborn errors of metabolism or acute liver 
failure. Clinical trials have proved that liver hepatocyte transplantation is safe 
and effective but it only partially corrects metabolic disorders and it only does it 
in the short-term. Additionally, working with hepatocytes presents a number of 
difficulties, including difficulty in obtaining an easy and reproducible hepatocyte 
source; poor survival of primary hepatocytes in hypothermic storage conditions 
and number variation, scarce availability of good quality hepatocyte; and poor 
traceability of cells post-transplantation (Gilgenkrantz and Collin de l'Hortet, 
2018). 
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All of these problems together with the limitations in treatment of CLD and 
HCC make the use of HPCs in therapy more attractive. However, understanding 
the molecular and signaling regulation of HPCs/oval cells is critical not only 
because it will help determine their true regenerative potential and utility in 
clinical strategies, but also because evidences show a role of HPCs/oval cells in 
liver fibrosis and HCC (Huebert and Rakela, 2014). Today, it is still not clear if 
HPCs/oval cells are a friend or foe in chronic injury.  
 
2.7. Oval cell in liver fibrosis and HCC 
We have already mentioned that HPCs/oval cells are present not only in 
rodent models of liver injury but in different human liver pathologies. Studies 
performed in humans and rodents have established a direct relationship 
between the degree of hepatic injury, the HPCs/oval cells expansion and the 
severity of fibrosis (Knight et al., 2007; Williams et al., 2014). So, opposed to the 
viewpoint of HPCs/oval cells as pro-regenerative cells, another current of 
opinion sees them as pro-fibrotic/pro-tumorigenic cells. 
A study published by Chobert et al. (2012) showed that expanded HPCs/oval 
cells, after strong fibrosis induction in mice, express TGF-β, contributing in this 
way to the accumulation of α-SMA-positive MFB and consequently, to the 
disease progression. Kuramitsu et al. (2013) studies also support the profibrotic 
role of HPCs/oval cells. In this work, failure of hepatocyte-mediated 
regeneration in fibrotic mouse livers triggers activation of HPCs/oval cells and a 
severe fibrotic response. In this setting, inhibition of HPC/oval cell response 
results in prevention of fibrotic process and in an improvement in liver 
regeneration. The work of Clouston et al. (2005) also demonstrates a correlation 
between the increase in hepatic fibrosis during chronic hepatitis C virus 
infection and a periportal ductular reaction. These evidences attribute 
HPCs/oval cells a role in the progression of fibrosis. The controversy about the 
precise role of HPCs/oval cells as pro-fibrogenic or anti-fibrogenic makes 
necessary further studies to clarify this point. It is worthy to understand that 
these two opposing ideas are not mutually exclusive, and this paradox can be 
resolved by recognizing heterogeneity in the ductular reaction activation and 
evolution in the specific context of the different models used.  
One of the theories proposed to explain the origin of HCC states that HCC 
derives from stem cells whose differentiation is blocked. Stem cells that are 
committed to form a certain tissue divide into two daughter cells, during normal 
cell renewal. One daughter cell remains as a stem cell and the other cell 
expresses a more differentiated state. These differentiating cells are capable of 
proliferating and lead to terminally differentiated cells. However, mutations can 
occur during the differentiation process and the mitotically active cells acquire a 
malignant phenotype due to an abnormal differentiation state with self-renewal 
ability, multi-directional differentiation, unlimited proliferation and high 
tumorigenic ability. In this line, HPCs/oval cells have been proposed to behave 
as a cancer stem cell in certain contexts (Sell, 1993; Wu and Chen, 2006). 
Different evidences support this theory. 1) Cells phenotypically similar to 
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HPCs/oval cells are observed in many hepatic tumors and several studies based 
on immunohistochemical analysis of HCCs have concluded that about 28–50% of 
HCCs express markers of progenitor cells (such as CK19, AFP and OV6) 
(Roskams, 2006; Yang et al., 2012). Interestingly, these tumors carry a 
significantly poorer prognosis and higher recurrence after surgical resection and 
liver transplantation (Kohn-Gaone et al., 2016; Lee et al., 2006). 2) Microarray 
analysis have revealed that many of the disrupted pathways in HCC are involved 
in stem cell maintenance and self-renewal such as Wnt/β-catenin, TGF-β, 
HGF/Met, Hedgehog (Marquardt and Thorgeirsson, 2010). 3) Both transfection 
of activated oncogenes or silencing of tumor suppressor genes in HPCs/oval 
cells can give rise to HCC (Braun et al., 1987; Dumble et al., 2002; Iidaka et al., 
2005). 
 
3. Transforming growth factor β (TGF-β) 
3.1. Signaling pathway 
Mammalian genome encodes 33 members of the TGF-β superfamily that 
includes isoforms of TGF-β, BMP (Bone Morphogenetic Proteins), nodal, activin, 
inhibin, GDPs (Growth Differentiation Factors), MIS/AMH (Müllerian Inhibiting 
Substance/Anti-Mullerian Hormone) and Lefty (Massague, 2012; Morikawa et 
al., 2016).   
Focusing on TGF-β sub-family, the mammalian genome encodes 3 different 
isoforms: TGF-β1, β2 and β3. TGF-β1 is ubiquitously expressed and is the most 
abundant isoform. The ligands of the TGF-β are synthesized as polypeptide 
precursors formed by 3 segments: an amino-terminal signal peptide, a large 
precursor segment or pro-segment (LAPs, latency-associated peptides) and the 
carboxy-terminal polypeptide. TGF-β precursor segment must be eliminated 
before binding to its receptor, process accomplished by proteolytic cleavage 
mediated by furin enzymes in the trans-Golgi. The still inactive TGF-β form is 
released into the ECM, where the final activation by integrins and proteases like 
plasmin or gelatinases takes place. To become active, TGF-β must form dimers 
stabilized by a disulphide bridge and hydrophobic interactions (Massague, 2012; 
Morikawa et al., 2016).  
Upon activation, TGF-β binds to a tetrameric complex consisting of two type 
I and two type II serine-threonine kinase receptors. There are 7 type I receptors 
(activin receptor-like kinase, ALK1-7) (TβRI) and 5 type II receptors (TβRII), but 
TGF-β preferentially signals through ALK5 (TβRI) and the type II receptor, TβRII. 
Thus, active TGF-β binds to TβRII that leads to recruitment and 
transphosphorylation of TβRI in a glycine and serine-rich domain (GS domain). 
This phosphorylation switches the GS region in TβRI from a site that binds the 
12KDa FK506-binding protein (FKBP12), a protein that silences the kinase 
activity, into a site that binds R-Smad (receptor-associated Smad) proteins for 
their phosphorylation. Among the 5 different R-Smads, TGF-β1 specifically 
activates Smad2 and Smad3. Then, they form a trimeric complex with the Co-
Smad4 (common mediator Smad4) and subsequently, this complex translocates 
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to the nucleus where it cooperates with other transcription factors, coactivators 
and corepressors to regulate the expression of specific target genes. Apart from 
R-Smad and Co-Smad, Smad family includes other members named I-Smads 
(inhibitory Smads), I-Smad 6 and 7, which regulate negatively TGF-β signaling 
pathway. Smad7 binds to and inhibits essentially all type I receptors in the TGF-
β family whereas Smad6 exhibits higher specificity on BMP mediated signaling. 
Smad family members consist in two domains (MH1 and MH2) coupled by an 
unstructured linker. The amino-terminal MH1 domain has a hairpin structure 
with DNA-binding ability. MH2 is the carboxy-terminal domain with hydrophobic 
segments that are able to interact with adaptor proteins, active TGF-β receptors 
and DNA coactivators and repressors. Apart from regulating genes expression, 
Smad also regulate miRNA expression and maturation, epigenetic changes, RNA 
splicing and RNA methylation (Derynck and Budi, 2019; Heldin and Moustakas, 
2016; Huse et al., 2001; Itoh and ten Dijke, 2007; Massague, 2012; Shi and 
Massagué, 2003). 
Besides the Smad signaling pathway, known as “canonical pathway”, TGF-β 
can activate other pathways that are referred to as “non-canonical” or “non-
Smad” pathway. These pathways are activated through the interaction between 
the members of the canonical response with other signaling pathways and 
through the ability to TGF-β receptors to activate other signaling molecules. 
Non-canonical pathways include among others, various branches of MAPK 
pathways (ERK, c-Jun N-terminal kinase (JNK) and p38 kinase pathways); Rho-
like GTPase, nuclear factor kappa-light-chain-enhancer of activated B cells 
(NFκB), JAK/STAT and PI3K/AKT signaling pathways. These signaling pathways 
act alone or in conjunction with Smads to control TGF-β activities (Derynck and 
Budi, 2019; Derynck and Zhang, 2003; Heldin and Moustakas, 2016; Massague, 
2012; Zhang, 2009).  
TGF-β signaling pathway is subjected to regulation (positive, negative, 
spacio-temporal) at different levels such as ligand activation, receptor complex 
formation, R-Smad activation and translocation, and transcriptional activity.  
I-Smad 6 and 7 negatively regulate TGF-β pathway by different mechanisms. 
These include: binding to activated type I receptor inhibiting R-Smad 
phosphorylation; interactions with Smad4 preventing R-Smad–Smad4 complex 
formation, degradation of TβRI through the proteasome pathway and 
recruitment of transcriptional Smad co-repressors (Itoh and ten Dijke, 2007; Yan 
et al., 2009). In addition to the regulation of the signaling pathway through I-
Smads, numerous points of control exist in TGF-β pathway, some of them are 
mentioned below. TGF-β receptor expression, activity and stability can be 
controlled by different means, including phosphorylation, ubiquitination, 
sumoylation and neddylation (Budi et al., 2017; Heldin and Moustakas, 2016). In 
the same manner, Smad proteins are also regulated by phosphorylation, 
ubiquitination, sumoylation and acetylation (Massague et al., 2005). TGF-β 
receptor signaling intensity, duration, specificity and diversity are modulated by 
cell surface co-receptors such as betaglycan/TβRIII, endoglin or Neuropilin-1 and 
other cell-surface proteins such as integrins or occludin. Moreover, signaling via 
TGF-β receptors is modulated by interactions with cytoplasmic proteins and 
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Figure 6. Canonical and non-canonical TGF-β signaling pathways. TGF-β dimer binds to the 
receptor complex and consequently activates the canonical Smad pathway, through Smad2/3 
and Smad4, and non-canonical signaling pathways. Adapted from Budi et al., 2017. 
 
with nuclear shuttling proteins (Heldin and Moustakas, 2016; Nickel et al., 
2018). Another point of control is the regulation of the receptor by endocytosis 
(Zhao and Chen, 2014) 
 
3.2. TGF-β responses 
In most cell types, in particular in normal epithelial cells, TGF-β family 
members regulate a large number of cellular responses including proliferation, 
differentiation, migration and apoptosis among others. Dysregulation of these 
signals is implicated in various human diseases including cancer, fibrosis, 
autoimmune diseases and vascular disorders (Akhurst and Hata, 2012; Heldin 
and Moustakas, 2016; Massague, 2008). 
 
3.2.1. TGF-β and growth inhibition 
TGF-β has a high growth inhibitory capacity in epithelial cells and many non-
epithelial cell types, which is irreversible if cytokine is eliminated. The inhibitory 
action is based on the induction of cyclin dependent kinase inhibitors (CKI 
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inhibitors) and/or the inhibition of proliferative drivers. The specific mechanisms 
depend on the cell type and context (Morikawa et al., 2016). 
In epithelial cells, TGF-β orchestrates the cytostatic effect primarily during 
G1 phase of the cell cycle through inhibition of CDKs, which leads to de-
phosphorylation of retinoblastoma protein (RB). Different studies show that 
TGF-β induces expression of p21 (Cdkn1a) and p57 (Cdkn1c), members of the 
Cip/Kip CKI family, which inhibit CDKs involved in the G1/S transition, and p15 
(Cdkn2b), member of INK4 family, which inhibits Cyclin D-cdk4/6 complexes. 
p27 (Cdk1b) is another member of Cip/Kip family involved in the mechanism of 
growth arrest. p27 when bound to Cyclin D-Cdk4/6 complex is in an inactive 
state and upon induction of p15 by TGF-β, p15 displaces p27 from Cyclin D-
Cdk4/6 and p27 moves on to inhibit Cdk2. At the same time, TGF-β induces c-
Myc downregulation, a transcription factor that promotes cellular growth and 
proliferation, and the inhibition of ID1, 2 and 3 expression, transcription factors 
that oppose cellular differentiation (Massague and Gomis, 2006; Siegel and 
Massague, 2003). Although the majority of these effects are Smad-dependent, 
TGF-β is also able to induce cell cycle arrest through non-Smad pathways 
(Petritsch et al., 2000). 
 
3.2.2. TGF-β and apoptosis 
TGF-β-regulated apoptosis is highly dependent on the cell type. In fact, 
there is not a clear TGF-β apoptotic program and various components link TGF-β 
signaling pathway with the machinery of programmed cell death (Zhang et al., 
2017). Different SMAD dependent and independent mechanisms have been 
described in the control of apoptosis in different cell types. 
TGF-β cooperates in several systems with the death receptor apoptotic 
pathways: Fas ligand (FasL) or apoptosis antigen-1 ligand and TNF-α, enhancing 
or inhibiting the apoptotic responses. Intracellularly, several apoptotic target 
genes, the TGF-β-inducible early response gene I (TIEG1) and the death-
associated protein kinase (DAP-kinase) among others, are regulated by Smad 
transcriptional complexes. But, at the same time, TGF-β activates pro-survival 
signals such as ERK MAPK, NF-κB and PI3K-AKT, and the pro-apoptotic JNK and 
p38 MAPKs. This intricate and complex response leads us to think that the 
balance between pro- and anti-apoptotic signaling pathways is essential to 
determine whether or not cells will undergo apoptosis in response to TGF-β 
(Sanchez-Capelo, 2005; Schuster and Krieglstein, 2002; Zhang et al., 2017). 
TGF-β also induces apoptosis via mitochondrial apoptotic pathway through 
cytochrome c release mediated by B-cell lymphoma 2 (BCL-2) family members. 
TGF-β modulate the expression, localization and activation of pro- and anti-
apoptotic BCL-2 proteins. In fact, TGF-β has been shown to induce ROS and 
oxidative stress by different means, by regulating ROS producing systems (as 
NADPH) or by down regulating antioxidant genes (Carmona-Cuenca et al., 2008; 
Herrera et al., 2001; Martinez-Palacian et al., 2013; Sanchez-Capelo, 2005; 
Sanchez et al., 1996; Schuster and Krieglstein, 2002; Zhang et al., 2017). 
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3.2.3. TGF-β and epithelial to mesenchymal transition (EMT) 
Definition of EMT 
Classically, EMT has been described as a biological process that allows an 
epithelial cell to undergo multiple biochemical changes that enable it to acquire 
a mesenchymal phenotype which includes enhanced migratory capacity, 
invasiveness, elevated resistance to apoptosis, and increased production of ECM 
components. Numerous biochemical changes take place during this phenotype 
transition: loss of junctions and apical-basal polarity, reorganization of 
cytoskeleton, and changes in signaling programs that altogether define cell 
shape and reprogramming of gene expression (Lamouille et al., 2014; Nieto et 
al., 2016). 
However, nowadays, EMT is not only described as a shift between two 
alternative states, full mesenchymal or full epithelial. Cells can transition 
through a spectrum of intermediary states that could be understood as partial 
EMT, states in which cells present a hybrid epithelial and mesenchymal 
phenotype. Many studies define the hybrid state as the co-expression of 
epithelial and mesenchymal markers, but cells do not need to gain 
mesenchymal proteins in a partial EMT, it is enough to repress epithelial 
properties. Likewise, induction of mesenchymal markers while maintaining E-
cadherin is considered a partial EMT. It is unknown whether this hybrid status 
reflects an intermediate phase during a mesenchymal transition or represents 
its own end state. Mechanisms driving partial EMT remain to be clarified (Aiello 
et al., 2018; Kai et al., 2018; Nieto et al., 2016). 
EMT transcription factors and inducers 
EMT process is orchestrated by specific transcription factors (EMT-TF): Zinc-
finger binding transcription factors Snail1 and Snail2 and several helix-loop-helix 
factors such as zinc finger E-box-binding homeobox 1 (Zeb1), Zeb2 and Twist 
(Twist 1 and 2). Expression of these transcription factors and their precise 
contribution to EMT regulation depend on the cell or the tissue in which EMT 
takes place and on the signaling pathway that initiates the process. EMT-TF 
often regulate each other and act coordinately to repress epithelial genes and 
induce mesenchymal genes. Additionally, epigenetic modifications, differential 
splicing of RNA and miRNA have been described as modulators of the EMT 
process (Lamouille et al., 2014; Nieto et al., 2016; Skrypek et al., 2017). 
Although different signals induce EMT process, TGF-β is one of the best 
known and studied. TGF-β triggers EMT through Smad proteins, regulating the 
transcriptional program that involves the EMT-TF. Besides the canonical 
pathway, non-canonical TGF-β effectors can mediate TGF-β ability to induce the 
transition between epithelial to mesenchymal features in cells. ERK/MAPK, 
p38/MAPK Rho GTPases, PI3K/AKT, NF-KB, JNK are some of the pathways 
associated with TGF-β-induced EMT (Gonzalez and Medici, 2014; Wendt et al., 
2009; Xie et al., 2004; Xu et al., 2009). 
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EMT-related phenotypic and functional changes 
Cell to cell contact is maintained through tight junctions, adherent 
junctions, desmosomes and gap junctions. After EMT induction, these cell 
junctions are deconstructed and the junction proteins are relocalized and/or 
degraded. Loss of tight junctions is characterized by decreased claudin and 
occludin expression and intracellular relocalization of zonula occludens 1 (ZO-1). 
Adherent junctions suffer a “cadherin switch”, that is, E-cadherin is down-
regulated, cleaved at the plasma membrane and degraded whereas N-cadherin 
expression is upregulated. EMT is also accompanied by desmosomes and gap 
disruption, being the later accompanied by a decrease in connexins levels 
(Lamouille et al., 2014). 
Another important event during EMT process is the re-organization of the 
actin cytoskeleton. This process enables cells to change their shape, and favors 
the formation of membrane projections that facilitate cell movement and 
invasion. Progressive alterations in cell morphology are accompanied by 
reorganization of actin filaments from thin cortical bundles in epithelial cells to 
thick and contractile bundles, actin stress fibers, that facilitate contractility in 
mesenchymal cells (Haynes et al., 2011; Lamouille et al., 2014; Yilmaz and 
Christofori, 2009). 
The intermediate filament composition also changes during the EMT 
process with a repression of cytokeratin and an activation of vimentin 
(Lamouille et al., 2014).   
In addition to these alterations, an increase in the expression of MMPs takes 
places. MMPs collaborate in ECM degradation, facilitating the invasion process. 
MMPS contribute to the loss of adherent junctions, targeting some 
transmembrane proteins, and more strikingly, some of them can induce the 
EMT program by inducing signaling molecules like the GTPase RAC1 that in turn 
leads to Snail activation (Lamouille et al., 2014). 
As previously mentioned, cells that have undergone EMT acquire resistance 
to senescence and apoptosis, which will be relevant to tumor progression 
(Brabletz et al., 2018). Different studies have associated resistance to TGF-β-
induced cell death with an EMT induction (Gal et al., 2008; Valdes et al., 2002) 
and others have demonstrated that some EMT-TF confer resistance to cell death 
(Snail and Twist) (Vega et al., 2004). EMT and cellular senescence are two 
processes that seem to cross paths, sharing transcription factors. In fact, some 
EMT-TFs prevent cells to undergo cellular senescence (Ansieau et al., 2008; 
Puisieux et al., 2014; Smit and Peeper, 2010).  
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Figure 7. General features of epithelial to mesenchymal transition. The transition of 
epithelial cells towards a mesenchymal phenotype, induced by several factors such as TGF-β, 
is characterized by the loss of junctions and apical-basal polarity and reorganization of 
cytoskeleton. These changes disrupt the epithelial architecture and mesenchymal cells 
acquire migratory and invasive competences. EMT is orchestrated by specific transcriptions 
factors (Snail1/2, Zeb1/2, Twist1/2) that modulate well-known markers such as E-cadherin, 
claudins or cytokeratin. The acquisition of mesenchymal markers sustains and stabilizes the 
newly acquired phenotype. Adapted from Morandi et al., 2017. 
 
 
3.3. Physiological and pathological activities of TGF-β in the liver 
In general, TGF-β regulates cell proliferation, migration and differentiation 
during embryonic development and has an essential role in maintaining tissue 
homeostasis. In the liver, TGF-β dosage and spatiotemporal activity is involved 
in different aspects of hepatogenesis, controlling gene expression and 
determining the differentiation of hepatoblasts to hepatocytes or 
cholangiocytes. Moreover, TGF-β regulates liver architecture and biliary 
morphogenesis (Karkampouna et al., 2012). Contrary to these beneficial 
activities, TGF-β is one of the main orchestrators of liver fibrogenesis and 
hepatocarcinogenesis processes upon liver injury. 
 
3.3.1. TGF-β in liver fibrosis 
After liver damage, active TGF-β levels increase, being the non-parenchymal 
liver cells, principally macrophages and HSCs, the main sources of TGF-β. 
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Moreover, hepatocytes appear to acquire and store latent TGF-β in the 
cytoplasm, that could be activated and released upon damage, providing a 
source of active cytokine. Active TGF-β plays important roles on different 
hepatic cell populations, therefore contributing to critical events from the initial 
liver injury to the final stages of CLD (Dooley and ten Dijke, 2012). 
Among the hepatic cell population, HSCs are the main target for TGF-β 
action during CLD; TGF-β induces the trans-differentiation of HSCs into MFB 
while promoting their proliferation. MFB play a key role in hepatic fibrosis since 
they are the principal cell type responsible for production of an excess of ECM 
proteins (Dewidar et al., 2015; Dooley and ten Dijke, 2012). 
TGF-β induces growth arrest and apoptosis in hepatocytes, events 
considered critical for hepatic fibrosis. It is important to mention that cytostatic 
properties of TGF-β are key during hepatocyte liver regeneration since they 
mark the end of the regenerative process (Karkampouna et al., 2012). In relation 
to this, our group has shown that low doses of TGF-β inhibit fetal hepatocyte 
growth whereas higher doses result in an apoptotic cell death (Sanchez et al., 
1995). TGF-β-induced apoptosis is associated with an induction of ROS that 
results in loss of mitochondrial transmembrane potential that leads to the 
release of cytochrome c, and subsequently, the activation of caspase-3. 
Upregulation of NOX4 by TGF-β is required for ROS induction and therefore, for 
its pro-apoptotic activity in fetal hepatocytes (Carmona-Cuenca et al., 2008; 
Herrera et al., 2001; Sanchez et al., 1996). It has also been suggested that 
oxidative stress mediates the progression of fibrosis, ROS acting as mediators of 
molecular and cellular events implicated in liver fibrosis. In fact, there are 
evidences sustaining critical roles for members of the NOX family, upon 
activation by TGF-β, both in hepatocyte apoptosis (NOX4) and HSC activation 
and proliferation (NOX1,4) during the fibrotic process (Crosas-Molist and 
Fabregat, 2015; Sanchez-Valle et al., 2012).  
Controversy exists regarding hepatocyte EMT as a source of MFB (Dooley et 
al., 2008; Herbst et al., 1997; Nitta et al., 2008; Wells, 2008; Zeisberg et al., 
2007). Our group has demonstrated that fetal hepatocytes undergo an EMT in 
response to TGF-β. After EMT, hepatocytes acquire progenitor markers and 
properties and become resistant to apoptosis (del Castillo et al., 2008a; Del 
Castillo et al., 2006; Pagan et al., 1999). However, if adult hepatocytes suffer an 
EMT process in response to TGF-β is still not clear, with some in vitro studies in 
favor of this hypothesis (Meyer et al., 2013) and others against it (Caja et al., 
2007). Despite these discrepancies, EMT seems to be key in the development of 
liver fibrosis. 
Additional potential targets of TGF-β in liver fibrosis are HPCs/oval cells. It 
has been reported that TGF-β induces apoptosis and inhibits proliferation of 
HPCs/oval cells in mouse models of liver damage (Park and Suh, 1999; 
Thenappan et al., 2010). Additionally, in vitro studies of our group reveal that 
TGF-β induces cell growth arrest and apoptosis in HPCs/oval cells by a 
mitochondrial apoptotic program associated with induction of oxidative stress. 
Similar to what was observed in hepatocytes, TGF-β induces disruption of 
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Figure 8. TGF-β effects on different hepatic cells population during liver fibrosis/cirrhosis. 
TGF-β plays important roles during CLD by acting on different hepatic cell populations. TGF-β 
induces the transdifferentation process of HSC to MFB, the main cell responsible for fibrosis. 
Additionally, TGF-β induces growth arrest and apoptosis in hepatocytes, critical for hepatic 
fibrosis. More controversial is that hepatocyte EMT could be another source of MFB. TGF-β 
could also participate in liver fibrosis targeting HPCs/oval cells. TGF-β induces apoptosis and 
inhibits proliferation of HPCs/oval cells. HPCs/oval cells could suffer EMT in response to TGF-β 
becoming MFB.  
mitochondrial transmembrane potential and increases the expression of pro-
apoptotic BCL-2 proteins, such as BCL-2 modifying factor (BMF) and BCL-2-like-
11 (BIM). These events are related to an oxidative stress process, which also 
involves increase in NOX4 expression and decrease in antioxidant enzymes 
protein levels (del Castillo et al., 2008b; Martinez-Palacian et al., 2013). 
Interestingly, it has been described that hepatocytes are more sensitive to TGF-
β-induced apoptosis than HPCs/oval cells, fact that allows this population to 
proliferate and repair the liver damage in a situation in which hepatocyte 
proliferation is blocked (Karkampouna et al., 2012; Nguyen et al., 2007). Besides 
the apoptotic effect of TGF-β in HPCs/oval cells, some authors have reported an 
induction of ECM genes and HSC markers in HPCs/oval cells in culture upon TGF-
β treatment, suggesting these cells might be an origin of HSC via EMT, becoming 
another source of MFB and so contributing to liver fibrosis (Wang et al., 2009).  
 Based on the key roles played by TGF-β in the pathogenesis of liver fibrosis 
and cirrhosis, different therapeutic strategies targeting TGF-β signaling have 
been proposed to treat these diseases, including anti-sense oligonucleotides, 
blocking antibodies, soluble receptors that bind the ligand and block ligand-
receptor binding or overexpression of I-SMADs (Smad7) among others. Anti 
TGF-β therapies have successful results in experimental models. However, 
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unfortunately these results have not been translated to humans, which might 
be a consequence of the multiple and cell- and context-dependent TGF-β 
functions (Cheng and Wong, 2017; Dooley and ten Dijke, 2012). Clearly, a better 
understanding of the TGF-β participation in CLDs is needed in order to develop 
efficient treatments in humans. 
 
3.3.2. TGF-β in HCC 
It is widely recognized that TGF-β has critical roles in tumor initiation, 
development and metastasis in several cancer types. Strikingly, TGF-β switches 
from a potent cytostatic and pro-apoptotic effect in normal epithelial cells to a 
tumor promoter activity at the late stages of the disease, phenomenon that is 
known as the “TGF-β paradox” (Seoane and Gomis, 2017; Siegel and Massague, 
2003). 
Accumulating mutations in components of the TGF-β pathway or selective 
impairment of the growth inhibitory response are some of the strategies 
developed in tumor cells to bypass the TGF-β suppressor activities (Seoane and 
Gomis, 2017). In HCC, mutations or alterations in Smad proteins or TGF-β 
receptors are not very frequent. However, TGF-β upregulation is found in a large 
number of HCC patients, and in contexts where the canonical pathway is 
blocked, TGF-β can still signal via non-canonical pathways (Fabregat et al., 
2016b). Alternative mechanisms to escape from TGF-β suppressor effects in HCC 
cells are: i) expression of specific miRNAs that allow them to escape from TGF-β-
induced apoptosis (Huang and He, 2011); ii) epigenetic silencing in genes 
encoding TGF-β pathway components (Seoane and Gomis, 2017); iii) over-
activation of growth factors that trigger survival signaling pathways 
(MAPK/ERKs, PI3K/AKT or NF-KB) (Colak and Ten Dijke, 2017; Fabregat et al., 
2016b; Huang et al., 2018).  
It has been also demonstrated that tumor cells that overcome TGF-β-
induced growth arrest/apoptosis undergo EMT in response to TGF-β. Acquisition 
of mesenchymal properties confers stemness, invasiveness and motility to 
tumor cells, properties that strongly influence their metastatic capacity. 
Therefore, tumor cells invade the surrounding environment being able to 
colonize distant sites and disseminate the disease (Seoane and Gomis, 2017). 
TGF-β pathway also exerts its pro-tumorigenic effects by remodeling tumor 
microenvironment. Accumulating evidence has demonstrated that immune 
microenvironment plays crucial roles in the development of HCC and that TGF-β 
generate a favorable microenvironment for tumor growth and metastasis. TGF-
β has immunosuppressive effects on innate and adaptive immune cells and also 
affects cytokine production by tumor cells (Colak and Ten Dijke, 2017; Shen et 
al., 2015; Yang et al., 2010). Another important aspect of the HCC 
microenvironment is its strong angiogenic activity, which seems to be induced 
by TGF-β (Colak and Ten Dijke, 2017; Mazzocca et al., 2009). TGF-β is also able 
to differentiate stromal mesenchymal cells into MFB that secrete ECM proteins 
and fibrotic growth factors to support tumor growth. Besides, TGF-β induces an 
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Figure 9. Regulation of non-cancerous cells and tumor microenvironment cells by TGF-β. 
TGF-β is expressed by tumor cells and stromal cells, including cancer-associated fibroblasts. 
TGF-β in normal cells induces cell-cycle arrest and/or apoptosis. However, tumor cells escape 
from these effects and undergo EMT in response to TGF-β. EMT is thought to foster tumor cell 
migration and invasion and plays an important role in conferring therapy resistance. TGF-β can 
also contribute to tumor progression by stimulating immune evasion and promoting 
angiogenesis. Adapted from Colak and Ten Dijke, 2017.  
endothelial to mesenchymal transition towards tumor-facilitating fibroblast-like 
cells in endothelial cells (Colak and Ten Dijke, 2017).  
Just like in the case of liver fibrosis, the pivotal role played by TGF-β during 
HCC development make it a promising target to develop new therapies. Similar 
strategies to those mentioned before have been develop to inhibit TGF-β 
pathway in cancer: antisense oligonucleotide, blocking antibodies and ligand 
traps, TβRII and/or ALK5 inhibitors, in addition to immune response-based 
strategies and other inhibitors of the TGF-β pathway (Fabregat et al., 2014). As 
an example, ongoing clinical trials evaluating galunisertib, a TβRI kinase inhibitor 
factor, has shown promising results in HCC patients. Nevertheless, further 
advances in HCC therapies targeting TGF-β signaling require a better 
understanding of the disease, and more particularly, the diverse functions of 
TGF-β in the hepatic cell populations (Giannelli et al., 2016; Neuzillet et al., 
2015). 
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4. Hepatocyte growth factor (HGF)/Met 
4.1. Signaling pathway  
HGF was discovered as a strong mitogen for hepatocytes (Miyazawa et al., 
1989; Nakamura, 1989). It is also known as Scatter Factor (SF), since a fibroblast-
derived cell motility factor for epithelial cells that was identified independently 
(Stoker et al., 1987)  was later found to be the same factor as HGF (Naldini et al., 
1991). 
HGF is produced and secreted primarily by stromal and mesenchymal cells 
(fibroblasts, macrophages, smooth muscle cells, among others) but acts mainly 
on epithelial cells, where its receptor Met is expressed, therefore acting in a 
paracrine fashion (Zarnegar, 1995). Some cells show an autocrine HGF/Met 
signaling, at least in certain contexts, expressing both the ligand and its 
receptor, as it is the case in HPCs/oval cells (del Castillo et al., 2008b). 
Additionally, Met is not only expressed in epithelial cells, but also in other cell 
types including vascular endothelial cells, lymphatic endothelial cells, neural 
cells, hematopoietic cells and pericytes (You and McDonald, 2008).  
HGF is secreted as an inactive single-chain peptide that is cleaved by 
proteases to generate an active heterodimer with two chains, α- and β-chains, 
held together by a disulphide bond. The α-chain is formed by an amino-terminal 
hairpin loop (HL) and four kringle domains (K1-K4, amino acid double-looped 
structures formed by three internal disulphide bridges. β-chain is a serine 
protease homology domain without proteolytic activity (Nakamura and Mizuno, 
2010; Trusolino et al., 2010). 
HGF triggers its signaling pathway by binding to its tyrosine kinase receptor 
Met. Met receptor is a heterodimer, consisting of an extracellular α-subunit and 
a transmembrane β-subunit, disulphide-linked. The entire α-subunit forms a 
semaphorin domain and is associated with the extracellular region of the β-
subunit, which is formed by a semaphorin domain (SEMA), a plexin- 
semaphorin-integrin (PSI) cysteine‑rich domain (also present in semaphorins 
and plexins), and four immunoglobulin-like domains shared by plexins and 
transcriptional factors (IPT) . The intracellular part of the β-subunit is composed 
by a juxtamembrane region, an intracellular tyrosine kinase domain (catalytic 
region) and a C-terminal tail (Kato, 2017; Trusolino et al., 2010). 
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Figure 10. Domain structures of Met and 
HGF. a) HGF is an α- and β-chain 
heterodimer. HGF consists of six domains: 
an amino-terminal hairpin loop (HL), four 
Kringle domains (K1-k4, amino acid 
double-looped structures formed by three 
internal disulphide bridges) and a serine 
protease homology (SPH) domain. b) MET 
receptor is a disulphide-linked 
heterodimer formed by an extracellular α-
subunit and a transmembrane β-subunit. 
The extracellular region of Met is 
composed of three domains: the Sema 
domain that includes the entire α-chain 
and part of the β-chain; the PSI domain 
and four IPT domains. The intracellular 
region is formed by a juxtamembrane 
sequence, a catalytic region and a 
carboxy-terminal multifunctional docking 
site. This portion of Met contains the 
catalytic tyrosines (Tyr1234 and Tyr1235) 
and the Tyr1003 that negatively regulates 
Met. The Tyr1349 and Tyr1356 recruit 
several transducers and adaptors after 
Met activation. Adapted from Trusolino et 
al., 2010. 
 
When HGF binds to the SEMA domain of Met receptor, two molecules of 
the receptor homodimerize and the intracellular tyrosine kinase domains of the 
two β-subunits trans-phosphorylate each other at tyrosine residues (Tyr1234 
and Tyr1235) in the catalytic loops. Subsequently, tyrosines 1349 and 1356 in 
the carboxy-terminal tail become phosphorylated. These two tyrosines form a 
tandem SH2 recognition motif (multifunctional docking site) that acts recruiting 
signaling molecules (Organ and Tsao, 2011; Trusolino et al., 2010). 
Upon ligand binding, numerous signaling adaptors and signaling effectors 
are recruited to activated Met receptor. Among adaptors proteins we find 
growth factor receptor bound protein 2 (GRB2), the non-receptor tyrosine 
kinase (Src), v-crk sarcoma virus CT10 oncogene homolog (CRK), and the SH2 
domain-containing transforming protein (SHC). Moreover, Met biological 
activity is principally due to the recruitment and phosphorylation of the scaffold 
protein GRB2-associated binding protein 1 (GAB1) to activated Met receptor, 
providing binding sites for additional downstream adaptors or signaling 
molecules. Interestingly, GAB1 binds to Met directly or indirectly through GRB2 
(Gherardi et al., 2012; Organ and Tsao, 2011). 
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Figure 11. HGF/Met signaling pathway. 
Binding HGF to Met initiates receptor 
activation, dimerization and trans-
phosphorilation of the Tyr1234 and 
Tyr1235. This results in the 
phosphorylation of the tyrosines in the 
multifunctional docking site (Tyr1349 and 
Tyr1356). They recruit signaling effectors 
and adaptor proteins that lead to the 
activation of signaling pathways including 
ERK/MAPK, PI3K, JNK, p38, NF-κB, STAT3, 
PLCγ and FAK pathways, which mediate 
HGF/Met biological effects. Adapted from 
Organ and Tsao, 2011. 
 
Different signaling pathways mediate the downstream response to Met 
activation. The two major pathways downstream of Met are the ERK/MAPK and 
PI3K/Akt. Activation of ERK/MAPK occurs through the SHC/GRB2/SOS/RAS/RAF 
pathway or via GAB1/Src homology 2 domain-containing phosphatase (SHP2). 
MAPK pathway activation results in the regulation of transcription factors that 
control the expression of genes related to cell proliferation and cell cycle 
progression and/or cell motility. Regarding PI3K/Akt pathway, the p85 subunit 
of PI3K binds to Met directly or indirectly through GAB1. This signaling pathway 
is responsible for Met-driven cell survival response. Other signaling pathways 
are: i) STAT3. STAT3 binds directly to Met, becomes phosphorylated, dimerizes 
and translocates to the nucleus. This signaling pathway has been implicated in 
tubulogenesis and invasion, although contradictory data has been reported in 
this respect. ii) JNK and p38. These pathways are stimulated by RAC GTPase, 
which is switched on by PI3K/RAS. JNK and p38 control differentiation, 
transformation, proliferation and apoptosis. iii) Focal adhesion kinase (FAK). FAK 
is activated through Src and has been related to cellular migration and 
anchorage-independent growth. iv) NF-κB. Met activation leads to the release 
of NF-κB through PI3K/Akt- and Src- dependent pathways. Once in the nucleus, 
stimulates the transcription of genes related with mitogenic and anti-apoptotic 
functions. v) Phospholipase Cγ (PLCγ). PLCγ binds directly to Met or indirectly 
through GAB1 and participates in the morphogenesis activity of Met (Gherardi 
et al., 2012; Kim and Salgia, 2009; Organ and Tsao, 2011; Trusolino et al., 2010). 
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HGF/Met signaling pathway is regulated at different levels. Thus, Met 
downstream signaling can be modulated, potentiated or inhibited through 
cross-talk with different membrane receptors such as plexins, integrins (α6β4), 
semaphorins, CD44 family members, intercellular adhesion molecule 1 (ICAM1), 
mucins, death receptors (Fas), and other tyrosine kinase receptors (EGFR, Her2) 
(Giordano and Columbano, 2014; Trusolino et al., 2010; Viticchie and Muller, 
2015), thus creating complex interacting networks that can operate in different 
ways. 
Additionally, Met is rapidly internalized by endocytosis and recycled back to 
the plasma membrane or degraded by lysosomal pathway. Phosphorylation of 
Tyr1003 at the juxtamembrane domain facilitates the recruitment of the E3 
ubiquitin ligase casitas B-lineage lymphoma (c-CBL) after internalization, 
therefore leading to Met ubiquitination and degradation (Parikh and Ghate, 
2018). However, Met continues signaling from endosomal compartments. Thus, 
the compartmentalization of the receptor in endocytic vesicles is required for 
the full activation of signals such as GAB1, ERK, STAT3 and RAC1 (Barrow-McGee 
and Kermorgant, 2014; Kermorgant and Parker, 2005). Phosphorylation of 
Ser985 in the juxtamembrane domain also inhibits the phosphorylation and 
activation of Met. Besides, tyrosine phosphatases such as protein-tyrosine 
phosphatase 1B (PTP1B) can attenuate Met signaling (Parikh and Ghate, 2018).  
 
4.2. Physiological and pathological activities of HGF/Met in the liver 
HGF/Met is essential for liver development. Homozygous null mice for both 
Met and HGF fail to complete the developmental process and die in utero due 
to impaired organogenesis of the placenta, the skeletal muscles of the limb and 
diaphragm, and the liver (Bladt et al., 1995; Schmidt et al., 1995; Uehara et al., 
1995). HGF/Met plays important roles in the migration of myogenic precursor 
cells and in epithelial morphogenesis through its mitogenic, motogenic, 
morphogenic and anti-apoptotic activities. The impaired development of the 
embryonic liver in Met or HGF knockout mice is known to be due to the 
submassive apoptosis of hepatoblasts (Fausto et al., 1995; Nakamura et al., 
2011; Stoker et al., 1987). 
 
4.2.1. HGF/Met in liver regeneration 
Despite the key roles exerted by HGF in developmental liver, selective 
ablation of Met in adult mouse livers seems not to be detrimental to hepatocyte 
function under physiological conditions. However, these conditional knockout 
models have demonstrated that the lack of Met dramatically affects the 
reparative responses of the liver against injury (Huh et al., 2004). 
 
Hepatocytes lacking a functional Met receptor display an augmented 
sensitivity to Fas-induced apoptosis which might be explained by the defects in 
the redox regulation and the lack of survival signaling pathway triggered by 
HGF/Met (Gomez-Quiroz et al., 2008; Huh et al., 2004). Liver specific Met 
knockout mice show delayed liver regeneration after partial hepatectomy. In 
this context, a decrease in mitotic hepatocytes due to a lack of ERK1/2 
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activation is observed in association with a persistent inflammatory reaction 
(Borowiak et al., 2004; Factor et al., 2010).  
However, HGF/Met is not only important during hepatocyte-mediated 
regeneration, it is also essential for liver regeneration associated with HPC/oval 
cell-expansion. Thus, in liver-specific Met knockout mice, HPC/oval cell-
mediated regenerative response after liver injury is abolished, which is 
associated with alteration in HPC/oval cell proliferation, survival, differentiation, 
migration and stemness capacities (Ishikawa et al., 2012). Moreover, other in 
vivo studies show that the increase in the expression of HGF accelerates 
proliferation of HPCs/oval cells in a damaged liver (Shiota et al., 2000). Our 
group and others have analyzed the effects of HGF/Met on HPCs/oval cells in 
vitro. We have demonstrated that HGF has a mitogenic activity while promotes 
invasion and migration and a morphogenic response in HPCs/oval cells (del 
Castillo et al., 2008b; Okano et al., 2003; Suarez-Causado et al., 2015; Yao et al., 
2004). Furthermore, HGF/Met protects HPCs/oval cells from TGF-β-induced 
apoptotic death (Martinez-Palacian et al., 2013). These results indicate a unique 
role for HGF/Met in regulation of HPCs/oval cells biology that is critical for their 
function during liver regeneration. 
Furthermore, liver specific Met knockout mice are more susceptible to 
chronic inflammation and liver fibrosis (Giebeler et al., 2009; Marquardt et al., 
2012). HGF/Met exerts its hepatoprotective effect against fibrosis by different 
mechanisms. On the one hand, HGF/Met opposes to TGF-β pro-fibrotic activity 
at different levels. It reduces the expression of TGF-β, impairs TGF-β-mediated 
hepatocyte apoptosis and TGF-β-dependent transcriptional activity (Inagaki et 
al., 2008; Ueki et al., 1999), induces MMPs expression, which is believed to 
contribute to the resolution of liver fibrosis (Kanemura et al., 2008), and blocks 
TGF-β-induced EMT on biliary epithelial cells, one of the process that might 
contribute to MFB generation (Xia et al., 2006). HGF anti-fibrotic activity also 
relies on the induction of collagenase expression (Matsuda et al., 1997; Ozaki et 
al., 2002) and a strong cytostatic effect on activated HSCs (Kim et al., 2005; Li et 
al., 2008).  
All of these findings set the basis to propose HGF/Met as a therapeutic 
target for the development of new anti-fibrotic and pro-regenerative liver 
treatments. 
 
4.2.2. HGF/Met in HCC 
As mentioned previously, HCC is a heterogeneous disease and the 
pathogenic mechanisms are still not clear. Dysregulation of HGF/Met signaling 
pathway has been associated with tumor onset but mainly tumor progression 
since this pathway can promote tumor growth, invasion, metastasis and 
angiogenesis (Giordano and Columbano, 2014). Contrarily, some works describe 
HGF/Met signaling as a tumor suppressor (Takami et al., 2007), highlighting the 
need to clarify the importance of HGF/Met in this context. 
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Met aberrations occur in approximately 50% of patients with HCC and can 
arise through gene mutation (4%), gene amplification (24%), increased mRNA 
expression (50%) and receptor overexpression (28%). Constitutively activating 
mutations in the kinase domain are rare in HCC. It is more frequent to find Met 
overexpression driving independent dimerization and activation. In other 
setting, abnormal high HGF levels also resulted in aberrant Met activity 
(Bouattour et al., 2018). In terms of the status and role of Met and HGF in liver 
cancer there are controversial results. While most of the studies show a 
decrease in HGF expression, there are disagreements on the percentage of liver 
tumor showing Met overexpression, and not only that, some works reveal 
opposite results, that is, a downregulation of Met in HCC (Giordano and 
Columbano, 2014). The prognostic utility of Met and HGF overexpression is also 
uncertain. While some works have not found any correlation between Met 
overexpression and tumor size, proliferation or invasive behavior (Boix et al., 
1994; Okano et al., 1999), others have related Met overexpression with poorly 
differentiated HCC, increased metastasis and angiogenesis, early tumor 
recurrence and shorter survival (Daveau et al., 2003; Kim et al., 2017b; Ueki et 
al., 1997; Xie et al., 2001). The discrepancies could be consequence of the 
different techniques used to determine the levels of Met, the size and diversity 
of the group of patients included in the study with different tumor origins, or 
lack of data on Met activation. Indeed, the analysis of Met activation is 
important to classify the cluster of patients that would be sensitive to therapy 
with Met inhibitors (Giordano and Columbano, 2014; Venepalli and Goff, 2013). 
In order to clarify the role of HGF/Met in HCC a number of in vitro and in 
vivo analyses have been performed, but unfortunately, findings are not 
conclusive. Thus, some early works described that HGF inhibits growth in most 
of HCC cell lines while exerts a pro-invasive action (Shiota et al., 1992; Tajima et 
al., 1991). Noticeably, the intracellular mechanisms triggered by HGF to impair 
HCC cell growth are not known. In later studies, inhibition or downregulation of 
Met interferes with both cell growth and invasion. Numerous studies show that 
Met overexpression promote HCC cell invasion and relate it to the ability of 
HGF/Met to induce EMT (Salvi et al., 2007; Xie et al., 2010) . Thus, HCC cells lines 
with high Met levels display a mesenchymal phenotype and markers (Ogunwobi 
and Liu, 2011; You et al., 2011).  
Unfortunately, in vivo studies are not much more clarifying. A number of 
laboratories have analyzed the effects of inactivating or overexpressing Met 
and/or HGF on HCC, but the results are discordant. Both stimulatory and 
inhibitory effects on liver tumor formation have been described after exogenous 
administration of HGF on rat models of carcinogen-induced HCC (Liu et al., 
1995; Ogasawara et al., 1998). Likewise, results from HGF transgenic mice 
showed either a pro-tumorigenic role of HGF or an inability to form HCC (Sakata 
et al., 1996; Santoni-Rugiu et al., 1996). The same variability is observed with 
Met receptor. Loss of Met in hepatocytes led to bigger tumors with shorter 
latency compared to controls in an experimental model of HCC. On the contrary, 
transgenic mouse models of MET overexpression in liver spontaneously 
generate liver tumors (Fan et al., 2017; Wang et al., 2001). The scenario is 
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complex and suggest that a fine balance of HGF/Met signaling is nessary for liver 
homeostasis. 
Despite the controversy, based on evidence supporting a pro-tumorigenic 
role of HGF/Met in liver, HGF/Met axis has emerged as a therapeutic target in 
HCC. Nevertheless, the uncertain results indicate the necessity of further studies 
in order to select those patients with HGF/Met-dependent tumors for whom 
developing therapies could be effective. Indeed, inhibitors of Met/HGF signaling 
have demonstrated signs of efficacy against Met-positive HCCs. HGF neutralizing 
antibodies, HGF antagonists and Met tyrosine kinase inhibitors are utilized to 
inhibit Met in the clinic. Recently, the HGF/Met inhibitor cabozantinib has been 
approved for patients with HCC previously treated with sorafenib; and to date, 
other five HGF/Met inhibitors have been investigated in clinical trials in HCC. 
Tivantinib is in phase III studies and others such as capmatinib are being 
investigated in phase II (Bouattour et al., 2018; Zhang et al., 2018). 
 
5.  Senescence 
Cellular senescence is defined as a long-term cell cycle arrest despite 
continued viability and metabolic activity (Kuilman et al., 2010). Senescence 
plays both beneficial and detrimental roles in the organism. Excessive 
accumulation of senescent cells and the inability to eliminate them can affect 
regenerative capacity and create a pro-inflammatory environment that favors 
the progression of some diseases, including cancer (Hernandez-Segura et al., 
2018). On the contrary, transient induction of this program followed by tissue 
remodeling contribute to eliminate damaged cells, and due to the cell cycle 
arrest works as a barrier against cancer progression (Munoz-Espin and Serrano, 
2014). 
In vitro cell senescence can be induced by different stimuli such as 
progressive shortening of telomeres (replicative senescence) but it can be also 
activated in the absence of detectable telomere loss or dysfunction by 
different conditions such as DNA-damage, oncogene signals, oxidative stress, 
mitochondrial dysfunction and epigenetic changes, among others. If these 
“types of senescence” occur in vivo is not clear (Hernandez-Segura et al., 2018; 
Kuilman et al., 2010; Munoz-Espin and Serrano, 2014). 
Mechanisms that ultimately lead to senescence depend on the cell type, 
conditions and stimuli. In general, many of the intracellular pathways driving 
senescence modulate p53, CKI such as p16 (cdkn2a), p15 (cdkn2b), p19 (ARF, 
cdkn2d)/p14 in humans, p21 (cdkn1a) and p27 (cdkn1b). Subsequently, hypo-
phosphorylated RB accumulates, a crucial event in senescence, that in turn 
results in proliferative growth arrest (Munoz-Espin and Serrano, 2014). In 
human cells, p53 can induce senescence through a pathway independent of the 
RB family (Smogorzewska and de Lange, 2002). 
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5.1. Biomarkers 
The identification of senescent cells is not an easy work. Many of the 
senescence-associated molecular and morphological features are present in 
other cellular states and the process is quite heterogeneous and dynamic 
(Hernandez-Segura et al., 2018). In spite of the complexity of the program, a 
panel of markers and hallmarks is often used to detect senescence in cultured 
cells and in tissue samples (Hernandez-Segura et al., 2018; Kuilman et al., 2010; 
Munoz-Espin and Serrano, 2014). 
 
- In vitro senescent cells usually undergo evident morphological 
changes. Cells become large, flat, vacuolized and sometimes, 
multinuclear. Contrarily, senescent cells in vivo maintain their normal 
morphology. 
- Histochemical detection of β-galactosidase activity at pH 6.0, 
commonly referred to as senescence-associated β-galactosidase (SA-
β-GAL). Its increased activity in senescent cells derives from lysosomal 
β-D-galactosidase and is due to an expansion of the lysosomal 
compartment giving rise to an increase in β-galactosidase activity that 
can be measured at suboptimal pH 6.0.  
- Lack of proliferative markers (Ki67, 5-bromodeoxyuridine) 
incorporation) and presence of common mediators of senescence: 
p16, p19, p53, p21, p15, p27 and hypo-phosphorylated RB. 
- Senescence-associated heterochromatic foci (SAHF). Cellular 
senescence can be associated with an altered chromatin structure, at 
least in vitro. Senescent cells show different heterochromatin 
patterns, but DNA SAHFs are enriched in repressive epigenetic 
markers.   
- Senescence-associated secretory phenotype (SASP). Senescent cells 
secrete numerous factors that include TGF-β, IGF-I, inflammatory 
cytokines and chemokines that can reinforce and propagate 
senescence in an autocrine and paracrine manner. 
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Figure 12. Overview of senescence biomarkers. Senescence program can be activated by 
different stress stimuli such as oxidative stress, oncogenic signaling, ionizing radiation and 
replicative stress (due to deficiencies in the DNA replication machinery or maintenance of cell 
cycle checkpoints). Hallmarks of senescent cells include an irreversible cell cycle arrest, 
secretion of growth factors, cytokines among others (SASPs factors), expansion of the 
lysosomal compartment and SA-β-GAL expression, and rearrangement of the chromatin 
landscape (SAHFs). Adapted from Gonzalez-Meljem et al., 2018. 
 
5.2. Physiological and pathological senescence 
Generally, senescence process has been related to cellular damage or 
stress. However, cells with senescence features are found in embryonic 
structures where might play a role in organogenesis. Although these cells 
express SA-β-GAL, they do not present other characteristics found in stress-
induced senescence. Thus, there is no relation with DNA damage; p53 and p16 
are not usually found in these cells and SASP is not present. Evidences suggest 
that this type of senescence process relies on p21. In addition to embryonic 
development, senescence also takes part in maturation programs in adult cells 
(He and Sharpless, 2017). 
In liver diseases, senescence may occur in different cell populations as part 
of the pathogenic mechanism.  
Senescence in activated HSCs during liver fibrosis can block their 
proliferation, inhibit their activation, reduce ECM secretion and enhance 
immune surveillance (Guo, 2017; Krizhanovsky et al., 2008). Some growth factor 
and cytokines induce senescence in this hepatic cell population during liver 
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fibrosis/cirrhosis: IL-22, through the activation of STAT3; cysteine-rich 
angiogenic inducer 61, a non-structural protein of the extracellular matrix 
whose expression is induced upon injury; GATA6 and IGF-I. Mechanism of HSC 
senescence may involve upregulation of p53, p16, p21 and p27 (Guo, 2017; 
Kong et al., 2012; Krizhanovsky et al., 2008; Panebianco et al., 2017). In this way, 
induction of HSC senescence could constitute a therapeutic approach against 
liver fibrosis.  
Immune cells also suffer the senescence process in patients with CLD. 
Accelerated telomere shortening in peripheral lymphocytes has been 
demonstrated in chronic viral hepatitis and cirrhosis (Guo, 2017). 
Senescence in parenchymal cells, hepatocytes and cholangiocytes, has been 
observed in chronic human liver disorders and has been demonstrated in animal 
models of liver disease (Wiemann et al., 2002; Yang et al., 2004). The 
mechanism driving senescence in these cells during liver disease remains 
undefined. Replicative senescence or telomeric and non-telomeric DNA damage 
by oxidative stress have been proposed as origin of these senescent cells, 
although a combination of mechanisms is more likely (Aravinthan and 
Alexander, 2016). The accumulation of senescent cells influence disease 
progression through an impact on the microenvironment and tissue 
homeostasis. Hepatocyte senescence is a way of limiting tissue injury during 
normal wound healing process. The recruitment of immune cells for clearance 
of cell debris and senescent cells also contributes to successful wound healing 
outcome. However, sustained liver insult, which continuously generate 
senescent cells, together with immune cell senescence found in patients with 
CLD, which avoids the clearance of senescent cells, contribute to senescent cells 
accumulation.  Additionally, animal models reveal that the accumulation of 
senescent hepatocytes leads to continuous activation of HSC and fibrosis 
progression. Although increased senescent cholangiocytes during CLD has also 
been demonstrated, it is not clear whether senescent cholangiocytes induce 
HSC activation or rather cholangiocyte senescence and HSC activation are 
parallel consequences of biliary injury. On the other hand, senescent 
hepatocytes undergo major metabolic changes such as alterations in the 
transport of bilirubin and acquisition of insulin resistance that lead to a decline 
in hepatocellular function (Aravinthan and Alexander, 2016). 
Interestingly, SASP factors have both beneficial and detrimental effects. 
SASP factors reinforce the senescent state in an autocrine manner and induce 
senescence in neighboring normal hepatocytes, a phenomenon known as 
senescence-induced-senescence. Additionally, these factors promote 
inflammation, which aids in clearance of senescent cells and cell debris, thus 
favoring tissue repair and remodeling (Aravinthan and Alexander, 2016).  
SASP factors may also promote tumorigenesis in neighboring cells. 
Accumulation of senescent cells during CLD results in a SASP-rich 
microenvironment, which promotes tumorigenesis in DNA-damaged, pre-
senescent hepatocytes (Aravinthan and Alexander, 2016; Coppe et al., 2010; 
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Davalos et al., 2010). Related with this, escape of hepatocytes from senescent 
process is consider a primary mechanism involved in HCC development, as 
demonstrated by gene expression analysis of cirrhosis and HCC. Therefore, a 
potential therapeutic strategy could be induction of senescence in HCC cells, 
regulating the influence of SASP on the tumor microenvironment (Aravinthan 
and Alexander, 2016; Yildiz et al., 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
5. Background 
  
 
 
 
 
 57 
 
 
HPC/oval cell response takes places during CLD in order to restore liver 
function (Duncan et al., 2009; Tanaka et al., 2011). However, the HPC/oval cell-
associated regenerative response sometimes fails and HPCs/oval cells have 
been involved in the progression of liver fibrosis (Kuramitsu et al., 2013; 
Williams et al., 2014). Thus, the HPCs/oval cells fate and the mechanisms that 
regulate their function during the regenerative process accompanying CLDs are 
not fully understood. Dr. Sánchez´s laboratory research is focused on 
deciphering signals and mechanisms that regulate the biology and function of 
oval cells. Specifically, over the past few years, major efforts have been put into 
characterizing the relevance of the interaction between TGF-β ligands (TGF-β 
and BMP9) and two tyrosine kinase receptors, Met and EGFR, on oval cells 
regulation. 
For that purpose, oval cell lines expressing a functional (Metflx/flx) or non-
functional (Met-/-) Met receptor that lacks tyrosine kinase activity, were 
established from a Met knock-out mouse model generated in Dr. 
S.S.Thorgeirsson´s lab (Huh et al., 2004). These cell lines have become a key tool 
for the study of HGF/Met axis in oval cell control. A detailed characterization of 
this in vitro model showed that Met-/- oval cells are more sensitive to both 
serum withdrawal- and TGF-β-induced apoptosis than Metflx/flx cells (del Castillo 
et al., 2008b) (Figure 13a and b). 
The differential behavior of these two cell lines in response to apoptotic 
signals evidenced the key pro-survival activity of HGF/Met signaling pathway on 
oval cells. This anti-apoptotic effect occurs through a paracrine (Figure 13b) and 
autocrine signaling, since an active autocrine HGF/Met loop is present in oval 
cells (Figure 14a and b). 
 
Figure 13. Met−/− oval cells are more sensitive to serum withdrawal and TGF-β-induced 
apoptosis than Metflx/flx oval cells. a) Apoptotic index at different time points after serum 
withdrawal. A total of 1000 to 2000 cells were counted per dish after propidium iodide (PI) 
staining under a fluorescence microscope in a blinded manner. Solid circles, Metflx/flx oval 
cells. Open circles, Met-/- oval cells. Data are mean ± S.E.M. of at least eight experiments. ** p 
< 0.01. b) Apoptotic index in oval cells treated with TGF-β (T; 1 ng/ml) for 48 hours in the 
absence or presence of HGF (H; 20 ng/ml). Apoptotic cells were determined as in a). Black 
bars, Metflx/flx oval cells. White bars, Met-/- oval cells. Data are mean ± S.E.M. of three 
experiments. *** p < 0.001 (versus T, Metflx/flx), ++ p < 0.01 (versus T, Metflx/flx) (del Castillo et 
al., 2008b). 
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It was also shown that TGF-β apoptotic process is mediated by intracellular 
ROS production. The upregulation of Nox4 suggested both mitochondrial and 
extra-mitochondrial sources for ROS (Figure 15a and b). Consistent with an 
increased sensitivity to apoptosis, intracellular ROS content and Nox4 
expression were increased in TGF-β-treated Met-/- (Figure 15a and b) respect to 
Metflx/flx oval cells. 
Figure 14. HGF/Met autocrine loop is active in Metflx/flx oval cells. a) HGF mRNA levels 
detected by RT-PCR analysis in untreated Metflx/flx and Met-/- oval cells. Bl, Blank, no reverse 
transcription. β-actin was used for normalization. b) Kinetics of Met activation in Metflx/flx cells 
cultured in serum-free medium or conditioned serum-free medium (CM). Whole protein 
extracts were used for immunoprecipitation of Met protein. Phosphorylation was detected by 
immunoblotting with anti-P-tyrosine antibody using Met as a loading control (del Castillo et 
al., 2008b). 
Figure 15. Intracellular oxidative stress induced by TGF-β in oval cells is amplified in cells 
lacking a functional Met receptor. Metflx/flx and Met-/- oval cell lines were serum starved and 
incubated in the absence (C) or presence of 1 ng/ml TGF-β (Tβ) for different periods of time. 
a) After 30 minutes incubation with DFCH-DA (5 µM) fluorescence intensity was measured in a 
FACScan flow cytometer. Data are expressed as fold induction over untreated cells and are 
mean ± S.E.M. of three independent experiments run in duplicate. b) Nox4 mRNA levels were 
analyzed by RT-qPCR and normalized to the housekeeping gene Gusb. Data are expressed 
relative to untreated samples and are mean ± S.E.M. of at least four independent 
experiments. * p < 0.05; ** p < 0.01; *** p < 0.001 (treated versus untreated); # p < 0.05 
(treated Met-/- versus treated Metflx/flx). Black bars, Metflx/flx oval cells. White bars, Met-/- oval 
cells (Martinez-Palacian et al., 2013).  
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Importantly, oxidative stress leads to Bmf upregulation and subsequent cell 
apoptosis. Indeed, pre-treatment of Metflx/flx and Met-/- oval cells with 
antioxidant agents abolishes ROS accumulation and Bmf expression induced by 
TGF-β (Figure 16a and b). Furthermore, pharmacological inhibition of PI3K 
impaired HGF-driven protection against TGF-β-induced cell death. Together, 
these results revealed that Met-driven PI3K activity exerts a pro-survival action 
against apoptosis and oxidative stress induced by TGF-β in oval cells.  
Besides this pro-survival activity, HGF/Met axis controls other biological 
processes in oval cells. Indeed, our data showed that HGF is a proliferative 
factor (del Castillo et al., 2008b) and promotes migration and invasion in oval 
cells (Suarez-Causado et al., 2015). Thus, HGF increases the rate of DNA 
synthesis in a dose dependent fashion in Metflx/flx oval cells (del Castillo et al., 
2008b) (Figure 17a), effect that was not observed in Met-/- oval cells. 
Furthermore, we demonstrated that HGF induces collective migration and 
invasion in oval cells, which requires a remodeling of cytoskeleton and cell-cell 
contacts but not an EMT process (Figure 17b and c). HGF pro-invasive activity is 
also triggered via PI3K activation (Figure 17d) and involves MMPs induction and 
activation (Suarez-Causado et al., 2015). 
 
 
 
Figure 16. Effect of antioxidant agents on intracellular ROS content and Bmf expression in 
oval cells. a) Metflx/flx and Met-/- oval cell lines were serum starved, pre-treated or not with 
radical scavengers (1 mM ascorbate + 50 µM PDTC) for 1 hour prior to TGF-β (1 ng/ml) 
treatment for 24 hours. After 30 minutes incubation with DFCH-DA (5 µM) fluorescence 
intensity was measured in a FACScan flow cytometer. Data are expressed as fold induction 
over untreated cells and are mean ± S.E.M. of two independent experiments run in duplicate.  
b) Metflx/flx oval cell lines were pre-treated or not with radical scavengers (1 mM ascorbate + 
50 µM PDTC) for 1 hour prior to TGF-β (1 ng/ml) treatment. After 5 hours, RNA was isolated 
and Bmf mRNA levels were analyzed by RT-qPCR and normalized to the housekeeping gene 
Gusb. Data are expressed as fold induction over untreated cells and are mean ± S.D. from one 
representative experiment out of two. * p < 0.05; ** p < 0.01; *** p < 0.001 (treated versus 
untreated); # P < 0.05 (TGF-β treated versus TGF-β+antioxidant agents treated). Black bars, 
Metflx/flx oval cells. White bars, Met-/- oval cells (Martinez-Palacian et al., 2013).  
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Importantly, in regard  to TGF-β-induced effects in oval cells, we observed 
that, not all the cells die in response to acute TGF-β treatment and there is a 
population of Metflx/flx and Met-/- oval cells that survive, as it occurs in fetal 
hepatocytes (Sanchez et al., 1999). Oval cells that survive to TGF-β-induced cell 
death undergo phenotypical changes that are consistent with an EMT process. 
Figure 17. HGF acts as a proliferative, pro-migratory and pro-invasive factor in oval cells. a) 
[3H] Thymidine incorporation assay in Metflx/flx and Met-/- oval cells treated for 48 hours with 
HGF (10 and 40 ng/ml) and epidermal growth factor (20 ng/ml). Results are expressed as 
cpm/dish. Data are mean ± S.E.M. of triplicate experiments. Black bars, Metflx/flx oval cells. 
White bars, Met-/- oval cells (del Castillo et al., 2008b). b) Quantitative analysis of in vitro 
wound closure. Metflx/flx and Met-/- oval cells were cultured at confluency on plastic dishes. 
Next day a wound was done using a sterile tip and cells were cultured during 48 hours with 
or without HGF (40 ng/ml). Data are expressed as % of closure and are mean ± S.E.M. of four 
independent experiments. c) Metflx/flx and Met-/- oval cells were plated on the upper chamber 
of a 24-transwell plate coated with matrigel and incubated for 24 hours in the absence or 
presence of HGF (40 ng/ml). Cells that passed through matrigel-coated filters were fixed and 
stained with crystal violet and counted by phase contrast microscopy. Data are number of 
invaded cells and are mean ± S.E.M. of at least 5 experiments performed in duplicate. d) 
Effect of p85 silencing on HGF-induced oval cell invasion. 24 hours after transfection with 
non-targeting (NT) small interference RNA (siRNA) or p85 specific siRNAs (sip85) cells were 
trypsinized and seeded on transwell chambers coated with matrigel and cultured for 24 
hours with or without HGF (40 ng/ml). Data are expressed as fold change with respect to 
control and are mean ± S.E.M. of 5 independent experiments run in triplicate. * p < 0.05; **p 
< 0.01; ***p < 0.001 (treated versus untreated or as indicated) (Suarez-Causado et al., 2015).  
d) 
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Both Metflx/flx and Met-/- oval cells upon acute TGF-β treatment showed an 
increased expression of mesenchymal markers (N-CADHERIN and VIMENTIN), 
decreased levels of epithelial markers (E-cadherin), and upregulation of EMT-
inducing TF (Snail, Zeb1) (Figure 18a and b) therefore confirming that an EMT 
has taken place (Almale et al., 2019). 
 
 
 
 
 
 
 
 
 
 
 
To further study the EMT response triggered by TGF-β in oval cells we 
established oval cell lines with a stable EMT phenotype induced by chronic 
treatment with TGF-β (Almale et al., 2019). For the generation of these cell 
lines, we used a modified version of the protocol used previously in fetal 
hepatocytes and tumor hepatic cells (Bertran et al., 2009; Valdes et al., 2002) as 
illustrated in Figure 19. Briefly, oval cells are treated with TGF-β (1 ng/ml) for 48 
hours in the absence of serum. Afterwards, the medium is changed to 10% FBS 
medium supplemented with 0.5 ng/ml of TGF-β (maintenance dose). From then 
on, cells are always maintained in presence of TGF-β. These cells are named as 
TβT-OC (TGF-β treated oval cells). 
Figure 19. Scheme of the establishment of TβT- OC. 
Figure 18. Acute TGF-β treatment induces EMT in Metflx/flx and Met-/- oval cells. a) Total RNA 
was isolated from Metflx/flx and Met-/- oval cells treated or not with 1 ng/ml TGF-β in 0% FBS 
medium for different periods of time. Cdh1, Snai1 and Zeb1 mRNA levels were determined by 
RT-qPCR and normalized to Gusb. Data are expressed relative to untreated cells and are mean 
± S.E.M. (n=2-4). Black bars, Metflx/flx oval cells. White bars, Met-/- oval cells.  b) Metflx/flx and 
Met-/- oval cells were untreated or treated with 1 ng/ml TGF-β in 0% FBS medium for 48 
hours, then fixed and stained with specific antibodies against VIMENTIN and N-CADHERIN for 
immunofluorescence analysis under a confocal microscopy. Nuclei were stained with DAPI. 
Representative images out of 2 experiments are shown. Scale bar=50 μm (Almale et al., 
2019). 
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Once TβT-OC were established, functional properties of these cells were 
analyzed (Almale et al., 2019).  
Figure 20. Chronic EMT induces functional changes in oval cells. a) Apoptotic index in oval 
cells and TβT-OC treated with TGF-β for 48 hours. A total of 1000 to 2000 cells were counted 
per dish after PI staining under a fluorescence microscope in a blinded manner. Data are 
mean ± S.E.M. of 4 experiments performed in triplicate. b) OCR and rate ECAR of oval cells, 
TβT-OC and Ras-oval cells were analyzed in 25 mM glucose medium. Ratios OCR/ECAR were 
calculated. Data are mean ± S.E.M. (n=8). c) Lactate production in oval cells, TβT-OC and Ras-
oval cells in 25 mM glucose medium. Data are mean ± S.E.M. of 2 independent experiments 
performed in triplicate. d) Oval cells, TβT-OC and Ras-oval cells were plated in soft agar and 
the colonies were counted after 2 weeks. Data are mean ± S.E.M. (n=4). * p < 0.05; ** p < 
0.01; *** p < 0.005 (versus  oval cells or untreated group or as indicated). (Almale et al., 2019) 
Figure 19. Scheme of the establishment of TβT- OC. 
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Firstly, cells chronically treated with TGF-β lost the apoptotic cell death 
response upon acute treatment with TGF-β, proving that EMT confers oval cells 
resistance against TGF-β-induced apoptosis (Figure 20a). Likewise, TβT-OC 
showed lower apoptosis under serum deprivation. Moreover, TβT-OC displayed 
a switch in their bio-energetic profile towards a more glycolytic phenotype, 
expressed as oxygen consumption rate/ extracellular acidification rate 
(OCR/ECAR) ratio, further confirmed by increased lactate production (Figure 
20b and c).  
These features (apoptotic resistance and switch of bio-energetic profile) 
found in TβT-OC are similar to those found in oval cells transformed with 
oncogenic v-Ha-Ras (Ras-OC), used as a control of tumorigenic cells (Figure 20b 
and c). However, despite these similarities with tumor cells, TβT-OC do not 
acquire anchorage independent growth capacity (Figure 20d) discarding a 
malignant transformation after EMT (Almale et al., 2019). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
  
  
6. Aims 
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TGF-β and HGF/Met pathways are important mediators during liver 
regeneration, fibrosis and hepatocarcinogenesis and play roles on different liver 
cell populations. Taking this into consideration, the general objective of this 
work was to analyze the relevance of the crosstalk between TGF-β and 
HGF/Met pathways in oval cell biology and fate in a context of chronic liver 
injury as well as to explore if such crosstalk could play a role during 
hepatocarcinogenesis.    
To achieve this general objective, we propose three specific objectives: 
Objective 1: To characterize the TGF-β-induced EMT response in oval cells 
in vitro and to evaluate the effects on oval cell fate upon transplantation into 
a fibrotic liver. 
Objective 2: To elucidate the HGF/Met signaling-mediated regulation on 
the EMT response induced by TGF-β and its contribution to oval cell 
properties. 
Objective 3: To analyze the TGF-β pathway in liver tumor cells from Met-
overexpressing livers and how affects tumor cell growth and survival 
properties. 
 
 
 
 
 
  
  
 
 
  
  
 
 
  
7. Materials 
and methods 
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1. Cell culture 
1.1. Cell models 
Metflx/flx oval cell lines derive from Met conditional knockout mice (Huh et 
al., 2004) fed with 0.1% DDC-supplemented diet for 13 days to induce liver 
damage and oval cell expansion. In order to generate Met-/- oval cells, in vitro 
inactivation of Met was achieved by infecting the parental Metflx/flx oval cells 
with adenovirus expressing the Cre recombinase under the control of the 
cytomegalovirus promoter (Ad-CMV-Cre) (Vector Biolabs). Cre-mediated 
conditional gene targeting resulted in the deletion of exon 16 containing a 
critical ATP-binding site in the intracellular tyrosine kinase domain, essential for 
Met catalytic activity. Removal of this region leads to the expression of a Met 
receptor lacking its tyrosine kinase activity. Cells were phenotypically and 
functionally characterized and validated (del Castillo et al., 2008b). Metflx/flx and 
Met-/- oval cells were used only in early passages. 
 
 
To generate TβT-OC (oval cells chronically treated with TGF-β), oval cells 
were treated for 2 days with TGF-β (1 ng/ml) in 0% foetal bovine serum (FBS) 
medium. Then, medium was replaced and remaining surviving cells were 
cultured in 10% FBS medium supplemented with TGF-β (0.5 ng/ml) until they 
reached confluency. Cells were sub-cultured in the same medium and after 4-5 
subsequent passages a stable cell line of TβT-OC was established. 
 
Green fluorescence protein (GFP) expressing oval cells and TβT-OC were 
generated by lentiviral transduction with GFP. For the transduction we used the 
lentiviral vector pLVX-SFFV-zsGFP. 250,000 cells were seeded in 10% FBS 
medium in 6-well plates. Following day, medium was removed and viral 
particles were added in 1 ml of DMEM-10% FBS with a multiplicity of infection 
(MOI) of 5 (from a 1.109 transducing units (TU)/ml titer). After 24 hours, 
medium was replaced by normal growth medium. Cells were sub-cultured 2-3 
times per week at 80%-90% confluency. GFP expressing cells were selected by 
cell sorting. These experiments were done at Dr. J.C. Segovia laboratory 
(CIEMAT). 
Figure 21. Representative phase 
contrast images of Metflx/flx and Met-/- 
oval cells lines in culture. 
Figure 22. Representative phase contrast images of TβT-OC 
lines in culture. 
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Alb-R26Met HCC cells derive from Alb-R26Met mice, mice with increased Met 
levels in the liver generated in Dr. F. Maina laboratory. For the generation of 
these animals, R26stopMet (international nomenclature Gt(ROSA)26Sortm1(Actb-
Met)Fmai) mice were crossed with Albumin-Cre, that is, mice expressing Cre 
recombinase under the control of albumin promoter. Thus, in R26Met mice, Met 
transgene is carried in the Rosa26 locus that is expressed in albumin positive 
cells. These mice spontaneously generate liver tumors (from 40 weeks of age). 
Several HCC cell lines from individual Alb-R26Met tumors were generated (Alb-
R26Met HCC cells). In this work, we use two different HCC cells lines expressing 
different Met levels: HCC1, with high Met levels (named as HCC1HMet) and HCC3, 
with low Met levels (named as HCC3LMet).    
 
1.2. Cell culture conditions 
Cell lines were grown in the appropiated medium (Table 1) and were placed 
in a humidified incubator at 37°C and 5% CO2. Cells were passaged at 80%-90% 
confluency using trypsin-ethylene diaminetetraacetic acid (EDTA) and medium 
was replaced every 3 days. 
For cryopreservation, cells were harvested and centrifuged (5 minutes, 
1,300 rpm). The cells pellet was resuspended in 10% (v/v) dimethyl sulfoxide 
(DMSO)-FBS and transferred to cryotubes. Cells were frozen slowly using the 
Mr. Frosty freezing container (Thermo Scientific) at -80°C and moved to the 
liquid nitrogen (-190°C) tank within a week. 
Cells thawing was done quickly in a water bath at 37°C. Once thawed, cells 
were placed in a culture dish with growth medium. Upon attachment, medium 
was replaced with fresh medium to completely remove the DMSO. 
 
 
 
 
Figure 24. Representative phase 
contrast images of HCC1HMet and 
HCC3LMet cells in culture . 
Figure 23. Representative fluorescence 
microscopy images of OC-GFP and TβT-
OC-GFP in culture. 
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Cell line Medium Supplements 
 
 
 
Metflx/flx 
Met-/- 
OC-GFP 
 
 
 
 
TβT-OC 
TβT-OC-GFP 
DMEM 
Dulbecco´s Modified 
Eagle Medium, 
4.5 g/l glucose 
10% FBS 
 
Hepes 20 mM 
(ph 7.4) 
 
Penicillin G 
120 μg/ml 
 
Streptomycin 
100 ug/ml 
 
Amphotericin B 
2.5 ug/ml 
 
TGFβ* 
0.5 ng/ml  
HCC1HMet 
HCC3LMet 
William´s Medium E 
(-) L-Glutamine 
10% FBS 
 
1X Penicillin/Streptomycin 
 
2 mM L-Glutamine 
 
0.0025  g/l Glucose 
 
0.7 mM Sodium Pyruvate 
 
0.4 ug/ml Dexamethasone 
 
10 μg/ml Insulin* 
 
20 ng/ml EGF* 
 
10 ng/ml HGF*  
1.3. Growth factors and inhibitors 
Growth factors and inhibitors used in this work are listed in Table 2 
 
Growth 
Factor/Inhibitor 
Final concentration Manufacturer 
TGF-β 1 ng/ml or 2 ng/ml Calbiochem 
HGF 40 ng/ml R&D systems/Peprotech 
PHA665752 3 μM or 5 μM Sigma Aldrich 
SB431542 10 μM Sigma Aldrich 
 
 
Oval cells were serum starved for 3-15 hours before treatment. For HCC cell 
lines, all treatments were performed in 10% FBS-medium to avoid cell death. 
Inhibitors were added 1 hour before treatment with the growth factors.  To 
inhibit Met activity in TβT-OC cell lines, cells were treated with the inhibitor 
Table 1. Cell culture media used for the different cell lines.  
(*) Supplements are added immediately before use 
Table 2. Growth Factors and inhibitors. 
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PHA665752 during 2 weeks prior to the experiment and during the course of the 
experiment.  
 
2. DNA analysis 
2.1. DNA isolation from cultured cells 
DNA was extracted for genotyping Metflx/flx and Met-/- oval cells. First, cells 
were washed with cold phosphate buffered saline (PBS) and lysed overnight in 
lysis buffer (Table 3) at 58°C in a rotating oven (400 rpm). DNA was isolated 
using a phenol/chloroform extraction protocol. An equal volume of phenol was 
added to cell lysates and mixed for 10 minutes. They were centrifuged at 12,000 
rpm for 3 minutes and the supernatant was transferred to a new tube. An equal 
volume of chloroform/isoamylalcohol (24:1) was added, mixed for 10 minutes, 
and centrifuged at 12,000 rpm for 3 minutes. Supernatant was transferred to a 
new tube and the extraction was repeated with chloroform alone. DNA was 
precipitated with 1/10 volume of 3M sodium acetate (pH 5.2) and 1 volume of 
isopropanol. Precipitated DNA was transferred into a tube with 70% ethanol and 
centrifuged at 9,000 rpm for 2 minutes. The pellet was resuspended in tris-EDTA 
(TE) buffer (Table 4) and incubated at 37°C to facilitate resuspension. 
 
   Component 
Final      
concentration 
Tris-HCl pH 8.5 100 mM 
EDTA 5 mM 
Sodium dodecyl 
sulphate (SDS) 
0.2% 
NaCl 200 mM 
Proteinase K* 100 μg/ml 
2.2. DNA isolation from liver tissue  
DNA from liver tissue was isolated for the detection of floxed allele in the 
liver of transplanted mice (analysis of cell engraftment). For genomic DNA 
isolation, hepatic tissue was digested overnight in lysis buffer (Table 3), as 
explained before. Next day samples were centrifuged at 13,000 rpm for 10 
minutes, supernatant was collected and genomic DNA was precipitated with 
cold isopropanol. DNA was diluted in TE buffer (Table 4) at 37°C. 
 
 
 
 
 
 
 
Table 3.  DNA isolation buffer. 
(*) Added immediately before use 
Component 
Final   
concentration 
Tris-HCl pH 8 10 mM 
EDTA 1 mM 
 
 
Table 4.  TE buffer 
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2.3. Polymerase chain reaction (PCR) 
1 μg of genomic DNA isolated from either liver tissue or cultured cells was 
incubated with a mix of 1 µM of specific primers (Table 5), 200 μM of dNTPs, 1.5 
mM of MgCl2 and 2 units of Taq polymerase. PCR conditions were: 
- 95°C for 5 minutes. 
- 39 cycles with 3 steps: 94°C for 1 minute (denaturation), 61°C for 30 
seconds (primer annealing) and 72°C for 1 minute (extension). 
- 72°C for 2 minutes. 
The obtained PCR products were analyzed in 1.3% agarose gels containing 
Gel Red Nucleic Acid Stain. In each reaction, we included a negative control 
containing H2O instead of cDNA (no-RT sample). 
 
Gene 
(mouse) Forward primer (5’-3’) Reverse primer (5’-3’) T (°C) Cycles # 
Flox Allele 
TTAGGCAATGAGGTGTCCCAC CCAGGTGGCTTCAAATTCTAACG 61 39 
Deleted 
Allele 
CAGCCGTCAGACAATTGGCAC CCAGGTGGCTTCAAATTCTAAGG 63 30 
 
 
 
3. mRNA expression analysis  
3.1. Total RNA extraction 
Cells were washed with cold PBS and total RNA was extracted following 
manufacturer’s instructions of GeneAll RibospinTM Kit. DNase treatment was 
included to avoid possible genomic DNA contamination. RNA was eluted with 
ultrapure water. Concentration of RNA was spectrophotometrically measured 
(A260nm), considering that 1 unit of absorbance at 260 nm corresponds to 40 
μg/ml of RNA. Estimation of its purity was based on the ratio A260/A280. A ratio 
between 1.8-2 was accepted as pure RNA. 
 
 
 
 
 
Figure 25. Illustrative PCR for 
genotyping of Metflx/flx and 
Met-/-. The PCR confirms the 
presence of the flowed allele 
(380bp) in Metflx/flx together 
with the presence of deleted 
allele (600bp) in Met-/- oval 
cells. 
Table 5. Sequences of primers used for PCR. 
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3.2. cDNA synthesis (reverse transcription, RT) 
cDNA synthesis was performed using two alternative protocols: 
For oval cells, we used 1 µg of total RNA. cDNA synthesis was performed in 
two consecutive reactions. In a first reaction, RNA was incubated with oligo dT 
(0.25 µg) and dNTPs (0.5 mM) at 65°C for 5 minutes to denature RNA. Then, this 
mix was incubated at 50°C for 1 hour in the presence of a cDNA synthesis mix 
(5X RT Buffer, 20 units of RNase inhibitor, 5 mM dithiothreitol (DTT), 200 units 
of SuperScript III) in a final volume of 20 μl. The enzyme was inactivated by 
heating samples at 70°C for 15 minutes. 
For HCC cells, 600 ng of total RNA was used for complementary DNA 
synthesis by iScripTM Reverse Transcription Supermix (Bio-Rad) following the 
manufacturer’s instructions. 
In both cases, cDNA was diluted as required with nuclease free water and 
stored at -20°C until further use. 
 
3.3. Quantitative reverse transcription PCR (RT-qPCR) 
Real time PCR was performed using specific primers (Table 6) and SYBR 
Green to detect DNA in the 7900 Fast Real Time System (Life technologies)/ QFX 
96 (BioRad). PCR reactions were done in triplicate. Gusb and Hprt were used as 
housekeeping genes. 
During the exponential phase of real time PCR, a fluorescence signal 
threshold was determined, so that it was significantly greater than background 
fluorescence. The fractional number of PCR cycles required to reach this 
threshold is defined as the cycle threshold or Ct. Based on this, quantification of 
RNA levels was performed through calculation of RQ (2-ΔΔCt). First, ΔCt value 
for each sample and gene is obtained by subtracting the Ct value for Gusb from 
the Ct value for the target gene under a particular experimental condition. Then, 
resulting ΔCt value is referred to control ΔCt value (sample ΔCt - control ΔCt = 
ΔΔCt) to calculate the RQ value. 
 
Protein 
Gene 
(Mus musculus) 
Forward primer 
(5’-3’) 
Reverse primer 
(5’-3’) 
AFP Afp TGTTGCCAAGGAAACTCG GCAGCACTCTGCTATTTTGC 
CD44 Cd44 GGCCACCATTGCCTCAACTGT TGCACTCGTTGTGGGCTCCTG 
E-CADHERIN Cdh1  CAGCCTTCTTTTCGGAAGACT GGTAGACAGCTCCCTATGACTG 
P21 Cdkn1a TATCCAGACATTCAGAGCCACA TCCAGCTTGCAGATGACCTT 
P27 Cdkn1b TTCGCAAAACAAAAGGGCCAA CTTAATTCGGAGCTCTTTACGTCTG 
p15 Cdkn2b CAATCCAGGTCATGATGATGGG TCGTGCACAGGTCTGGTAAG 
P19 Cdkn2d CATCTGGAGCAGCATGGAGTC ATCATCATCACCTGAATCGGGG 
CTGF Ctgf CACTCTGCCAGTGGAGTTCA AAGATGTCATTGTCCCCAGG 
CYP7A1 Cyp7a1 CAACCTGCCAGTACTAGAT AAGGTGTAGAGTGAAGTCCTCC 
EPCAM Epcam ACCTGAGAGTGAACGGAGAGCC TGCATGGAGAACTCGGGTGCCT 
GGT Ggt TGCGGTTTCAGAGGATGGCAG AACAGGATGCCACTGACCCGA 
GUSB Gusb AAAATGGAGTGCGTGTTGGGTCG CCACAGTCCGTCCAGCGCCTT 
HGF Hgf GAGTCTGAGTTATGTGCTGGG AGGACGATTTGGGATGGC 
HNF1B Hnf1b TCTCAGAACCTCATCAGACC GCTAGCCACACTGTTAATGACC 
 77 
 
 
HNF4A Hnf4a GGCATGGATATGGCCGACTAC TTCAGATGGGGACGTGTCATT 
HPRT Hprt CTGGTGAAAAGGACCTCTCGAAG CCAGTTTCACTAATGACACAAACG 
MMP10 Mmp10 AACACGGAGACTTTTACCCTTTT GGTGCAAGTGTCCATTTCTCAT 
MMP13 Mmp13 TTGGTCCCTGCCCCTTCCCTAT CGCAAGAGTCGCAGGATGGT 
MMP2 Mmp2 CAACGGTCGGGAATACAGCA AGCCATACTTGCCATCCTTCTC 
MMP9 Mmp9 CAAACCCTGTGTGTTCCCGT TGGTCATAGTTGGCTGTGGTG 
NOX4 Nox4 CCTCAACTGCAGCCTCATCC CAACAATCTTCTTGTTCTCC 
HNF6 Onecut1 CCTGGAGCAAACTCAAGTCG GTCCTTCCCGTGTTCTTGC 
PAI1 Pai1 CGGCGGCAGATCCAAGATGCTA TTGTTCCACGGCCCCATGAGCT 
PDGFA Pdgfa ACCATCGGGAGGAGGAGAC CACGGAGGAGAACAAAGACC 
PDGFB Pdgfb ACTTGAACATGACCCGAGCA ATCTGGAACACCTCTGTGCG 
PDGFC Pdgfc AGGTTGTCTCCTGGTCAAGC CCTGCGTTTCCTCTACACAC 
PDGFD Pdgfd CCAAGGAACCTGCTTCTGAC CTTGGAGGGATCTCCTTGTG 
CD133 Prom1 CTGGGATTGTTGGCCCTCTC AGGGCAATCTCCTTGGAATCA 
SMAD6 Smad6 TGCGACCTCTGCTTCGGTGGAT TGGGGCAAGTCTCTCCTGAACG 
SMAD7 Smad7 ATCGGTCACACTGGTGCGTG TCCGAGGCAAAAGCCATTCCCC 
SNAI1 Snai1  TCCAAACCCACTCGGATGTGAAGA TTGGTGCTTGTGGAGCAAGGACAT 
TGF-α Tgfa TCCTCATTATCACCTGTGTGC GTCTCAGAGTGGCAGCAAGC 
TGF-β1 Tgfb1 ATGAACCGGCCCTTCCTGCT TTGGTATCCAGGGCTCTCCGGT 
TGFβR1 Tgfbr1 GCTCCAAACCACAGAGTAGGCAC CCCATTGCATAGATGTCAGCGCG 
TIMP1 Timp1 TGGGTGGATGAGTAATGCGT GGTATCTGCTCTGGTGTGTCTC 
TIMP3 Timp3 AGGCTTCAGTAAGATGCCCC TTCATACACGCGCCCTGTC 
TWIST2 Twist 2 GCAAGAAGTCGAGCGAAGAT GCTCTGCAGCTCCTCGAA 
TWIST1 Twist1 CCGGAGACCTAGATGTCATTGT CCACGCCCTGATTCTTGTGA 
 
 
4. Protein expression analysis  
4.1. Protein expression analysis by western blot 
4.1.1. Cell extract preparation 
Cells were washed with cold PBS and lysed with RIPA (Table 7) or EBM 
(Table 8) lysis buffer.  
RIPA lysis buffer  EBM lysis buffer 
Component 
Final 
concentration 
 Component 
Final 
concentration 
Na-
deoxycholate 
1% (p/v)  Glycerol 10% 
Tris-HCl (pH 7.4) 10 mM  Tris-HCl (pH 7.5) 20 mM 
SDS 0,1% (p/v)  Triton 1% 
NaCl 150 mM  NaCl 150 mM 
Table 6. Sequences of primers used for RT-qPCR. 
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NP-40 1% (v/v)  EGTA 5 mM 
EDTA 2 mM  EDTA 5 mM 
Na3VO4* 0,1 mM  NaPP* 1 mM 
NaF * 20 mM  NaF * 10 mM 
Aprotinin * 10 µg/ml  Na3VO4* 1 mM 
Leupetin * 10 µg/ml 
 β-glycero-
phosphate* 
10 mM 
PMSF * 1 mM  Leupeptin* 5 µg/ml 
   Pepstatin* 5 µg/ml 
   Aprotinin* 2 µg/ml 
   Benzamidin 5 mM 
   PMSF * 1 mM 
 
 
Cells were detached from the plate by scraping in presence of lysis buffer 
and collected in an eppendorf tube. Cell lysates were incubated for 30 minutes 
at 4°C, vortexed every 5 minutes and centrifuged at 13,000 rpm for 10 minutes 
at 4°C. The supernatant was collected in a new eppendorf tube and stored at      
-80°C until use. 
 
4.1.2. Protein quantification 
Protein concentration was determined using the Bradford method. 
Absorbance at 595 nm was measured using a plate reader (Powerwave XS, 
Biotek). Different concentrations of bovine serum albumin (BSA) were used (0-
10 μg) to generate a standard curve and calculate protein concentration of cell 
extracts. 
 
 
 
Table 7. RIPA buffer composition. 
(*) Inhibitors are added immediately before use 
Table 8. EBM buffer composition. 
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4.1.3. Protein electrophoresis and blotting 
Samples were prepared using Laemmli buffer 4X (Table 9) and were 
denatured at 95°C for 5 minutes. Then, samples were loaded into the gel 
together with a molecular weight standard (ThermoFisher). 
 
 
 
 
 
 
 
 
 
Electrophoresis conditions are listed in the table below: 
 
 
 
 
 
 
 
 
4.1.4. Protein transfer 
After electrophoresis, proteins were transferred onto a Nitrocellulose or 
Immobilon membrane using a wet transfer equipment. Protein transfer 
conditions are indicated in Table 11: 
 Transfer conditions 
SDS-PAGE 
0.3 A, 90-110 min, room temperature (RT) 
20% Methanol, 25mM Tris-HCl, 190 mM Glycine 
Anderson gels 
0.4 A, 4 h, 4°C 
20% 2-propanol, 1X Carbonate buffer 
 
 
After transfer, membranes were stained with Ponceau Red (0.5% in 1% 
acetic acid solution) to evaluate the efficiency of the protein transfer. 
 
4.1.5. Immunodetection 
Membranes were blocked for 1 hour at RT in Tween-tris-buffered saline 
(TTBS) or Tween-PBS (TPBS) 5% non-fat dry milk or BSA (depending on the 
primary antibody) (Table 12) to block unspecific binding. Then, membranes 
were incubated overnight at 4°C with the primary antibody diluted as indicated 
in Table 13 in TTBS or TPBS supplemented with 0.5-5% milk or BSA. Next day, 
membranes were washed with TTBS or TPBS (3 times, 5 minutes each) and were 
incubated with the secondary antibody at 1:5000 dilution in TTBS or TPBS 
Component 
Laemmli buffer 4x 
Final concentration 
SDS 8% 
Tris-HCl pH 6.8 250 mM 
Glycerol 40% 
Bromophenol blue 0.002% 
β-mercaptoethanol 5% 
 Electrophoresis conditions 
SDS-polyacrylamide 
gel electrophoresis 
(SDS-PAGE) 
80-120 V 
25 mM Tris-HCl (pH 8.3), 0.2 M Glycine and 
0.1% SDS 
Anderson gels 
25-30 V/ gel 
250 mM Tris-HCl, 2 M Glycine and 20% SDS 
Table 9. Laemmli buffer composition. 
Table 10. Electrophoresis conditions.  
Table 11. Transfer conditions. 
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supplemented with 0.5-1% milk or BSA for 1-2 hours at RT. After this period, 
membranes were washed 3 times (5 minutes each) and incubated with a 
chemiluminescent solution (Pierce ECL western blotting substrate). 
 
SDS-PAGE Anderson gels 
TTBS TPBS 
20mM Tris-HCl (pH 7.6) 
150mM NaCl 
0.05% Tween-20 
PBS 
0.1% Tween 20 
 
 
Primary Antibody Laboratory Dilution 
Secondary 
antibody 
ALBUMIN (RaRa/Alb/PO) Nordic Immunology 1:1000 Rabbit 
β-ACTIN 
Sigma-Aldrich (A-5441) 1:5000 
Mouse 
Sigma-Aldrich (A-3853) 1:10000 
E-CADHERIN 
BD Transduction Laboratories 
(610181) 
1:1000 Rabbit 
ERK1/2 
Cell Signaling Technology 
(9102) 
1:10000 Rabbit 
L-CADHERIN 
Santa Cruz Biotechnology  
(25628) 
1:1000 Rabbit 
MET 
Santa Cruz Biotechnology  
(162) 
1:1000 
Rabbit 
Cell Signaling Technology 
(3127) 
Mouse 
N-CADHERIN 
BD Transduction Laboratories 
(610921) 
1:1000 Mouse 
OCCLUDIN 
Thermo Fisher Scientific 
(711500) 
1:1000 Rabbit 
Phospho-AKT 
Cell Signaling Technology 
(Ser473) (9271)  
1:1000 Rabbit 
Phospho-ERK1/2 
Cell Signaling Technology 
(Thr202/Tyr204) (9101)   
1:1000 Rabbit 
Cell Signaling Technology 
(T202/Y204) (9106) 
1:10000 Mouse 
Phospho-GAB1 
Cell Signaling Technology 
(Y627) (3231)  
1:2000 Rabbit 
Phospho-MET 
Cell Signaling Technology 
(Tyr1234/1235) (3077) 
1:1000 
Rabbit 
Cell Signaling Technology 
(Y1234/1235) (3126) 
1:2000 
Phospho-SMAD2 
Cell Signaling Technology 
(Ser465/467) (3101) 
1:1000 Rabbit 
SMAD2/3 
Cell Signaling Technology 
(5678) 
1:1000 Rabbit 
TUBULIN 
Santa Cruz Biotechnology 
(8035) 
1:5000 Mouse 
TWIST Abcam (50887) 1:1000 Mouse 
Table 13. Primary antibodies used for western blot. 
Table 12. TTBS and TPBS buffer composition.  
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4.2. Protein expression analysis by immunoprecipitation assay 
Total cell extracts for Met immunoprecipitation were prepared using RIPA 
buffer (section 4.1.1.). 1,000 μg of protein were diluted in lysis buffer to 1 μg/μl 
and anti-Met antibody (SC-162) was added (7 μg/mg of protein). This mix was 
incubated overnight at 4°C under rotation in presence of protein A-agarose 
beads (Roche), previously washed and resuspended in lysis buffer. 
Next day, immunoprecipitates were washed 3 times with lysis buffer and 
resuspended in Laemli buffer 4X (section 4.1.3.). Then, samples were heated at 
95°C for 5 minutes and centrifuged to separate the protein A-agarose. In 
parallel, we prepared a mock IP control (lacking protein extract) and IP control 
(without antibody).  
Samples were loaded into an 8% SDS-PAGE gel together with a molecular 
weight standard. Gel electrophoresis and wet transfer (2 hours, 100V) were 
performed as described before (section 4.1.3. and 4.1.4) to detect 
phosphorylated and total Met by western blot (section 4.1.5) using the 
antibodies listed in Table 14 (del Castillo.et al., 2008b). 
Primary Antibody Laboratory Dilution 
  Secondary 
antibody 
MET 
Santa Cruz  
Biotechnology  
(162) 
    1:1000 
   TTBS-0.5% milk 
Rabbit 1:5000 
TTBS-0.5% milk 
Anti-phospho-Tyr 
Kinase 
Upstate 
Biotechnology 
(4G10) 
    1:1000 
TTBS-3% milk 
Mouse 1:3000 
TTBS-0.5% milk 
 
 
 
4.3. Protein expression analysis by flow cytometry 
For protein expression analysis by flow cytometry, cells were detached with 
trypsin-EDTA and centrifuged at 1,200 rpm for 5 minutes at 4°C. Then, cells 
were washed and centrifuged again in the same conditions and resuspended in 
PBS. 1x106 cells were collected for each condition and the following protocols 
were followed to analyze different proteins. 
EPCAM analysis 
A blocking step was performed by incubating cells in PBS-5% mouse serum 
for 15 minutes at 4°C. Cells were washed with PBS-3% BSA and centrifuged at 
2,000 rpm for 5 minutes at 4°C. The cell pellet was resuspended in PBS-3% BSA 
and incubated with EPCAM-Phycoerythrin or with Isotype control mouse IgG1 
(Table 15) or with PBS-3% BSA only, as a control, for 30 minutes at 4°C in 
darkness. Then, cells were washed with PBS and centrifuged at 2,000 rpm for 5 
minutes at 4°C. The pellet was resuspended in PBS and transferred to cytometry 
tubes. 
 
 
Table 14. Antibodies used for immunoprecipitation and western blot assays. 
  
82 
 
 
CD44 analysis 
Cells were resuspended in PBS-0.1% BSA and incubated with CD44-Alexa 
488 or with Isotype control Rat IgG (Table 15) or with PBS-0.1% BSA only, as a 
control, for 30 minutes at 4°C in darkness. Then, cells were washed with PBS 
and centrifuged at 2,000 rpm for 5 minutes at 4°C. The pellet was resuspended 
in PBS and transferred to cytometry tubes. 
In both cases, 10,000 cells per condition were analysed by FACScalibur 
(Becton Dickinson; Flow Cytometry and Microscopy Core Facility at UCM 
      Antibody    Laboratory   Dilution 
EPCAM-Phycoerythrin 
Santa Cruz 
Biotechnology 66020 
    1:50 
EPCAM isotype control Mouse IgG1 
Santa Cruz 
Biotechnology 2866 
    1:50 
CD44-Alexa 488 BioLegend 103016     1:50 
CD44 Isotype control Rat IgG BioLegend 400625     1:50 
 
 
4.4. Protein expression analysis by immunocytochemistry  
150,000 oval cells or 700,000 HCC cells were seeded on gelatin-coated glass 
coverslips in 12-wells plates or in 6 cm dishes, respectively. Next day, cells were 
washed with PBS and the following protocols were followed for detecting 
specific proteins (Suarez-Causado et al., 2015; Almale et al., 2019). 
E-CADHERINE, N-CADHERIN and ALBUMIN analysis 
Cells were fixed in cold methanol (-20°C) for 2 minutes at RT and then 
coverslips were washed twice with PBS and blocked in PBS-2% BSA for 1 hour at 
RT. Next, they were incubated with primary antibody (Table 16) in PBS-1% BSA, 
in a humidified chamber for 1 hour at 37°C. Coverslips were washed 3 times in 
PBS (5 minutes each) and incubated with secondary antibody in PBS-1% BSA for 
1 hour at 37°C. Finally, cells were washed 3 times in PBS (5 minutes each) and 
mounted with Slowfade gold antifade reagent containing 4′,6-diAmidino-2-
phenylIndole (DAPI) (Invitrogen).  
CK19 
Cells were fixed in ethanol 95% for 10 minutes at 4°C. Then, coverslips were 
washed twice with TBS (Table 12), blocked and fixed in TBS-0.3% Triton X-100-
5% goat serum for 2 hours at RT. After washing once with TBS cells were 
incubated with primary antibody (Table 16) in blocking solution, in a humidified 
chamber overnight at 4°C. Coverslips were washed 3 times in TBS (5 minutes 
each) and incubated with secondary antibody in PBS-0.1% BSA for 1 hour at 
37°C. Finally, cells were washed and mounted as explained before. 
 
Table 15. Antibodies used for protein expression analysis by flow cytometry. 
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ZO-1 analysis 
Cells were fixed in 4% paraformaldehyde (PFA) for 20 minutes at RT and 
permeabilized with PBS-0.1% Triton X-100-0.1% BSA for 20 minutes. Then 
coverslips were washed twice with PBS and blocked in PBS-2% BSA for 1 hour at 
RT. Next, they were incubated with primary antibody (Table 16) in PBS-1% BSA, 
in a humidified chamber for 1 hour at 37°C. Coverslips were washed 3 times in 
PBS (5 minutes each) and incubated with secondary antibody in PBS-1% BSA for 
1 hour at 37°C. Finally, cells were washed and mounted as explained before. 
In all cases, cells were examined in a confocal microscope (Olympus FV1200, 
Flow Cytometry and Microscopy Core Facility at UCM). 
Cleaved CASPASE-3 analysis 
For detecting activated CASPASE-3, we used an antibody against the large 
fragment (17/19 kDa) resulting from cleavage of the pro-caspase (Table 16). 
Cells were fixed in 4% PFA for 10 minutes followed by two washes with PBS. The 
unmasking was done in PBS supplemented with 50 mM Lysine-50 mM NH4Cl2 
for 15 minutes at RT. Then, cells were washed 3 times (5 minutes each), 
permeabilized with PBS-0.1% Triton X-100 for 15 minutes, washed 3 times (5 
minutes each) with TPBS (Table 12) and blocked in TPBS-10% donkey serum for 
1 hour. Incubation with primary antibody (Table 16) was done overnight at 4°C 
in blocking solution using a humidified chamber. Coverslips were washed 3 
times (10 minutes each) with TPBS and incubated with the secondary antibody 
in blocking solution 1 hour at RT. Then, cells were washed with TPBS 3 times (10 
minutes each) and once with PBS. For nuclear counterstaining cells were 
incubated in PBS-DAPI (1 μg/ml) for 15 minutes at RT. Finally, cells were washed 
with PBS and mounted in Prolong Gold antifade reagent (Thermofisher).  
 
Primary 
Antibody 
Laboratory Dilution 
Secondary 
Antibody 
Dilution 
E-CADHERIN 
BD Transduction  
Laboratories (610181) 
1:50 
Mouse 
Alexa 488 
1:200 
ALBUMIN 
(RaRa/Alb/PO) 
Nordic Immunology 1:50 
Rabbit 
Alexa 594 
1:200 
CK19 (TROMAIII) 
Hybridoma Bank 1:50 
Rat 
Fitc 
1:200 
N-CADHERIN 
BD Transduction  
Laboratories (610921) 
1:50 
Mouse 
Alexa 488 
1:200 
ZO-1 
Thermo Fisher Scientific  
(617300) 
1:50 
Rabbit 
Alexa 594 
1:200 
Cleaved 
CASPASE-3 
Cell Signaling 
Technology (Asp175) 
(9661) 
1:500 
Rabbit 
Alexa 488 
1:500 
Table 16. Antibodies used for immunofluorescence staining for confocal microscopy analysis. 
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Cells were visualized under a Zeiss Apotome Microscope with a 20X 
objective. The fluorescence intensity was measured in at least 6 fields per 
condition by Image J program. 
4.5. Protein expression analysis by immunohistochemistry and 
immunofluorescence in hepatic tissues 
4.5.1. pSMAD2 staining on liver sections: paraffin embedding and 
immunohistochemistry 
For paraffin embedding, liver tissue was fixed in 4% PFA for 4 hours at 4°C, 
rinsed twice with PBS and dehydrated by immersion in increasing 
concentrations of alcohol Dehydrated samples were then embedded in paraffin 
as indicated in Table 17. Following day, samples were allowed to solidify at RT. 
 
Step Time 
Ethanol 50% 40 minutes 
Ethanol 70% 40 minutes 
Ethanol 95% 40 minutes 
Ethanol 95% (4°C) Overnight 
Ethanol 100% 40 minutes 
Ethanol 100% 40 minutes 
Ethanol 100% 40 minutes 
Acetone:Paraffin (1:1) (62°C) 30 minutes 
Paraffin (62°C) 1 hour 
Paraffin (62°C) 1 hour 
Paraffin (62°C) Overnight 
 
 
Paraffin-embedded samples were cut into 4 μm-thick sections using a 
microtome, placed in slides and left air-drying at 37°C. For pSMAD2 staining, 
paraffin was removed and tissue was rehydrated. For that, samples were placed 
at 50°C for 30 minutes and passed through alcohol solutions with decreasing 
concentrations as indicated in Table 18. 
 
Step Time 
Xylene 10 minutes 
Xylene 10 minutes 
Xylene 10 minutes 
Ethanol 100% 5 minutes 
Ethanol 100% 5 minutes 
Ethanol 100% 5 minutes 
Ethanol 96% 5 minutes 
Ethanol 96% 5 minutes 
Ethanol 70% 5 minutes 
Distilled water 5 minutes 
 
Table 18. Hydration steps for immunohistochemistry. 
Table 17.  Steps for paraffin-embedding. 
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Next, samples were immersed in 10 mM citric buffer (pH6) and boiled for 12 
minutes. This step breaks the methylene bridges and exposes the antigenic sites 
to allow binding of antibodies. When temperature of the buffer reached 35-
45°C, samples were washed with PBS for 5 minutes. Samples were then 
permeabilized in PBS-0.1% Triton X-100 for 5 minutes and washed in PBS for 5 
minutes. Endogenous peroxidase was inactivated to reduce the background by 
incubating the tissue in methanol-3% H2O2 for 10 minutes at RT. Slides were 
rinsed with water and with TPBS (Table 12) (10 minutes). Blocking was 
performed in TPBS supplemented with-2% BSA and 20% FBS for 2 hours. Then 
slides were incubated overnight with pSMAD2 primary antibody (Cell Signaling, 
3106, S465,467) diluted 1:100 in blocking solution in a humidified chamber at 
4°C overnight. Samples were washed 3 times with TPBS (10 minutes each) and 
incubated for 1 hour with anti-rabbit peroxidase-conjugated secondary antibody 
diluted 1:500 in blocking solution in a humidified chamber at RT. Then, samples 
were washed 3 times with TPBS (10 minutes each). Peroxidase staining was 
revealed with D.A.B (SK-410 Vector Laboratories). Upon acquisition of an 
adequate signal, the reaction was stopped by soaking the samples into tap 
water for 5 minutes. Finally, samples were dehydrated as indicated in Table 19 
and slides were mounted with Eukitt quick-hardening mounting medium 
(Sigma). 
 
Step Time 
Distilled water 5 minutes 
Ethanol 70% 5 minutes 
Ethanol 96% 5 minutes 
Ethanol 96% 5 minutes 
Ethanol 100% 5 minutes 
Ethanol 100% 5 minutes 
Ethanol 100% 5 minutes 
Xylene 10 minutes 
Xylene 10 minutes 
Xylene 10 minutes 
 
 
Staining was observed with bright light under a Zeiss Apotome with a 20X 
objective. The intensity and the number of pSMAD2 positive nuclei were 
analysed using image J in at least 6 fields per sample. 
 
4.5.2. Detection of GFP by confocal microscopy/immunofluorescence  
For immunofluorescence staining of GFP on paraffin-embedded liver 
sections (performed Department of Pathological Anatomy of the Hospital Clínico 
San Carlos (HCSC)), firstly paraffin was removed by heating sections at 65°C for 
15 minutes and then tissue was rehydrated by immersion in decreasing 
concentrations of alcohol as indicated in Table 20. 
 
 
 
Table 19. Dehydration steps for immunohistochemistry. 
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 Step Time 
Xylene 20 minutes 
Ethanol 100% 3 minutes 
Ethanol 80% 3 minutes 
Ethanol 60% 3 minutes 
PBS 5 minutes 
Next, samples were washed with PBS for 5 minutes and incubated with 0.3% 
pepsin-0.1N HCl solution for 5 minutes at 37°C to unmask the antigenic sites. 
Samples were washed in PBS for 5 minutes and blocking was performed in PBS-
0.05% Tween 20-5% HyClone serum for 30 minutes at RT. Incubation with the 
primary antibody (Rabbit αGFP, A11122 ThermoFisher) was done in blocking 
solution for 1 hour at RT at 1:100 dilution. After 3 washes (5 minutes each) with 
PBS-0.05% Tween20 sections were incubated with the secondary antibody 
(Alexa 488 donkey antirabbit IgG A21206 ThermoFisher) diluted 1:1000 in the 
blocking solution. DAPI (1 ng/μl) was added for nuclei counterstaining. Finally, 
slides were washed with PBS 3 times (5 minutes each) and mounted in Mowiol.  
Staining was visualized under a confocal microscope (Olympus FV1200, Flow 
Cytometry and Microscopy Core Facility at UCM). 
 
5. Clonogenic assay 
To measure colony-forming/self-renewal capacity, 200 and 500 oval cells 
were seeded in 6-well dishes. Medium was replaced every 3 days. After 8-10 
days, medium was removed, dishes were washed with PBS and colonies were 
stained with a crystal violet solution (0.2% crystal violet in 2% ethanol) for 20 
minutes.  
Total number of colonies per condition was quantified using Image J 
program. 
 
6. Spheres formation assay 
5,000 cells were seeded into low-attachment 6-well plates in a defined 
medium (Table 21). Culture was maintained for 15 days adding fresh medium 
twice a week (Ocana et al., 2012). 
 
 
 
 
Table 20. Hydration steps of paraffin sections for GFP 
detection by immunofluorescence. 
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Medium Supplements 
Final 
Concentration 
DMEM 
4,5 g/l glucose 
Hepes (pH 7.4) 20 mM 
Penicilin G 120 µg/ml 
Streptomycin 100 µg/ml 
Amphotericin B 2.5 µg/ml 
Insulin* 5 μg/ml 
hEGF* 20 ng/ml 
Heparin* 4 μg/ml 
B27 (w/ vit A)* 2% 
Hydrocortisone* 0.5 μg/ml 
For spheroid formation analysis, photographs of all spheroids in each well 
were taken under a phase contrast microscopy (Eclipse TE300, Nikon, connected 
to a camera Nikon digital Sight DS-U2) using a 20X objective. Both number of 
spheroid and spheroid diameter were measured using the Image J program. 
Spheroids were classified in three groups based upon size: [25-50 µm], (50-100 
µm], > 100 µm. 
 
7. Analysis of cell number 
7.1. Analysis of cell number in the presence of serum 
20,000 oval cells were seeded in 12-well plates in triplicates in DMEM-10% 
FBS. Media was replaced twice a week and cells were counted daily for 7 days 
using trypan blue staining and a Neubauer chamber. 
7.2. Analysis of cell number in the absence of serum 
57,000 oval cells or 25,000 HCC cells were seeded in 12-well plates in 
triplicate in 10% FBS media. The following day, serum (oval cells) or medium 
supplements (HCC cells) were removed prior to stimuli addition. Cells were 
counted at specific times as explained before (section 7.1). 
 
8. Invasion assay 
Analysis of cell invasive/migratory capacity was performed using transwell 
inserts (24-well plate inserts; 8 μm pore size; cell growth area 0.3 sq cm, BD 
Bioscience) coated with Matrigel (330 μg/ml) or type IV collagen (7.5 μg/ml) 
according to the manufacturer´s recommendation. 50,000-67,000 oval cells 
were seeded in triplicate on the upper chamber and incubated in the presence 
of stimuli in DMEM-0% FBS. DMEM-0% FBS was added in the lower 
compartment. 
(*) Supplements are added immediately before use 
Table 21. Medium used for spheres formation assay. 
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After 24 hours in culture, cells in the upper chamber were carefully 
removed with a cotton swab and cells that had invaded the membrane were 
fixed with 4% PFA for 20 minutes and stained with 0.2% crystal violet for 20 
minutes. 
Quantification of cell invasion was done by counting stained invaded cells in 
at least 14 fields/insert using a phase-contrast microscopy (Eclipse TE300, 
Nikon) and a 10X objective. 
 
9. Analysis of MMP2 and MMP9 activities 
by zymography 
Zymography is an electrophoretic technique for the detection of matrix 
degrading catalytic activity. We assessed gelatinase (MMP9) by gelatin 
zymography. 
Cells at 80% confluency were serum starved for 48 hours and the culture 
medium was collected. Samples were prepared using non-reducing conditions 
and a non-reducing loading buffer 4X (Table 22) to avoid protein denaturation 
and loss of MMP activity. 
Component     Final concentration 
Tris-HCl pH 6.8 250 mM 
Glycerol 25 % 
SDS 2.5 % 
Bromophenol blue 1 mg/ml 
Then, samples were loaded in an 8% SDS-PAGE, polymerized with 1% 
gelatin. Electrophoresis was carried out at a constant voltage of 80 V for 3-4 
hours. Then, gels were incubated in 2.5% Triton X-100 to remove SDS from the 
gels and rinsed with substrate buffer (Table 23). Next, gels were incubated in 
substrate buffer for 15 hours at 37°C to allow protein renaturation and MMP 
activation. Following day, gels were stained with Coomassie Brilliant Blue 
(BioRad, 161-0400). Gelatin degradation was visualized as clear bands on the 
gel. 
Component Final concentration 
NaCl 0.2 M 
CaCl2 5 mM 
Triton X-100 1 % 
NaN3 0.02 % 
Tris-HCl pH 7.5 50 mM 
 
Table 22. Loading buffer used for zymography. 
Table 23. Substrate buffer used for zymography. 
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10. Senescence associated 
β-galactosidase staining (SA-β-Gal) 
To evaluate cell senescence, staining with SA-β-Gal was performed. After 
treatment, cells were washed with PBS and fixed with PBS-2% PFA and 0.2% 
glutaraldehyde for 5 minutes at RT. Then, cells were washed with PBS and 
incubated for 16 hours at 37°C with the staining solution (Table 24). Next day, 
cells were washed with PBS and then with methanol. Cells were air-dried at RT 
in the darkness (Debacq-Chainiaux et al., 2009). 
Component Final concentration 
Citric acid/sodium phosphate (pH 6.0) 40 mM 
Potassium ferrocyanide 5 mM 
Potassium ferricyanide 5 mM 
NaCl 150 mM 
MgCl2 2 mM 
5-bromo-4-chloro-3-indolyl-βD-
galactopyranoside in methylformamide 
1 mg/ml 
 
Photographs were taken under a phase contrast microscopy (Eclipse TE300, 
Nikon, connected to a camera Nikon Digital Sight DS-U2). 
 
11. Analysis of apoptosis by propidium 
iodide (PI) staining  
250,000 oval cells were seeded in triplicate in 35 cm dishes in DMEM-10% 
FBS. After treatment, plates were washed twice with cold PBS and fixed using a 
mixture of methanol and acetic acid (3:1) for 30 minutes at RT. Next, cells were 
washed twice with PBS and stained for 20 minutes at 37°C with a staining 
solution prepared in PBS (Table 25). Finally, dishes were washed with PBS and 
coverslipped with Mowiol mounting medium (del Castillo et al., 2008b). 
 
Component Final concentration 
PI ( Sigma P-417) 5 µg/ml 
TritonX-100 0.1 % 
EDTA 0.1 M 
RNAsa (Sigma) 25 U/ml 
Apoptotic cells were observed under an inverted fluorescence microscope 
(Eclipse TE300, Nikon) using a 60X objective, following standard morphological 
criteria. At least 15 fields were counted per plate in a blinded manner. 
 
Table 24. SA-β-Gal staining solution. 
Table 25. PI staining solution. 
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12. Measurement of intracellular ROS 
For visualization and analysis of intracellular ROS the oxidation-sensitive 
probe DCFH-DA (2′, 7′-Dichlorofluorescein diacetate, Molecular Probes) at 5 μM 
was used. This compound diffuses into cells and turns into highly fluorescent 
2′,7′-dichlorofluorescein upon oxidation by reactive oxygen species, mainly 
hydrogen peroxide (Herrera et al., 2001). 
 
12.1. Analysis by confocal microscopy  
For confocal microscopy analysis, cells were seeded on gelatin-coated glass 
coverslips in 6 cm dishes in DMEM-10% FBS. After treatment with different 
factors cells were washed with PBS and loaded with DCFH-DA (5 µM) for 30 
minutes at 37°C. Cellular fluorescence intensity was visualized by using a 
confocal microscope and a 60X objective (Olympus FV1200, Flow Cytometry and 
Microscopy Core Facility at UCM). 
 
12.2. Analysis by flow cytometry  
To analyze the intracellular generation of ROS by flow cytometry cells were 
detached by trypsinization and centrifuged at 1,200 rpm for 5 minutes at 4°C. 
Then, cells were washed and resuspended in PBS, transferred to cytometry 
tubes and incubated with DCFH-DA for 30 minutes (37°C). The cellular 
fluorescence intensity was measured by FACScalibur (Becton Dickinson, Flow 
Cytometry and Microscopy Core Facility at UCM). 10,000 cells were recorded in 
each analysis. 
 
13. Gene silencing by siRNA 
Transient Twist1 knockdown was performed by transfection with a mouse 
Twist1 siRNA-SMART pool (Dharmacon, M-055047-01-0005). Non-targeting 
siControl (NT) (Dharmacon, D-001210-03-05) was used as a negative control. For 
siRNA transfection, we used TransITsiQuest reagent (Mirus) according to the 
manufacturer´s recommendation and a final siRNA concentration of 100 nM. 
Cells were transfected twice to warrant down-regulation during the whole 
process. 24 hours after first transfection, cells were serum starved and treated 
with TGF-β for 48 hours. Then, medium was removed and we performed a 
second transfection. Medium was subsequently replaced with complete 
medium supplemented with TGF-β. Experiment was stopped at different time 
points. 
 
14. Intrasplenic transplantation of oval cells  
As recipients for cell transplantation we used mice submitted to CCl4-
induced liver injury. For that, five-nine week-old mice (C57/Bl6) received bi-
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weekly intraperitoneal injections of 3 μl CCl4/g body weight (solution of 10% 
CCl4 in mineral oil) for four weeks before transplantation. CCl4 treatment 
continued post-transplantation until mice sacrifice. 
At transplantation, mice were randomly assigned to 3 groups: PBS-group 
(animals injected with PBS); OC-GFP-group (animals transplanted with OC-GFP), 
and TβT-OC-GFP-group (animals transplanted with TβT-OC-GFP). 
Surgery was performed as follows: once mouse was anesthetized (isoflurane 
inhalation anesthesia), an incision was made to allow access to the spleen. 
Either PBS or cells (2.5x106cells/100 μl PBS) were slowly infused into the spleen 
with a 29 gauge needle. Spleen was ligated with thread to avoid hemorrhage. 
Finally, the wound was closed with suture. 
Animals were sacrificed 1 week or 8 weeks after transplantation and 72 
hours after last injection to eliminate acute effects of CCl4. 
 
14.1. Sample collection 
Under anesthesia (using inhalatory isoflurane), the thoracic cavity was 
opened to expose the heart. Blood was obtained by cardiac puncture using a 1 
ml heparinized hypodermic syringe and a 25 gauge needle and placed in 
eppendorf tubes. Blood samples were allowed to clot at RT and centrifuged at 
1,800 rpm for 10 min at RT for serum separation. Serum was immediately frozen 
and stored at -80°C until analysis.  
The whole liver was removed. Part of the liver lobes were thinly sectioned 
and fixed in 10% formalin solution (Sigma) overnight. Then, they were washed 3 
times with PBS and immersed in PBS-30% sucrose, PBS-20% sucrose and PBS-
10% sucrose, consecutively. Next, the tissue was embedded in paraffin, 
sectioned (4 μm) and stained with hematoxylin and eosin (H&E). Preparation of 
the tissue samples in paraffin and H&E was performed at the Department of 
Pathological Anatomy of the HCSC. 
The remaining portions of the liver were immediately snap-frozen in liquid 
nitrogen and collected in RNase-free tubes for DNA extraction. 
 
15. Analysis of serum parameters  
L-aspartate aminotransferase (L-AST) and alanine aminotransferase (L-ALT) 
activities were measured in blood serum at the laboratory of “Centro de Análisis 
Sanitarios” (Madrid) using gold-standard methods. 
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16. Histopathological analysis of liver 
damage 
H&E stained liver sections were analyzed by Dr. Julián Sanz (head of the 
Department of Pathological Anatomy, HCSC). He evaluated histopathological 
changes observed in the CCl4 experimental model (Liedtke et al., 2013) such as 
central hepatocytes damage (ballooning) and necrosis with steatosis and a 
mixed inflammatory cells infiltrate, with variable intensity and extent (by 
confluent bridging) that were scored as follows: 
0: Normal liver. 
1: Minimal centrilobular steatosis and hepatocytic changes. 
2: Centrilobular steatosis with occasional bridges. 
3: Frequent centro-central and centro-portal bridges without complete 
lobulation. 
4: Extense lobulation. 
 
17. Statistical analysis 
Means ± standard error of the mean (S.E.M) were used to describe each of 
the variables analysed. When only one experiment was shown, data have been 
represented as the mean value ± standard deviation (S.D.). An unpaired 
Student´s t-test or one-way ANOVA followed by the Bonferroni post hoc test 
were used to compare different variables between two or more experimental 
groups, respectively. Longitudinal studies were performed using paired or 
unpaired Student´s t-test as appropriate. For all analysis, p values below 0.05 
were considered statistically significant and were indicated in each figure. All 
statistical analyses were performed using GraphPad Prism 8 software. 
 
 
 
  
  
 
 
 
 
 
8. Results 
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1. TGF-β induces partial EMT in oval cells 
TGF-β participates in different stages of chronic liver disease, having a 
critical role in the development of liver fibrosis. In this context, TGF-β-induced 
EMT is believed to be very important (Watsky et al., 2010; Zeisberg et al., 2007). 
On the other hand, HGF/Met signaling has been shown to be crucial for an 
efficient liver regenerative response, both hepatocyte and oval cell-mediated 
(Huh et al., 2004; Ishikawa et al., 2012). However, whether oval cells are an 
important target for TGF-β during liver fibrosis and whether HGF/Met signaling 
could modulate oval cell response to TGF-β in this context need to be clarified.  
As indicated in background section, previous experiments performed in our 
laboratory (Almale et al., 2019) indicated that acute treatment with TGF-β 
induces EMT in oval cells and that loss of Met tyrosine kinase activity does not 
interfere with such response. Further studies also showed that under chronic 
treatment with TGF-β, oval cells with a functional Met receptor acquire a stable 
EMT phenotype and functional advantages, like apoptosis resistance and 
glycolytic shift. Taken all this into consideration, we decided to further 
characterize the effect of TGF-β-induced EMT on oval cell biology and function 
and to investigate the potential relevance of the crosstalk between TGF-β and 
HGF/Met pathways for oval cells in the context of an EMT.  
1.1. TGF-β induces phenotypic changes in oval cells 
First, we performed a detailed characterization of the phenotypic changes 
induced in oval cells in response to chronic TGF-β treatment. For this, oval cells 
were treated with 1 ng/ml TGF-β for 48 hours followed by continuous 
subculture in the presence of TGF-β 0.5 ng/ml. We used untreated oval cells as 
control and oval cells treated with 1 ng/ml TGF-β for 48 hours (acute treatment) 
as a reference for acute TGF-β treatment. Hereinafter, oval cells chronically 
treated with TGF-β will be referred to as TGF-β treated oval cells (TβT-OC) to 
distinguish them from untreated oval cells. 
RT-qPCR analysis of Snai1 (Snail) and its target Cdh1 (E-cadherin) was 
performed. Snai1 is one of the most relevant EMT-inducing TF and Cdh1 (E-
cadherin) is a cell-to-cell contact protein of the cadherin family considered as an 
epithelial cell marker (Cano et al., 2000). Results showed an important induction 
of Snai1 together with a decrease in the expression of Cdh1 after acute 
treatment with TGF-β respect to untreated oval cells. Chronically treated cells 
maintained Snai1 induction although lower than acutely treated cells, however, 
Cdh1 expression was heterogeneous, being low in some cell lines while in others 
was even higher than in parental oval cells (Figure 26) 
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We next analyzed the protein levels of E-CADHERIN and other EMT markers 
by western blot and/or immunocytochemistry. Consistent with RT-qPCR data, 
we found a decrease in E-CADHERIN levels during acute treatment together 
with a heterogeneous profile in chronically treated cells with TβT-OC lines 
showing either low or high E-CADHERIN levels (Figure 27a, b and c). As 
additional epithelial markers we chose L-CADHERIN, another member of the 
cadherin superfamily of proteins whose expression is restricted to epithelial 
cells of the gastrointestinal system (Liu et al., 2009); and OCCLUDIN, a protein 
component of tight junctions. While L-CADHERIN showed a decrease after acute 
TGF-β treatment, OCCLUDIN did not show significant changes. However, both 
were downregulated in TβT-OC lines (Figure 27a and b). Contrarily, analysis of 
N-CADHERIN and VIMENTIN, two mesenchymal markers, showed an increased 
expression in TβT-OC lines (Figure 27a, b and c).  
In parallel, we analyzed ZO-1 expression pattern by confocal microscopy as 
other component of the tight junctions. ZO-1 protein displayed a change from 
cell to cell contact sites to a diffuse intracellular distribution (Figure 27c), a 
phenomenon commonly observed during EMT (Polette et al., 2007). 
Altogether, these results would indicate that chronic treatment with TGF-β 
induces an EMT in oval cells as it mediates the loss or reorganization of some 
epithelial markers and the gain of mesenchymal markers. The fact that the 
phenotypic change is not associated with E-cadherin loss suggests a partial 
rather than a full EMT response. 
  
 
 
 
Figure 26. Analysis of the expression of Snai1 and Cdh1 in oval cells treated with TGF-β. 
Total RNA was isolated from oval cells untreated (Ut) or treated with TGF-β (1 ng/ml) in 0% 
FBS medium for 48 hours (Acute) or oval cells chronically treated with TGF-β (cultured in 0% 
FBS medium for 48 hours) (Chronic). Snai1 and Cdh1 mRNA levels were determined by RT-
qPCR and normalized to Gusb. Data are expressed relative to the untreated group and are 
mean ± S.E.M. of 11 independent experiments. ** = p < 0.01, *** = p < 0.001 versus untreated  
oval cells. Five different TGF-β chronically treated cell lines were used. 
 97 
 
 
 
1.2. TGF-β-induced EMT in oval cells is associated with decreased 
stemness 
Evidence in the literature supports the concept the EMT process induced by 
TGF-β in epithelial cells correlates with a less differentiated phenotype and 
acquisition of stem cell properties (Abell and Johnson, 2014; Jayachandran et 
Figure 27. Epithelial and mesenchymal markers in oval cells treated with TGF-β. a) Total 
proteins were extracted from oval cells untreated (Ut) or treated with TGF-β (1 ng/ml) in 0% 
FBS medium for 48 hours (Acute) or oval cells chronically treated with TGF-β cultured in 0% 
FBS medium for 48 hours (Chronic). Western blot assay was performed for the analysis of the 
indicated proteins using β-ACTIN as loading control. A representative experiment using three 
different TβT-OC lines (designated #1, #2 and #3) is shown. b) Optical density values relative 
to loading control were calculated. Data are expressed relative to untreated (Ut) oval cells 
and are mean ± S.E.M. of 3-5 independent experiments (n=3-18). * = p < 0.05, ** = p < 0.01 
versus untreated oval cells. c) Untreated and TGF-β chronically treated oval cells maintained 
in 10% FBS medium were fixed and stained with specific primary antibodies for the indicated 
proteins and a fluorescent secondary antibody. Nuclei were counterstained with DAPI. 
Representative confocal microscopy images from 2-3 independent experiments are shown. 
Scale bar=20 μm. At least three different TβT-OC lines were used in both analyses. 
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al., 2016). We therefore analyzed if TGF-β-induced EMT somehow affected oval 
cell stemness. 
We first checked the mRNA levels of different stem cell markers, Epcam, 
Cd44 and Prom1 (CD133), in oval cells and TβT-OC. Our data revealed a 
downregulation of Epcam and Prom1 in TβT-OC, markers usually associated 
with epithelial cells (Malfettone et al., 2017), with no significant changes in Cd44 
(Figure 28a). In parallel to the RT-qPCR analysis, we also studied EPCAM and 
CD44 protein levels by flow cytometry. EPCAM-positive oval cells, measured 
both as percentage of positive cells and mean of fluorescence intensity, 
decreased in TβT-OC (Figure 28b and c). However, CD44-positive cells did not 
change between OC and TβT-OC (Figure 28b and c). Therefore, flow cytometry 
analyses confirmed RT-qPCR results.  
Figure 28. Analysis of stem cell markers in oval cells and TβT-OC. a) Oval cells and TβT-OC 
were maintained in 0% FBS medium for 48 hours, and total RNA was isolated. Epcam, Prom1 
and Cd44 mRNA levels were determined by RT-qPCR and normalized to Gusb. Data are 
expressed relative to oval cells and are mean ± S.E.M. of 4-6 independent experiments 
performed in triplicate. *** = p < 0.001 versus oval cells. b-c) Oval cells and TβT-OC maintained 
in 10% FBS medium were stained with specific antibodies for EPCAM and CD44 or with isotype 
controls, and  analyzed by flow cytometry. b) Representative histograms are shown. c) 
Percentage of positive cells and fluorescence intensity (F.I.) values are mean ± S.E.M. of 2 
independent experiments (n=2-6). Three different TβT-OC lines were used in both analyses. 
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Additionally, we performed clonogenic and sphere formation assays under 
anchorage-independent conditions. This could help us to determine if there 
were any alterations in the clonogenic and self-renewal capacity, typical stem 
cells properties (Cao et al., 2011; Pastrana et al., 2011) that are observed in oval 
cells, in TβT-OC.   
 
Clonogenic assay revealed a decrease in the clonal growth capacity of TβT-
OC in comparison to oval cells (Figure 29a). Interestingly, colonies formed by 
TβT-OC were bigger than oval cell colonies and morphologically different. 
Consistent with the acquisition of a mesenchymal and more migratory 
phenotype upon EMT, TβT-OC loosed cell adhesion, occupied a larger cell 
spreading area and grew in a more disorganized manner overall resulting in less 
tight colonies. This phenomenon was very clear at the colonies periphery where 
cells become very loose. This was opposed to what was seen with oval cells, 
which showed stronger cell-cell adhesions and formed tightly packed colonies 
Figure 29. Analysis of stem cell properties in oval cells and TβT-OC. a) Oval cells and TβT-OC 
were seeded at low density and maintained in 10% FBS medium for up to 8-10 days and 
number of colonies were counted. Data are expressed relative to oval cells and are mean ± 
S.E.M. of 3 experiments performed in triplicate. ** = p < 0.01 versus oval cells. b) 
Representative images of the whole plate and phase contrast microscopy images of individual 
colonies (border areas) are shown. Scale bar=100 μm. c) Oval cells and TβT-OC were seeded in 
ultra-low-attachment plates in 0% FBS medium supplemented with factors for up to 15 days. 
Graph shows the number of spheroids per well, distributed according to their diameter. Data 
are mean ± S.E.M. of 2 independent experiments (n=2-5). d) Representative phase contrast 
microscopy images of formed spheroids are shown. Scale bar=50 μm. At least two different 
TβT-OC lines were used in both analyses. 
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with more defined borders (Figure 29b). Concerning the spheroid formation 
assay, culture was maintained over time and once per week we took pictures of 
the spheres formed by each cell line. Number and diameter of spheres were 
measured to control the evolution of the spheres. The assay failed to reveal 
significant differences in the ability to form spheres between TβT-OC and oval 
cells, although TβT-OC showed a tendency to form bigger spheres (Figure 29c 
and d). 
Collectively, these data suggest that EMT induced in oval cells by chronic 
treatment with TGF-β does not result in acquisition of stem cell properties. 
 
1.3. TGF-β-induced EMT in oval cells is associated with alterations in 
hepatic lineage markers 
Since Epcam is also a marker of hepatic progenitor cells (Chen et al., 2017; 
Itoh and Miyajima, 2014), and showed a decreased expression in TβT-OC, we 
further explored the effects of EMT on the intrinsic lineage features of oval cells. 
We first analyzed the expression of CK19 and ALBUMIN, two commonly 
used markers of oval cells (Chen et al., 2017). 
Figure 30. Analysis of oval cells markers in oval cells and TβT-OC. a) Oval cells and TβT-OC 
were maintained in 0% FBS medium for 48 hours, and total proteins were isolated. Western 
blot assay was performed for the indicated proteins using β-ACTIN as loading control. A 
representative experiment using three different TβT-OC lines (designated #1, #2 and #3) is 
shown. b) Optical density values relative to loading control were calculated. Data are 
expressed relative to oval cells and are mean ± S.E.M. of 2 independent experiments (n=2-
10). c) Oval cells and TβT-OC maintained in 10% FBS medium were fixed and stained with 
specific primary antibodies for the indicated proteins and a fluorescent secondary antibody. 
Nuclei were counterstained with DAPI. Representative confocal microscopy images out of 2-3 
independent experiments are shown. Scale bar=20 μm. At least two different TβT-OC lines 
were used in both analyses.  
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Western blot analysis showed no changes in CK19 expression levels in TβT-
OC as compared to oval cells whereas ALBUMIN showed a slight increase (Figure 
30a and b). Same results were obtained by confocal microscopy analysis (Figure 
30c). 
To characterize in more detail the phenotype of TβT-OC, we studied the 
expression of other hepatocyte and biliary epithelial cell lineage markers 
including members of the hepatocyte nuclear factors family (HNF) since oval 
cells are bipotential progenitor cells that can differentiate into both hepatocytes 
and cholangiocytes.  
We found a sharp decrease in Hnf1b, Onecut1 (Hnf6) mRNA levels of TβT-
OC when compared to oval cells (Figure 31). All of these genes are 
predominantly expressed in biliary epithelial cells and are required for the 
normal development of biliary tract (Clotman et al., 2002; Limaye et al., 2008; 
Nagy et al., 1994). Gamma-glutamyltransferase (Ggt), a biliary epithelial cell 
marker expressed in oval cell, was also downregulated in TβT-OC (Figure 31). On 
the other hand, Hnf4a, a transcription factor that is essential for the 
differentiation into hepatocytes (Watt et al., 2003), and alpha-fetoprotein (Afp), 
a marker of immature hepatocytes, were upregulated in TβT-OC (Figure 31). 
Based on these results, we could state that chronic treatment of oval cells 
with TGF-β results in a decrease of biliary epithelial cell markers and increase in 
hepatocyte markers. These data suggest that EMT could be associated with a 
step forward in the hepatocyte lineage differentiation of oval cells. 
Figure 31. Analysis of biliary epithelial and hepatocyte lineage markers in oval cells and 
TβT-OC. Oval cells and TβT-OC were maintained in 0% FBS medium for 48 hours, and total 
RNA was isolated. Hnf1b, Onecut1, Ggt, Hnf4a and Afp mRNA levels were determined by RT-
qPCR and normalized to Gusb. Data are expressed relative to oval cells and are mean ± S.E.M. 
of 3-7 independent experiments. * = p < 0.05, *** = p < 0.001 versus oval cells. At least two 
TβT-OC lines were used. 
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1.4. TGF-β-induced EMT in oval cells is associated with alterations in 
the autocrine signaling 
EMT is able to induce changes in the secretory phenotype of cells, 
increasing the expression of some ligands (Reka et al., 2014). Concretely, our 
group has demonstrated that EMT in fetal hepatocytes induces an autocrine 
loop of TGF-β1, which increases EGFR ligands production (Del Castillo et al., 
2006). 
Taking these results into account, we wanted to determine possible changes 
in the TβT-OC autocrine signaling, thus we checked the expression of TGF-β1, 
TGF-α, as an EGFR ligand, and other growth factors related to EMT.  
Our RT-qPCR analysis showed that oval cells secrete Tgfb1, Tgfa or Ctgf, an 
extracellular matrix-associated protein of the CCN family, but no changes in the 
expression of these ligands were observed in TβT-OC (Figure 32). However, we 
found differences in the expression levels of some isoforms of PDGF family 
ligands. PDGF ligands through binding to tyrosine-kinase receptors stimulate 
proliferation, growth differentiation, secretion of growth factors and, in some 
circumstances, contribute to regulate EMT (Andrae et al., 2008; Gotzmann et 
al., 2006). Among the different Pdgf isoforms analyzed, Pdgfb expression was 
not altered in TβT-OC, but Pdgfa and c were upregulated in TβT-OC respect to 
oval cells (although data did not reach statistical significance) and Pdgfd was 
significantly down-regulated in TβT-OC (Figure 32). These data suggest TGF-β 
chronic treatment of oval cells modifies gene expression profile of some growth 
factors, which could be relevant for cell phenotype and behavior. 
Figure 32. Analysis of ligands in oval cells and TβT-OC. Oval cells and TβT-OC were 
maintained in 0% FBS medium for 48 hours, and total RNA was isolated. Tgfb1, Tgfa, Ctgf, 
Pdgfa, b, c, and d mRNA levels were determined by RT-qPCR and normalized to Gusb. Data 
are expressed relative to oval cells and are mean ± S.E.M. of 3-6 independent experiments. 
*** = p < 0.001 versus oval cells. At least three TβT-OC lines were used. 
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1.5. TGF-β-induced EMT in oval cells confers functional advantages 
It is widely established that cells that have undergone an EMT acquire 
growth, survival, migratory and invasive advantages (Brabletz et al., 2018; Kim 
et al., 2017a). We therefore investigated if TβT-OC have gained any of these 
functional changes. 
First, we analyzed cell growth capacity in response to the mitogenic signals 
present in the serum. In these conditions, we found that TβT-OC showed 
identical cell growth rate than parental cells (Figure 33a). When we performed 
this assay in the absence of serum, oval cells displayed a significant decrease in 
cell number, because of the apoptotic response elicited by serum withdrawal 
(del Castillo et al., 2008b). However, TβT-OC showed an increase in cell number 
(Figure 33b), indicating that TβT-OC have acquired an intrinsic growth capacity. 
We next examined the invasive capacity of TβT-OC in comparison with oval 
cells. To address this question, we plated cells on matrigel-coated transwells. 
Due to their invasive cell capacity, cells passed through the matrigel to the other 
side of the membrane in the absence of exogenous stimuli. Quantitative 
analysis of cell invasion assays showed that TβT-OC have acquired invasive 
advantages as compared to oval cells (Figure 34a and b). 
 
 
 
 
Figure 33. Analysis of cell growth in oval cells and TβT-OC. a) Oval cells and TβT-OC were 
maintained in 10% FBS medium for different periods of time up to 7 days and were counted. 
Data are expressed respect to zero time and are mean ± S.E.M. of 2-7 independent 
experiments performed in triplicate. b) Oval cells and TβT-OC were maintained in 0% FBS 
medium for 48 hours and were counted. Data are expressed respect to zero time and are 
mean ± S.E.M. of 14 independent experiments performed in triplicate. *** = p < 0.001 versus 
zero time or as indicated. At least three different TβT-OC lines were used in both analyses. 
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The role of MMPs in the extracellular matrix degradation during cell 
migration/invasion is well recognized (Kessenbrock et al., 2010). Particularly, 
results of our group have demonstrated the involvement of some MMPs in the 
pro-invasive activity triggered by HGF/Met in oval cells (Suarez-Causado et al., 
2015). This prompted us to analyze a potential implication of MMPs in the TβT-
OC invasive phenotype. 
Hence, we analyzed in oval cells and TβT-OC the mRNA levels of Mmp2, 9, 
10 and 13 and Timp1 and 3. As shown in figure 35a, Mmp2, 10 and 13 were 
significantly increased in TβT-OC. However, chronic EMT in oval cells did not 
modify the Mmp9 mRNA expression. With respect to TIMPs, while Timp1 was 
downregulated, Timp3 mRNA levels were higher in TβT-OC (Figure 35a). 
Additionally, we measured the gelatinase activity by performing gelatin 
zymography, and found that MMP9, whose expression hardly changes in TβT-
OC, showed an increased activity in TβT-OC, as compared to oval cells (Figure 
35b), suggesting post-transcriptional regulation of MMP9. Besides, despite the 
increase in Timp3 expression in TβT-OC, zymography assays demonstrated 
MMPs activity in TβT-OC.  
These results show that chronic EMT induces changes in MMPs and TIMPs 
expression in oval cells, which likely participate in the TβT-OC invasive capacity. 
A specific role for MMP9 is suggested. 
 
 
 
 
Figure 34. Analysis of the invasive capacity in oval cells and TβT-OC. a) Oval cells and TβT-OC 
were plated in 0% FBS medium in the upper 24-transwell units coated with matrigel. Cells 
were allowed to pass through matrigel-coated filters for 24 hours and then were fixed in PFA 
and stained with crystal violet and counted by phase contrast microscope (14 random fields). 
Data are expressed relative to oval cells and are mean ± S.E.M. of 9 independent experiments 
performed in triplicate. *** = p < 0.001 versus oval cells. b) Representative phase contrast 
microscopy images of invading cells are shown. Scale bar=100 μm. Five different TβT-OC lines 
were used. 
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Putting it all together, the acquisition of intrinsic growth capacity and a 
higher invasive capacity of TβT-OC, added to previous results of the group (see 
background section) such as an apoptosis-resistant phenotype and a switch in 
their bio-energetic profile towards a more glycolytic phenotype, indicate that 
EMT confers key functional advantages to oval cells. 
 
1.6. EMT enhances oval cells repopulation capacity in a damaged 
liver 
Since the in vitro approaches taken so far show that TβT-OC had acquired 
functional advantages, our next goal was to analyze whether these changes 
conferred growth/survival advantages to TβT-OC in vivo, in an injured liver. 
To this end, we used an animal model of hepatic fibrosis induced by CCl4 
injections. Wild type mice were subjected to 4 weeks of CCl4 treatment 
(intraperitoneal injections of 3 μl CCl4/g of body weight twice a week), and then 
Figure 35. Analysis of MMPs and TIMPs in oval cells and TβT-OC. a) Oval cells and TβT-OC 
were maintained in 0% FBS medium for 48 hours, and total RNA was isolated. Mmp2, 9, 10, 
13, Timp1 and Timp3 mRNA levels were determined by RT-qPCR and normalized to Gusb. 
Data are expressed relative to oval cells and are mean ± S.E.M. of 3-7 independent 
experiments. b) Pro-MMP9 activities were analyzed by zymography. The bar graph shows 
the quantitative analysis of zymography. Optical density values are expressed relative to oval 
cells and are mean ± S.E.M. of 3 independent experiments. * = p < 0.05 versus oval cells. Two 
different TβT-OC lines were used in both analyses. 
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we performed intrasplenic injection of parental oval cells and TβT-OC, 
previously transduced with GFP (OC-GFP, TβT-OC-GFP), and PBS as control. CCl4 
treatment was maintained after transplantation and mice were sacrificed 1 
week or 8 weeks after transplantation as depicted in figure 36. 
 
First, we analyzed the engraftment of oval cells and TβT-OC in the liver of 
transplanted mice by two different approaches.  
Figure 36. Scheme of CCl4-induced liver fibrosis model and cell transplantation assay. 
Figure 37. Detection of transplanted cells in host livers. a) Immunofluorescence staining was 
performed using a specific anti-GFP antibody in liver sections 1 week after transplantation. 
Nuclei were stained with DAPI. Representative confocal microscopy images of one mouse and 
two mice transplanted with OC-GFP and TβT-OC-GFP, respectively are shown. Arrowheads 
indicate GFP-positive cells corresponding to engrafted OC-GFP and TβT-OC-GFP. b) Genomic 
DNA was isolated from livers of mice injected with PBS, OC-GFP and TβT-OC-GFP 1 and 8 
weeks after transplantation. DNA was used for PCR analysis of the floxed allele. DNA from 
cultured oval cells and water were used as a positive (Pos.) and negative (Neg.) control, 
respectively.  
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On the one hand, we performed immunofluorescence staining with anti-GFP 
antibody on liver sections to visualize GFP-positive cells engrafted in the liver 
parenchyma after 1 week of transplantation (Figure 37a). Interestingly, GFP-
positive cells are more abundant and form larger cell clusters in livers from mice 
transplanted with TβT-OC when compared to those transplanted with oval cells, 
suggesting a better engraftment or enhanced cell survival and/or proliferation 
upon engraftment. Unfortunately, we were not able to detect GFP-positive cells 
8 weeks after transplantation using this approach, so we decided to run a PCR 
for detection of the floxed allele carried by oval cells and TβT-OC to confirm the 
presence of transplanted cells in the liver, obtaining positive results at both time 
points (Figure 37b). 
Once we had confirmed that oval cells and TβT-OC were integrated in host 
livers, we evaluated the impact of transplanted cells on damaged liver. We 
measured liver function parameters in serum, in particular aspartate 
aminotransferase (AST) (Figure 38a) and alanine aminotransferase (ALT) (Figure 
38b), which are elevated during liver damage. TβT-OC-transplanted animals 
showed a reduction in the increase of AST and ALT provoked by CCl4 treatment, 
in comparison to mice that received PBS only or those transplanted with oval 
cells. In the case of AST, differences were statistically significant. 
To reinforce these data we analyzed the collagen deposition by Sirius red 
staining as a way to measure the grade of fibrosis. As expected, 1 week after 
transplantation (e.g. after 5 weeks of treatment with CCl4) PBS-injected livers 
presented a high-degree of fibrosis, compared with untreated mice, which was 
not altered in livers of mice transplanted with oval cells and TβT-OC (Figure 
39a). However, results corresponding to 8 weeks after transplantation support 
those obtained from liver function test, being the livers from TβT-OC-
transplanted mice the ones that display the lowest fibrosis degree. Interestingly, 
oval cell transplanted animals also showed a trend to present a decreased liver 
fibrosis (Figure 39b and c). 
 
 
Figure 38. Analysis of liver function parameters in mice transplanted with oval cells and TβT-
OC. a-b) Analysis of AST and ALT serum levels in untreated mice, CCl4-treated mice and mice 
transplanted with OC-GFP, TβT-OC-GFP and PBS 8 weeks after transplantation. Data are 
expressed respect to untreated mice and are mean ± S.E.M. of 4-9 animals per group. * = p < 
0.05, ** = p < 0.01 versus untreated group or as indicated. 
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These data were confirmed by a histopathological assessment of the grade 
of liver damage performed by a single pathologist. Common histopathological 
changes caused by CCl4 treatment (Liedtke et al., 2013) were detected in H&E-
stained liver sections from all mice groups (Figure 40a). However, differences in 
the intensity and the extension of the damage were observed between groups. 
A scoring system was established (see material and methods for details), which 
comprised values between 0, normal liver, to 4, severe damage. Thus, while the 
majority of the mice from PBS and OC-transplanted groups were assigned scores 
2-4, TβT-OC-transplanted mice got lower scores (1 and 2) (Figure 40b). It is 
noteworthy that no hepatocarcinoma nodules were identified in any case. 
 
 
 
 
 
Figure 39. Analysis of liver fibrotic area in mice transplanted with oval cells and TβT-OC. a-
b) Fibrotic area (Sirius red-stained area) was measured in liver sections from untreated mice, 
CCl4-treated mice and mice transplanted with OC-GFP, TβT-OC-GFP and PBS 1 and 8 weeks 
after transplantation. 4-6 animals per experimental group were used. Data are expressed as 
% mean of fibrotic area. * = p < 0.05, *** = p < 0.005 versus untreated group or as indicated. 
c) Representative phase contrast images of Sirius red staining in liver tissue sections (8 weeks 
after transplantation). Scale bar=500 μm (upper panels) and 100 μm (lower panels). 
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These results, all together, provide evidence supporting that transplanted 
TβT-OC improve liver function in CCl4-damaged livers, therefore, treatment with 
TGF-β confers unique properties to oval cells that improve their regenerative 
potential, ultimately resulting in a reduction of liver damage. 
In order to understand the molecular mechanisms that could explain how 
TβT-OC could attenuate liver fibrosis, we analyzed mRNA levels of Hgf, a well-
known anti-fibrotic and pro-regenerative factor. Livers 8 weeks post-
transplantation showed higher expression levels of Hgf in mice transplanted 
with OC and TβT-OC when compared to PBS infusion, reaching the highest levels 
with TβT-OC, although differences are not significant (Figure 41). Additionally, 
based on the results showing a step forward in the hepatocyte lineage in oval 
cells after EMT (Figure 31), we checked Cytochrome P450 7a1 (Cyp7a1) 
expression, as a marker of liver maturation. Cyp7a1 showed the same pattern 
observed for Hgf expression, with the highest levels in livers from TβT-OC-
transplanted mice (Figure 41).  
These results serve as evidence of a regeneration process taking place in 
transplanted livers and suggest a role of HGF in this process. 
 
 
 
 
 
Figure 40. Histopathological assessment of liver damage in mice transplanted with oval cells 
and TβT-OC. a-b) H&E staining of liver sections from untreated mice, CCl4-treated mice and 
mice transplanted with OC-GFP, TβT-OC-GFP and PBS 8 weeks after transplantation were 
evaluated. a) Representative phase contrast images. Scale bar=100 μm. b) Number of mice 
with a particular score in each experimental condition (n=4-6) is indicated.  
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2. Relevance of HGF/Met pathway in TGF-
β-induced-EMT in oval cells 
 
As described in background section, previous results of our group using oval 
cells expressing a mutant Met receptor lacking tyrosine kinase activity (Met-/-) 
showed that Met-/- oval cells undergo an acute EMT by TGF-β treatment in a 
similar manner to their normal counterparts, Metflx/flx oval cells (Almale et al., 
2019). These data indicate that absence of Met kinase activity does not interfere 
with acute induction of EMT by TGF-β in oval cells. However, whether Met 
signaling could somehow be involved in the chronic EMT response triggered by 
TGF-β was not clear. So, we decided to explore this question. 
2.1. Lack of Met tyrosine kinase activity induces replicative senescence 
and impedes oval cell expansion after chronic EMT 
Following the same experimental protocol used to generate TβT-OC Metflx/flx 
lines, we tried to generate TβT-OC from Met-/- oval cells (Figure 42a and b). 
As expected, the behavior of the two cell lines, Metflx/flx and Met-/-, was 
similar during the acute treatment with TGF-β except for the higher apoptosis 
rate of Met-/- oval cells compared to Metflx/flx. However, after the first passage 
differences between cell lines emerged. Metflx/flx oval cells maintained a typical 
mesenchymal phenotype and after a brief interval of time they acquired a 
growth rate similar to that of untreated cells (prior to TGF-β treatment). Thus, 
subsequence passages lead to establishment of a stable TβT-Metflx/flx oval cell 
line. However, Met-/- oval cells acquired senescent cell-like appearance after the 
first passage. They became large flat cells with a big cytoplasm, which were not 
able to progress in culture (Figure 42b). Phenotypical appearance of Met-/- oval 
Figure 41. Analysis of the expression of Hgf and Cyp7a1 in hepatic tissue from mice 
transplanted with oval cells and TβT-OC. Total RNA was isolated from CCl4-treated mice and 
mice transplanted with OC-GFP, TβT-OC-GFP and PBS 8 weeks after transplantation. Hgf and 
Cyp7a1 mRNA levels were determined by RT-qPCR and normalized to Gusb. Data are 
expressed respect to PBS group and are mean ± S.E.M. of 4-6 animals per group. * = p < 0.05, 
** = p < 0.01 versus PBS group. 
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cells suggested that these cells were undergoing a senescence process in 
response to chronic TGF-β treatment. 
 
To confirm this hypothesis, we analyzed some of the common markers used 
for identifying senescent cells. First, we performed a SA-β-Gal staining to detect 
the β-galactosidase activity, a hydrolase enzyme that catalyzes the hydrolysis of 
β-galactosides into monosaccharides only in senescent cells (Debacq-Chainiaux 
et al., 2009). The assay showed a positive staining for SA-β-Gal in TβT-Met-/- cells 
already at passage 1, while TβT-Metflx/flx cells were negative for this staining 
(Figure 43a). 
Additionally, we studied the expression of CKIs, cell cycle inhibitors 
considered as senescence markers, due to the strong link between cell cycle 
arrest and senescence (Hernandez-Segura et al., 2018; Kuilman et al., 2010). 
Particularly, we checked the expression of two members of INK4 family, Cdkn2b 
(p15) and Cdkn2a (p19) and two members of Cip/Kip family, Cdkn1a (p21) and 
Cdkn1b (p27). 
The expression of these CKIs was analyzed during the course of 
establishment of TβT-OC lines. Thus, we collected samples from TβT-Metflx/flx 
and TβT-Met-/- oval cells at different passages (p1/2 and p5). However, samples 
of passages after p1 could only be collected in the case of TβT-Metflx/flx cells, 
because TβT-Met-/- oval cells did not progress in culture after the first 
subculture. As reference, samples were also collected from Metflx/flx and Met-/- 
Figure 42. Generation of TβT-Metflx/flx and TβT-Met-/- oval cells. 
a) Scheme of the protocol followed for the generation of TβT-
Metflx/flx and TβT-Met-/- oval cells. b) Representative phase 
contrast microscopy images corresponding to Metflx/flx and Met-/- 
oval cells at specific phases during the TβT-OC generation 
process: prior to TGF-β treatment, acute and chronic treatment 
with TGF-β.  
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oval cells untreated and acutely treated with TGF-β. In agreement with the SA-
β-Gal staining results (Figure 43a), TβT-Met-/- cells at p1/2 showed a significantly 
higher expression of Cdkn2b (p15), Cdkn2a (p19), Cdkn1a (p21) and Cdkn1b 
(p27) than TβT-Metflx/flx (Figure 43b), further demonstrating the senescent 
phenotype. 
 
Figure 43. Analysis of senescence markers after chronic treatment of oval cells with TGF-β. 
a) SA-β-Gal staining in TβT-Metflx/flx and TβT-Met-/- oval cells. Bright-field microscopy images 
are shown. Scale bar=50µm. b) Total RNA was isolated from Metflx/flx and Met-/- oval cells 
treated or not (Ut) with TGF-β (1 ng/ml) in 0% FBS medium for 48 hours. Metflx/flx and Met-/- 
oval cells were chronically treated with TGF-β in 10% FBS medium and total RNA was isolated 
at different passage number (p1/p2 and p5). mRNA levels of the CKIs p15, p19, p21 and p27 
were determined by RT-qPCR and normalized to Gusb. Data are expressed relative to 
untreated Metflx/flx oval cells and are mean ± S.E.M. (n=2-8). * = p < 0.05, ** = p < 0.01, *** = p 
< 0.001 versus untreated oval cells or as indicated.  
 113 
 
 
Next, we wanted to confirm that the senescence response of Met-/- oval 
cells to chronic TGF-β treatment was a direct consequence of the lack of Met 
tyrosine kinase activity. Thus, we used the Met inhibitor PHA665752, an ATP 
competitive inhibitor of the tyrosine kinase activity, to chemically mimic the 
behavior of Met-/- oval cells. First, we confirmed PHA665752 activity in Metflx/flx 
oval cells as it completely abolished HGF-induced activation of its downstream 
target ERKs (Figure 44a). Then, we proceed to generate TβT-OC from Metflx/flx 
oval cells in the presence of PHA665752. Interestingly, the treatment with Met 
inhibitor phenocopied Met-/- oval cells. Thus, cells displayed the same 
senescent-like phenotype observed in Met-/- cells upon subculture with TGF-β 
and stopped dividing (Figure 44b). This served to prove that the senescence 
response in oval cells was a consequence of the absence of a functional Met 
receptor.  
Altogether, these data evidence that Met-/- oval cells undergo cellular 
senescence after chronic treatment with TGF-β while highlighting that Met 
kinase catalytic activity is critical to allow oval cell expansion after TGF-β-
induced EMT. 
 
2.2. Met tyrosine kinase activity is essential for oval cell expansion 
and contributes to TβT-OC properties 
To further explore the role of Met in oval cell expansion after an EMT 
process, we focused our efforts on the study of the role of Met tyrosine kinase 
activity on the functional and phenotypic properties of TβT-OC. 
  
Figure 44. Generation of TβT-Metflx/flx oval cells in the presence of PHA665752. a) Metflx/flx 
oval cells were serum starved and treated or not with HGF (40 ng/ml) for 10 minutes in the 
absence or presence of the Met inhibitor PHA665752 (5 µM, 1 hour-pretreatment), and total 
proteins were isolated. Western blot assay was performed for the indicated proteins. A 
representative experiment is shown. b) Representative phase contrast microscopy images of 
Metflx/flx and TβT-Metflx/flx oval cells during the TβT-OC generation process in the presence of 
PHA665752 (5 µM) are shown.  
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Since we had previously identified an autocrine HGF/Met loop in oval cells 
(del Castillo et al., 2008b), as previously mentioned, we wondered if this 
signaling loop was still operative in TβT-OC. We performed an analysis of the 
expression of Hgf by RT-qPCR and we observed that TβT-OC expressed higher 
levels of Hgf than oval cells in basal conditions, i.e. in the absence of exogenous 
stimulation (Figure 45a). To provide additional evidence of the HGF/Met 
autocrine signaling loop, we studied MET tyrosine phosphorylation by running 
immunoprecipitation assays in oval cells and TβT-OC in basal conditions. Our 
results confirmed MET phosphorylation, that is MET activation, in both cell lines 
(Figure 45b), proving that an autocrine HGF/Met signaling remains operative in 
oval cells after EMT.  
To further clarify the role of Met signaling in oval cell expansion and 
properties post-EMT, we used PHA665752 Met inhibitor. TβT-OC were pre-
treated with the inhibitor for 2 weeks prior to the experiments and during the 
course of experiment in order to mimic Met-/- oval cell conditions (Figure 42). 
PHA665752 inhibitory activity in TBT-OC was confirmed at the same dose used 
in oval cell. Indeed, pretreatment for 2 weeks with PHA665752 completely 
abolished HGF-induced MET phosphorylation and activation of its downstream 
target AKT (Figure 46a).  
 
Importantly, long-term exposure of TβT-OC to PHA665752 inhibitor resulted 
in a reduced cell growth capacity. In other words, pharmacological inhibition of 
Met signaling inhibited the intrinsic TβT-OC growth capacity (Figure 46b). This, 
together with the cell cycle arrest observed in Met-/- oval cells after chronic 
treatment with TGF-β (Figure 43) support the existence of an autocrine loop 
Figure 45. Analysis of autocrine HGF/Met signaling in oval cells and TβT-OC. a) Oval cells 
and TβT-OC were maintained in 0% FBS medium for 48 hours, and total RNA was isolated. 
Hgf mRNA levels were determined by RT-qPCR and normalized to Gusb. Data are expressed 
relative to oval cells and are mean ± S.D. of one representative experiment using three 
different TβT-OC lines. b) Oval cells and TβT-OC (designated #1, #2 and #3) were maintained 
in 0% FBS medium for 16 hours, and total proteins were isolated. Protein extracts were used 
for MET immunoprecipitation (IP). Phosphorylation was detected by immunoblotting (IB) 
with anti P-tyrosine antibody. Western blot assay for MET was used as a loading control. 
Control IP (without antibody) and Mock IP (without proteins) were used as controls. A 
representative experiment out of 4 is shown. 
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through HGF/Met, which sustains TβT-OC growth and it is essential to allow oval 
cells expansion after EMT.  
Besides, our data clearly showed that under PHA665752 treatment, TβT-OC 
cell number decreased below baseline (i.e. number of TβT-OC after 48 hours 
culture in the absence of serum was lower that number of cells at zero time) 
(Figure 46b). These data evidence that PHA665752 sensitizes TβT-OC to serum 
deprivation. This hypothesis was further confirmed with the analysis of 
apoptotic cell death. Indeed, results in Figure 46c show that treatment with 
PHA665752 increased TβT-OC apoptotic index under serum withdrawal. 
Figure 46. Analysis of Met tyrosine kinase inhibition in functional TβT-OC properties. a-d) 
TβT-OC were treated with Met inhibitor PHA665752 (5 μM) for 2 weeks. a) PHA665752 
treated TβT-OC were serum starved and treated with HGF (40 ng/ml) for 10 minutes, and total 
proteins were isolated. Western blot assay was performed for the analysis of the indicated 
proteins using β-ACTIN as loading control. A representative experiment is shown. b) TβT-OC 
and PHA665752 treated TβT-OC were maintained in 0% FBS medium for 48 hours and 
counted. Data are expressed respect to zero time and are mean ± S.E.M. of 9 independent 
experiments performed in triplicate. c) TβT-OC and PHA665752 treated TβT-OC were 
maintained in 0% FBS medium for 24 hours and number of apoptotic nuclei after PI staining 
were counted under a fluorescence microscope (15 random fields). Data are expressed 
relative to untreated TβT-OC and are mean ± S.E.M. of 6 independent experiments performed 
in triplicate. d) TβT-OC and PHA65752 treated TβT-OC were plated in 0% FBS medium in the 
upper 24-transwell units coated with collagen. Cells were allowed to pass through collagen-
coated filters for 24 hours and stained with crystal violet and counted by phase contrast 
microscope (14 random fields). Data are expressed relative to untreated TβT-OC and are mean 
± S.E.M. of 5 independent experiments performed in triplicate. * = p < 0.05; ***, = p < 0.001 
versus untreated TβT-OC. At least three TβT-OC lines were used in all analyses. 
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In addition to this, TβT-OC treated with PHA665752 underwent a moderate 
but significant decrease in their invasive capacity, as demonstrated by the 
decrease in the number of cells that pass through collagen-coated transwells 
(Figure 46d). 
Interestingly, besides the differences in cell functional capabilities, in the 
presence of Met inhibitor TβT-OC showed changes in the expression of 
epithelial (E-CADHERIN) and mesenchymal (VIMENTIN) markers consistent with 
acquisition of a more mesenchymal phenotype (Figure 47a and b). 
 
All together, results indicate that HGF/Met autocrine loop critically 
regulates the phenotypic and functional properties acquired by oval cells after 
TGF-β-induced EMT.  
On the other hand, it is worth highlighting a change in cell response to HGF 
after EMT. We and others have previously demonstrated that HGF is a 
mitogenic factor for oval cells (del Castillo et al., 2008b). However, treatment of 
TβT-OC with HGF did not increase their proliferation over the intrinsic cell 
growth capacity (Figure 48a). 
A similar trend is observed in in vitro invasion assays. Our previous data 
showed that HGF increased the invasive capacity of oval cells (Suarez-Causado 
et al., 2015). In contrast, HGF failed to increase TβT-OC invasive capacity, which 
once again was higher than that observed in parental oval cells (Figure 48b). 
 
 
 
 
Figure 47. Analysis of Met tyrosine kinase inhibition in TβT-OC phenotype. a) TβT-OC were 
treated with Met inhibitor PHA665752 (5 μM) for 2 weeks. TβT-OC and PHA65752 treated 
TβT-OC were maintained in 0% FBS medium for 48 hours, and total proteins were isolated. 
Western blot assay was performed for the indicated protein using TUBULIN as loading control. 
A representative experiment using three different TβT-OC lines (designated #1, #2 and #3) is 
shown. b) Optical density values relative to loading control were calculated. Data are 
expressed relative to untreated TβT-OC and are mean ± S.E.M. of 2-4 independent 
experiments (n=6-9). *** = p < 0.001 versus untreated TβT-OC.  
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Since TβT-OC did not response to exogenously added HGF in terms of 
proliferation and invasion, we next study whether these cells presented 
alterations in the signaling pathway triggered by HGF. For that, we analyzed 
phosphorylation of AKT and ERKs, two downstream targets of HGF, by western 
blot. We detected activation of AKT and ERKs after 10 minutes of HGF 
treatment, in both oval cells and TβT-OC, and was maintained along the 
treatment. Although differences did not reach statistically relevance, data 
suggest that levels of activated ERKs were higher in parental cells than TβT-OC, 
a) b) 
Figure 48. Analysis of the response triggered by exogenous HGF in oval cells and TβT-OC. a) 
Oval cells and TβT-OC were treated or not with HGF (40 ng/ml) in 0% FBS medium for 48 
hours and counted. Data are expressed respect to zero time and are mean ± S.E.M. of 10 
independent experiments performed in triplicate. b) Oval cells and TβT-OC were plated in 0% 
FBS medium in the upper chamber units coated with matrigel and were treated or not with 
HGF (40 ng/ml). Cells were allowed to pass through matrigel-coated filters for 24 hours and 
stained with crystal violet and counted by phase contrast microscope (14 random fields).  
Data are expressed relative to untreated cells and are mean ± S.E.M. of 9 independent 
experiments performed in triplicate. c) Oval cells and TβT-OC were serum starved and treated 
with HGF (40 ng/ml) for different periods of time, and total proteins were isolated. Western 
blot assay was performed for the indicated proteins using β-ACTIN as a loading control. A 
representative experiment is shown. d) Optical density values relative to loading control were 
calculated. Data are expressed relative to untreated oval cells and are mean ± S.E.M. of 3-4 
independent experiments. * = p < 0.05 ***, = p < 0.001 versus untreated oval cells or TβT-OC 
or as indicated. At least three TβT-OC lines were used in all analyses. 
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and a similar trend, although less pronounced, was also observed in AKT 
activation (Figure 48c and d). These data could suggest that EMT results in a 
decreased activation of the HGF/Met pathway, which might explain the absence 
of proliferative and invasive response in TβT-OC upon HGF stimulus.  
 
2.3. EMT-induced senescence in Met deficient oval cells is 
associated with oxidative stress and decreased Twist expression 
Cumulative evidence support the concept that there is a strong association 
between cellular senescence, oxidative stress and ROS production 
(Chandrasekaran et al., 2017; Hernandez-Segura et al., 2018). 
Previous results of our group indicated that TGF-β induces oxidative stress 
in oval cells, which is impaired by antioxidant signals triggered by the HGF/Met 
signaling axis (Martinez-Palacian et al., 2013). Therefore, we hypothesized that 
oxidative stress might be the driving force of the senescence response observed 
in Met-/- oval cells undergoing EMT. 
To analyze this possibility, we first analyzed intracellular levels of ROS at the 
early stages of chronic TGF-β treatment in Metflx/flx and Met-/- respect to 
untreated oval cells. For that, we employed DCFH-DA, a fluorescent probe used 
for the detection of intracellular peroxide content, and analyzed fluorescence 
intensity by flow cytometry and confocal microscopy. Both approaches revealed 
an exacerbated oxidative stress in Met-/- oval cells in comparison with Metflx/flx 
oval cells after chronic treatment with TGF-β (Figure 49a and b). 
Additionally, given that Nox4, a member of the Nox family of NADPH 
oxidases, is involved in TGF-β-induced ROS production (Carmona-Cuenca et al., 
2008; Martinez-Palacian et al., 2013), we studied Nox4 expression. We found 
higher basal mRNA levels as well as a stronger upregulation of Nox4 during 
acute and chronic TGF-β treatment in Met-/- than in Metflx/flx, in parallel with the 
increase in ROS intracellular levels (Figure 49c). 
These data suggest that an exacerbated oxidative stress in Met-/- oval cells 
after chronic treatment with TGF-β could be the cause of the senescence and 
growth arrest. 
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One of the proteins that have been linked to abrogation of cellular 
senescence programs is Twist (Zhao et al., 2017). Twist has been also described 
as an antioxidant factor (Floc'h et al., 2013). Thus, as we aimed to further 
characterize the mechanisms underneath the senescence process that occurs in 
our cellular model, we decide to analyze Twist levels in cells chronically treated 
with TGF-β. Western blot analysis revealed higher levels of TWIST in TβT-OC 
cells than in their normal counterparts (Figure 50a and b). Moreover, Twist was 
downregulated in Met-/- compared to Metflx/flx oval cells, both at the mRNA and 
protein levels (Figure 50c, d and e). 
Figure 49. Analysis of oxidative stress in Metflx/flx and Met-/- oval cells chronically treated 
with TGF-β. a-b) Metflx/flx and Met-/- oval cells (Ut) were cultured in 0% FBS medium for 48 
hours. Metflx/flx and Met-/--TβT-OC were maintained in 10% FBS medium and analysed at 
different passages (p1 and p2) during chronic treatment. Cells were incubated for 30 minutes 
with DCFH-DA (5 µM) and cellular fluorescence intensity was analysed. a) Confocal 
microscopy images from one experiment out of 2 are shown. Scale bar=20 μM. b) DCFH-DA 
fluorescence intensity measured by flow cytometry. Data are expressed relative to untreated 
oval cells and are mean ± S.D. (n=3) from one representative experiment. c) Total RNA was 
isolated from Metflx/flx and Met-/- oval cells treated or not (Ut) with TGF-β (1 ng/ml) in 0% FBS 
medium for 48 hours or from Metflx/flx and Met-/- oval cells chronically treated with TGF-β in 
10% FBS medium (TβT-OC) at different passages (p1/p2 and p5). Nox4 mRNA levels were 
determined by RT-qPCR and normalized to Gusb. Data are expressed relative to untreated 
Metflx/flx oval cells and are mean ± S.E.M. (n=3-6). * = p < 0.05, ** = p < 0.01, *** = p < 0.001 
versus untreated cells or as indicated. 
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Next, we tested whether HGF/Met was responsible for the upregulation of 
Twist levels as previously published in other cell types (Wang et al., 2015a; 
Yoshida et al., 2014). We demonstrated that HGF treatment increases Twist1 
mRNA levels in Metflx/flx oval cells at different time points. To confirm that this 
effect was specifically dependent on the signaling triggered by HGF/Met, we 
submitted Metflx/flx oval cells to Met inhibitor (PHA65752). In the presence of 
PHA65752, Metflx/flx oval cells showed a decrease in basal Twist1 mRNA levels. 
Furthermore, combined treatment of PHA665752 and HGF abolished the 
expression of Twist1 induced by HGF (Figure 51a). We also studied Twist2 
mRNA levels. Results showed the same tendency, although they were less 
Figure 50. Analysis of Twist expression in Metflx/flx and Met-/- oval cells and TβT-OC. a) Oval 
cells and TβT-OC were cultured in 0% FBS or 10% FBS medium for 24 hours, and total proteins 
were isolated. Western blot assay was performed for the analysis of TWIST using β-ACTIN as 
loading control. A representative experiment using two different TβT-OC lines (designated #1 
and #2) is shown. b) Optical density values relative to loading control were calculated. Data 
are expressed relative to oval cells and are mean ± S.E.M. of 2 independent experiments 
(n=2-7). Three different TβT-OC lines were used. c) Metflx/flx and Met-/- oval cells were 
cultured in 0% FBS medium for 24 hours, and total proteins were isolated. Western blot assay 
was performed for the analysis of TWIST using β-ACTIN as loading control. A representative 
experiment is shown. d) Optical density values relative to loading control were calculated. 
Data are expressed relative to Metflx/flx oval cells and are mean ± S.E.M. of 2 independent 
experiments (n=6). e) Metflx/flx and Met-/- oval cells were cultured in 0% FBS medium for 48 
hours, and total RNA was isolated. Twist1, 2 mRNA levels were determined by RT-qPCR and 
normalized to Gusb. Data are expressed relative to Metflx/flx oval cells and are mean ± S.E.M. 
of (n=3-5). * = p < 0.05, ** = p < 0.01, *** = p < 0.001 versus Metflx/flx.  
e) 
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robust (Figure 51a). Parallel analyses by western blot confirmed the results 
showed in Figure 51a, thus TWIST protein levels were upregulated in response 
to HGF, effect that was abolished by chemical inhibition of Met (Figure 51b and 
c). These data demonstrate that HGF regulates Twist expression in oval cells.  
Based on these results, we decided to perform a silencing-based approach 
to further confirm the involvement of Twist in cell response to chronic TGF-β 
treatment. We transiently knocked-down Twist, using a Twist1-targeted siRNA, 
in Metflx/flx oval cells. Then, we treated cells with TGF-β following the protocol 
shown in results section 2.1. We checked Twist1 levels by RT-qPCR analysis and 
data showed that a 70% reduction of Twist1 levels was achieved (Figure 52a). 
When we analyzed the expression levels of cell cycle inhibitors, we observed a 
strong upregulation of cdkn2b (p15) and cdkn2a (p19) suggesting that Twist 
silencing results in activation of a senescence process. Furthermore, Twist1 
transient knockdown led to an upregulation of Nox4 levels after treatment with 
TGF-β (Figure 52b). 
Figure 51. Analysis of Twist induction in response to HGF in oval cells. a) Metflx/flx oval cells 
were treated or not with HGF (40 ng/ml) ± PHA665752 (5 μM) in 0% FBS medium for different 
periods of time, and total RNA was isolated. Twist1, 2 mRNA levels were determined by RT-
qPCR and normalized to Gusb. Data are expressed relative to untreated Metflx/flx oval cells and 
are mean ± S.E.M. of 6 different experiments performed in triplicate. Data were compared as 
follows: untreated vs HGF, * = p < 0.05, ** = p < 0.01, *** = p < 0.005; untreated vs 
PHA665752, # = p < 0.05; untreated vs PHA665752+HGF, && = p < 0.01. b) Metflx/flx oval cells 
were treated or not with HGF (40 ng/ml) ± PHA665752 (5 μM) in 0% FBS medium for 48 
hours, and total proteins were isolated. Western blot assay was performed for the analysis of 
TWIST using β-ACTIN as a loading control. A representative experiment is shown. c) Optical 
density values relative to loading control were calculated. Data are expressed relative to 
untreated Metflx/flx oval cells and are mean ± S.E.M. of 3 independent experiments (n=8-9). 
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Collectively, these data support that HGF is able to induce Twist expression 
in oval cells and that Twist silencing promotes a senescence program in oval cell 
through the upregulation of Nox4 
 
 
 
 
 
 
 
 
 
 
 
Figure 52. Analysis of the effects of Twist1 silencing on Metflx/flx oval cells. a-b) Oval cells 
were transiently transfected with targeting negative control siRNA (NT) or Twist1 targeting 
siRNA (siTwist1). a) Twist1 mRNA levels were determined by RT-qPCR. Data are expressed 
respect to NT. b) NT and siTwist1 oval cells were maintained in 0% FBS medium for 48 hours. 
NT and siTwist1 were chronically treated with TGF-β in 10% FBS medium and were analyzed at 
passage 1 (p1 TβT-OC) of chronic treatment. Total RNA was isolated and Cdkn2b, Cdkn2a and 
Nox4 mRNA levels were determined by RT-qPCR and normalized to Gusb. Data are expressed 
relative to NT oval cells and are mean ± S.E.M. of 2 different experiments performed in 
duplicated. * = p < 0.05, ** = p < 0.01 as indicated.  
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3. Relevance of the crosstalk between 
HGF/Met and TGF-β in hepatocellular 
carcinoma 
 
Both Met and TGF-β pathways are known to play a critical role in HCC. 
Although there are some evidences of crosstalk between these pathways in liver 
cells, e.g. results included in this thesis and published work from our laboratory 
and others (del Castillo et al., 2008b; Martinez-Palacian et al., 2013), there is 
hardly any information about the potential relevance of a functional interaction 
between Met and TGF-β in HCC (Amicone et al., 2002; Liang et al., 2018). For this 
reason, we thought it would be interesting to study this crosstalk in a context of 
liver cancer.  
To this aim, we used the following in vivo and in vitro approaches, generated 
and available at Dr. Maina´s laboratory (Fan et al., 2017) : i) a conditional mouse 
model of overexpression of Met in the liver (Alb-R26Met), which has been shown to 
lead to spontaneous development of liver tumors with a progenitor-like 
phenotype, and ii) HCC cell lines isolated from these tumors, with different levels 
of expression of Met (low and high). 
3.1. TGF-β signaling pathway is activated prior to tumor appearance 
and during tumor development in Alb-R26Met mice 
First, we analyzed the activation of TGF-β-triggered signaling pathway in WT 
and Alb-R26Met liver sections (pre-neoplastic stage, before 40 weeks old Alb-
R26Met), and in HCC samples (neoplastic stage, from 40 to 67 weeks old Alb-
R26Met mice which have developed tumors), by detecting the phosphorylated 
form of SMAD2, the TGF-β canonical signaling mediator, by 
immunohistochemistry. A quantitative analysis of the immunohistochemistry 
assay showed enhanced nuclear staining of pSMAD2 in Alb-R26Met mice, which is 
higher in HCC samples (Figure 53a and b).  
These results evidence an interesting over-activation of the TGF-β pathway 
in livers with Met overexpression, both in pre-neoplastic and neoplastic stages. 
This suggests a role for TGF-β signaling during HCC development and in the 
regulation of the properties of these tumors. 
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3.2. Activation of TGF-β signaling pathway inversely correlates with 
Met expression levels in HCC lines derived from Alb-R26Met mice 
Considering these results, we decided to take in vitro approaches that 
allowed us to study more in detail the interplay TGF-β/Met and how it could 
affect HCC properties in a context of liver cancer driven by overexpression of 
Met. 
We selected two HCC lines with different expression levels of Met, 
established from liver tumors developed in Alb-R26Met mice: HCC1 and HCC3 cell 
lines. As shown in Figure 54a and b, HCC1 cells, displayed about two fold higher 
levels of MET (HCC1HMet) than HCC3 (HCC3LMet), levels that were not modified 
neither in presence of exogenous TGF-β nor HGF in both cell lines. In terms of 
activation of MET, analyzed by the detection of its phosphorylated form (pMET) 
(Figure 54a and b), the receptor was constitutively phosphorylated in HCC1HMet 
and remained unaltered regardless of HGF and/or TGF-β treatment. However, 
activation of MET in HCC3LMet was only observed upon HGF stimulus. 
Interestingly, TGF-β prevented HGF-induced MET activation in HCC3LMet, which 
could indicate that TGF-β interferes with HGF/Met pathway. 
Figure 53. Analysis of TGF-β/Smad signaling activation in WT and Alb-R26Met mice. a-b) 
Immunohistochemistry staining was performed using a specific anti-pSMAD2 antibody on 
liver section of WT, Alb-R26Met mice and HCC samples. a) Representative bright-field images 
of WT, Alb-R26Met mice and HCC sample are shown. Magnification=20X. b) Intensity of 
nuclear staining per area in WT, Alb-R26Met and HCC was measured in at least 8 areas per 
mice. Data are expressed relative to WT group and are mean ± S.E.M. of 4 animals per group. 
* = p < 0.05, ** = p < 0.01 versus WT group. 
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Additionally, we analyzed the activation of HGF/Met pathway through the 
phosphorylation levels of GAB1 (pGAB1), a Met´s adaptor protein that mediates 
many of the Met-initiated signals (Organ and Tsao, 2011; Trusolino et al., 2010) 
(Figure 54a and b). Similar to MET, GAB1 was constitutively activated in 
HCC1HMet, but in this case, pGAB1 levels were further increased in the presence 
of HGF, regardless of the presence or absence of TGF-β. These results suggest 
that basal activation of MET only triggers a partial activation of its major 
adaptor. In HCC3LMet cells, we only detected pGAB1 in response to exogenous 
addition of HGF. TGF-β had no effect on HGF activation of GAB1. 
Once we had done a basic characterization of MET expression and 
activation in HCC1HMet and HCC3LMet cells, we wondered if differential 
expression/activation of MET could affect to TGF-β signaling activation in HCC 
Figure 54. Analysis of canonical and non-canonical TGF-β and HGF/Met pathways in 
HCC1HMet and HCC3LMet cells. a) HCC1HMet and HCC3LMet cells were treated or not with TGF-β (2 
ng/ml) ± HGF (40 ng/ml) in 10% FBS medium for 30 minutes and total proteins were isolated. 
Western blot assay was performed for the analysis of the indicated protein using β-ACTIN as a 
loading control. A representative experiment out of 2 is shown. b) Optical density values were 
calculated. Data are expressed relative to untreated HCC1HMet cells or as total protein levels 
and are mean ± S.E.M. of 2 independent experiments.  
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cells. Interestingly, although differences did not reach statistical significance, 
western blot analysis revealed a stronger activation of SMAD2 triggered by TGF-
β treatment in cells with low Met levels, HCC3LMet, than in HCC1HMet. The 
presence of exogenous HGF did not significantly affect the activation of the TGF-
β pathway (Figure 54a and b). Both the increased activation of SMAD2 in 
HCC3LMet cells and the decreased activation of Met in HCC3LMet cells in the 
presence of TGF-β suggest a negative functional crosstalk between TGF-β and 
HGF/Met pathways in HCC Alb-R26Met lines. 
In an attempt to further characterize this interaction, we next analyzed an 
additional downstream signaling pathway, ERK-MAPKs, activated by both TGF-β 
and HGF. ERK-MAPKs is one of the signaling pathways that mediates the 
downstream response to Met activation and is considered a non-canonical 
pathway for TGF-β (Massague, 2012; Trusolino et al., 2010). Active ERKs (pErks) 
were only detected after HGF treatment, both in HCC1HMet and HCC3LMet, but 
levels tended to be higher in HCC3LMet cells, particularly under TGF-β and HGF 
combined treatment (Figure 54a and b). These results suggest that different 
levels of Met in HCC cells could affect MAPKs activation induced by HGF or   
TGF-β. 
 
3.3. TGF-β-dependent transcriptional activity is enhanced in HCC 
cells with low levels of Met 
Signaling studies performed evidenced that lower levels of Met expression 
and activation in mouse HCC cells correlate with a higher activation of TGF-β 
canonical pathway. Next, we ought to determine if differential SMAD activation 
results in changes in the expression of well-known Smad transcriptional targets. 
Specifically, we analyzed the expression of Tgfb1, Tgfbr1, Smad6, Smad7 and 
plasminogen activator inhibitor 1 (Pai1). As a way to prove the specificity of the 
effects induced by TGF-β and HGF/Met, we treated cells with some specific 
inhibitors of Met and TGF-β receptor, PHA665752 and SB431542, respectively. 
Upregulation of Tgfb1 mRNA levels was observed by RT-qPCR only under 
TGF-β treatment in both HCC1HMet and HCC3Lmet with no obvious differences 
between the two cell lines. Neither combined treatment with HGF or with Met 
inhibitor had a significant effect on Tgfb1-mediated induction. Likewise, 
treatment with Met inhibitor alone did not affect baseline levels of Tgfb1 
expression. In other words, activation of HGF/Met pathway, in mouse HCC cell 
lines, either basal or by stimulation with HGF, did not affect Tgfb1 expression 
(Figure 55). 
Interestingly, a strong upregulation of the mRNA levels of Tgfbr1, Smad6, 
Smad7 and Pai1 were observed in response to TGF-β treatment in HCC3LMet, 
whereas in HCC1HMet was either null or very mild. Among all these genes, Pai1 
was the one showing significant changes between HCC3LMet and HCC1HMet. Again, 
neither co-treatment with HGF or with Met inhibitor altered TGF-β-mediated 
induction with the exception of Smad6 and 7 where Met inhibitor seemed to 
increase the basal expression in HCC1HMet (Figure 55). 
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All these data suggest that lower levels of Met in mouse HCC lines lead to a 
stronger TGF-β/Smad-dependent transcriptional activity. But, further activation 
or inhibition of HGF/Met pathway does not seem to affect TGF-β-mediated 
transcriptional response. 
Figure 55. Analysis of TGF-β-dependent transcriptional activity in HCC1HMet and HCC3LMet 
cells. HCC1HMet and HCC3LMet cells were treated or not with TGF-β (2 ng/ml) ± HGF (40 ng/ml) 
in the presence or absence of PHA665752 (3 µM) or SB43152 (10 µM) in 10% FBS medium for 
24 hours and total RNA was isolated. Tgfb1, Tgfbr1, Smad6, 7 and Pai1 mRNA levels were 
determined by RT-qPCR and normalized to Hprt. Data are expressed relative to untreated 
cells and are mean ± S.E.M. of 2 independent experiments. * = p < 0.05, ** = p < 0.01, *** = p 
< 0.001 versus untreated cells or as indicated.  
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3.4. HCC lines with low levels of Met are more sensitive to anti-
proliferative and apoptotic effects of TGF-β  
TGF-β plays a dual role in tumorigenesis. Thus, TGF-β can promote cell cycle 
arrest and apoptosis or on the contrary, induce cell motility, invasion, EMT and 
cell stemness (Seoane and Gomis, 2017). Since we found that HCC cells with low 
levels of Met, HCC3LMet cells, show stronger activation of TGF-β signaling 
pathway than HCC1HMet, we next explored whether this differential response to 
TGF-β led to differences in terms of cell growth and death. 
Analysis of cell growth capacity revealed that HCC1HMet present a higher 
growth rate than HCC3LMet. HCC1HMet did not show difference in the cell number 
when treated with TGF-β. However, HCC3LMet displayed a slight decrease in cell 
number in response to TGF-β (Figure 56). 
In parallel, we performed an immunofluorescence assay to detect active 
caspase-3, a crucial mediator of programmed cell death, as a way to specifically 
analyze if the HCC cell lines displayed an apoptotic response to TGF-β. HCC1HMet 
cells showed an increase in the levels of active caspase-3 after TGF-β treatment. 
In HCC3LMet cells we did not observe response at 6 hours, however, a strong peak 
of caspase-3 activation was seen at 16 hours, notably higher than that seen in 
HCC1HMet at the same time point (Figure 57a and b). 
 
 
 
 
 
 
 
Figure 56. Analysis of cell growth capacity in HCC1HMet and HCC3LMet  cells. HCC cells were 
treated or not with TGF-β (2 ng/ml) in 10% FBS medium for 6 and 24 hours and then counted. 
Dara are expressed respect to zero time and are mean ± S.D. (n=3) from one representative 
experiment performed in triplicate. 
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To further test if the differential expression and activation of Met could 
account for the differential cell response seen in terms of cell number and 
apoptosis, we run similar experiments but in the absence or presence of HGF 
and/or the Met inhibitor PHA665752. We focused on the 16 hours-time point 
since it seemed to be the more appropriate timing to detect the peak of 
apoptosis and the differences between cell lines. HCC1HMet cells treated with 
TGF-β showed a moderate increase in caspase-3 activity however in 
combination with PHA665752, TGF-β induced a sharp drop in cell number 
together with a strong increase in caspase-3 activity as compared to TGF-β 
alone (Figure 58a and b). It is noteworthy that PHA665752 alone was able to 
trigger apoptosis in HCC1HMet cells, although at a lesser extent than in 
combination with TGF-β (Figure 58b). Exogenous HGF had no apparent effect 
neither in cell number nor in caspase-3 activity (Figure 58a and b). These results 
suggest that HCC1HMet are dependent on autocrine Met signaling for protection 
against TGF-B induced apoptosis. 
Parallel experiments were run in HCC3LMet cells. These cells responded to 
TGF-β with a slight decrease in cell number and activation of caspase-3. 
Interestingly, despite not showing a basal activation of Met, combined 
treatment with TGF-β and PHA665752 resulted in an amplified response to TGF-
β, both in terms of decrease in cell number and activation of caspase-3 (Figure 
58c and d). It is worth noting that the levels of active caspase-3 in HCC3LMet cells 
are much higher than those reached in HCC1HMet, which is consistent with a 
higher sensitivity to apoptosis (Figure 58d). In contrast to HCC1HMet, HCC3LMet 
cells showed no apoptotic response when treated with PHA665752 alone. 
Similarly to HCC1HMet, exogenous HGF had no effect on cell number but reduced 
active caspase-3 levels (Figure 58c and d). 
Figure 57. Analysis of active caspase-3 in HCC1HMet and HCC3LMet in response to TGF-β. a-b) 
HCC1HMet and HCC3LMet cells were treated or not with TGF-β (2 ng/ml) in 10% FBS medium for 
6 and 16 hours and then fixed and stained with a specific primary antibody for caspase-3 and 
a fluorescent secondary antibody. Nuclei were counterstained with DAPI. a) Fluorescence 
intensity was measured in at least 6 fields per condition. Data are expressed relative to 
untreated cells and are mean ± S.E.M. of 2 independent experiments. b) Representative 
apoptome microscopy images from 2 independent experiments are shown. 
Magnification=10X. 
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Collectively, all these results evidence a pro-survival activity of Met in HCC 
cells. HCC cells with high levels of Met and endogenous activation of Met 
become dependent of Met catalytic activity for survival. But, Met activity 
protects HCC cells against TGF-β independently of Met levels since inactivation 
of Met sensitizes both HCC1HMet and HCC3LMet cells to TGFβ-induced apoptosis. 
 
 
 
 
 
 
Figure 58. Analysis of cell growth capacity and active caspase-3 levels in HCC1HMet and 
HCC3LMet cells. a and c) HCC1HMet  and  HCC3LMet were treated or not with TGF-β (2 ng/ml) ± 
HGF (40 ng/ml) in the absence or presence of PHA665752 (3 µM) in 10% FBS medium for 24 
hours and then counted. Data are expressed relative to untreated cells. A representative 
experiment performed in triplicate is shown. b and d) HCC1HMet and  HCC3LMet were treated or 
not with TGF-β (2 ng/ml) ± HGF (40 ng/ml) in the absence or presence of PHA665752 (3 µM) in 
10% FBS medium for 16 hours. Then, cells were fixed and stained with a specific primary 
antibody for caspase-3 and a fluorescent secondary antibody. Fluorescence intensity was 
measured in at least 6 fields per condition. Data are expressed relative to untreated cells and 
are mean ± S.E.M. of 2 independent experiments.  
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1. HGF/Met signaling is essential to allow 
oval cells expansion after TGF-β-induced 
EMT 
 
The purpose of this study was to characterize the TGF-β-induced EMT in 
oval cells, how it could affect cell function and fate in vivo, and the potential 
relevance of a TGF-β-HGF crosstalk in this context. 
It is recognized that HPCs/oval cells a bipotential hepatic progenitors 
population participate in the regenerative process accompanying chronic liver 
injury. It has been established that these cells can either contribute to re-
establish liver function (Riehle et al., 2011) or contribute to the progression of 
liver fibrosis (Kuramitsu et al., 2013; Williams et al., 2014) and even become 
tumor-initiating cells (Kohn-Gaone et al., 2016). These opposite effects show us 
the plasticity of HPCs/oval cells and the importance of understanding the 
mechanisms controlling their behavior. This would allow us to modulate or favor 
their pro-regenerative activity, providing new therapeutic approaches for the 
treatment of CLDs. TGF-β and HGF are among the key signals involved in liver 
fibrosis and regeneration and are components of HPC/oval cell niche that 
regulate HPC/oval cell biology (Giannelli et al., 2016; Nakamura et al., 2011), 
what makes them interesting signals in the study of HPC/oval cell fate in CLD.  
Several groups have reported that TGF-β induces EMT in rat HPCs/oval cells 
in vitro and increases expression of HSC or myofibroblast markers, being able to 
contribute to the progression of liver fibrosis and cirrhosis (Chen et al., 2015; 
Deng et al., 2011; Wang et al., 2009) or to convert them into tumor-initiating 
cells (Wu et al., 2018). Co-expression of epithelial and mesenchymal proteins 
has been found in HPCs/oval cells isolated from a rat model of liver disease 
(Yovchev et al., 2008). Interestingly, other authors suggest that active HSCs 
could undergo mesenchymal to epithelial transition (MET) and originate 
HPCs/oval cells (Deng et al., 2011) supported by the fact that markers of active 
HSCs and HPCs/oval cells were observed simultaneously in HPCs/oval cells 
(Tennakoon et al., 2015). These findings might indicate a role for EMT-MET in 
regulation of HPC/oval cell biology although its precise contribution and 
mechanisms involved need to be clarified. According to these previous 
evidences of EMT in HPCs/oval cells, our results show that chronic treatment 
with TGF-β in oval cells induces an EMT process that is maintained over time. 
Thus, TGF-β represses the expression of some epithelial markers (L-CADHERIN, 
OCCLUDIN), increases the expression of mesenchymal markers (N-CADHERIN, 
VIMENTIN) and promotes a change in the subcellular localization of ZO-1 (Figure 
27). However, the co-expression of E-Cadherin with mesenchymal markers, led 
us to think that TGF-β treatment induces a partial rather than a full EMT in oval 
cells (Figure 26 and 27). These results might be not surprising, considering that 
EMT is seen nowadays as a broad spectrum of transitional states with multiple 
and dynamic intermediary phases (Nieto et al., 2016). In support of the 
hypothesis of a partial EMT induction in oval cells chronically treated with TGF-β 
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(TβT-OC), we found coexistence of ALBUMIN and CK19, markers of liver 
epithelial cells (hepatocyte and cholangiocyte, respectively) (Figure 30), and 
Cd44 (Figure 28), considered as a critical regulator of TGF-β-mediated EMT in 
HCC cells (Fernando et al., 2015; Gao et al., 2015; Malfettone et al., 2017; Mima 
et al., 2012). Our data are also in line with the finding of partial EMT states 
HPCs/oval cells derived cell lines LE/6 and WB-F344, states that were at least 
partly maintained by autocrine TGF-β and activin A/Smad signaling (Wu et al., 
2018). CD44, CD133 and EPCAM are all stem cell markers. However, unlike 
Cd44, Cd133 (prom1) and Epcam show a decreased expression in TβT-OC 
(Figure 28). It is widely accepted that EMT induces the expression of stem cell 
markers and enhances stem cell properties in epithelial cells (Fabregat et al., 
2016a). Indeed, it has been demonstrated that TGF-β treatment in rat and 
human hepatocytes, induces a less differentiated and a more mesenchymal 
phenotype with loss of expression of hepatic genes and acquisition of specific 
stem cell markers (Caja et al., 2011; Sanchez et al., 1999). However, our results 
do not fit this model. Partial EMT in oval cells does not result in an increase of 
stem cell markers (Figure 28) nor increases the clonogenic capacity or the 
sphere formation capacity of the cells (Figure 29). EMT in oval cells instead of 
favoring a stem cell phenotype, lean cells forward along the hepatic lineage, as 
deduced from the increase in some hepatocyte markers (Hnf4a and Afp) and the 
decrease in biliary epithelial markers (Hnf1b, Onecut1, Ggt) in TβT-OC (Figure 
31). In this sense, our group has previously demonstrated that TGF-β besides 
inducing EMT also promotes a more differentiated phenotype in hepatocytes, 
particularly in the presence of HGF or EGF, resulting in a mixed phenotype in 
which hepatocytes co-express liver specific genes and epithelial and 
mesenchymal marker genes (Pagan et al., 1997; Pagan et al., 1999; Sanchez et 
al., 1995; Sanchez et al., 1998). Therefore, EMT and a differentiated phenotype 
are not mutually exclusive. Likewise, HPCs/oval cells from human fetal liver 
display a phenotype consistent with mesenchymal-epithelial transitional cells 
(Dan et al., 2006). Furthermore, recent findings show that a sequential EMT-
MET process drives differentiation of human embryonic stem cells toward 
hepatocytes, and that TGF-β and SNAI1 induction plays a key role not only in 
EMT but also in definitive endoderm induction (Li et al., 2017). 
Among other phenotypic changes, EMT results in changes in the secretory 
phenotype of cells, increasing the expression of growth factors and cytokines 
(Reka et al., 2014) that could be critical for phenotype acquisition or 
maintenance, thus controlling the mesenchymal state and properties (Del 
Castillo et al., 2006; Jahn et al., 2012; Scheel et al., 2011). An increase in the 
mRNA levels of Ctgf together with changes in the mRNA of specific members of 
the Pdgf family, specifically upregulation of Pdgfa and c and downregulation of 
Pdgfd, are seen in TβT-OC (Figure 32). Interestingly, CTGF, protein is 
upregulated in many fibrotic disorders and promotes fibrogenesis, and it has 
been described to directly bind TGF-β in the extracellular space and enhance 
receptor binding and signaling (Abreu et al., 2002). Regarding the modulation of 
PDGF family members, it is important to highlight that PDGF family ligands have 
an important role in EMT having been correlated with cell survival and 
invasiveness in human mammary carcinomas and chemoresistance in HCC 
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(Jechlinger et al., 2006; Wang et al., 2015b). Upregulation of PDGFA and PDGF 
receptors in p19 null hepatocytes after TGF-β-induced EMT provides in vitro 
adhesive and migratory properties and proliferative stimuli during tumor 
formation (Fischer et al., 2007). On the contrary, a reduction in the expression 
of PDGFD in lung fibrosis correlates with the production of TGF-β, so that 
downregulation of PDGFD by TGF-β might serve as a negative feedback 
regulation of cytokines that control fibrosis (Charni Chaabane et al., 2014). 
These observations support the idea of a role for these factors in cell phenotype 
regulation. Nevertheless, if these signals are somehow involved in the chronic 
EMT triggered by TGF-β in our cellular model needs to be further investigated. 
Further in this regard, our results show that TβT-OC autocrinely produce 
HGF. Our group has already shown that oval cells have an HGF autocrine loop 
that exerts antioxidant and anti-apoptotic actions (del Castillo et al., 2008b; 
Martinez-Palacian et al., 2013). Now, we demonstrate that HGF autocrine loop 
remains operative in TβT-OC (Figure 45). Strikingly, although TβT-OC express 
higher Hgf levels, they do not display higher Met activation. Further studies are 
needed to clarify this result, but one possible explanation is that the amount of 
ligand is greater than that of Met receptor due to either limiting expression or 
enhanced degradation of the receptor, so that it is not able to bind the available 
ligand. In any event, HGF autocrine loop counterbalances the TGF-β-induced 
EMT maintaining and/or promoting their epithelial properties (Figure 47). 
Evidences in the literature suggest the capacity of HGF to induce EMT. Indeed, 
HCC cells secret HGF which contribute to maintain a mesenchymal phenotype, 
favoring invasion, proliferation and metastasis in vivo (Ding et al., 2010). 
Likewise, HGF induces down-regulation of cell junctions in HCC cells through 
Snail induction via MAPK/ early growth response factor-1 activation, which have 
critical roles in HGF-induced cell scattering, migration and invasion (Grotegut et 
al., 2006). Contrarily, we had reported that HGF/Met does not induce EMT in 
oval cells despite enhancing oval cell migration/invasion capacities (Suarez-
Causado et al., 2015), and results presented here go in the same direction. 
Recapitulating, our results provide further evidence of the HPC/oval cell 
plasticity and the importance of dynamic phenotypic transitional states of liver 
cells during liver injury, while pointing to an important functional cooperation 
between the TGF-β and HGF signaling pathways in its regulation. 
Partial EMT in oval cells not only has consequences on phenotypic 
properties, but additionally confer cells some advantages in terms of invasion 
capacity in vitro (Figure 34). These results are in agreement with other studies 
performed in epithelial cells in which EMT enhance invasiveness (Brabletz et al., 
2018; Thiery et al., 2009; Zhang and Weinberg, 2018). The increase in the 
invasive capacity after EMT in oval cells correlated with an increase in the 
expression of some MMPs (Mmp2, Mmp10 and Mmp13) (Figure 35). Although 
non-parenchymal cells are the main source of MMPs in the liver, they are also 
produced by hepatocytes and cholangiocytes; and we have shown expression of 
some MMPs in oval cells as well (Suarez-Causado et al., 2015). This is not 
surprising since these proteinases are crucial not only for fibrosis development 
but also for healing, and play an active role in modulation of stem cell niches 
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(Hemmann et al., 2007; Roderfeld, 2018). In fact, it is well known that HPC/oval 
cell-mediated regenerative response involves ECM degradation and deposition, 
processes in which MMPs participate (Williams et al., 2014). Interestingly, 
upregulation of MMP2 and MMP13 has been associated with resolution of liver 
fibrosis (Fallowfield et al., 2007; Radbill et al., 2011). Although Mmp9 expression 
is not altered in TβT-OC, these cells show higher MMP9 activity than untreated 
oval cells (Figure 35). This lack of relationship between MMP9 expression and 
activity should be investigated in detail but the existence of a wide range of 
MMPs regulatory mechanisms at different levels including transcriptional, 
epigenetic and post-transcriptional levels may help explain it (Chernov and 
Strongin, 2011; Chicoine et al., 2002; Hadler-Olsen et al., 2011; Piedagnel et al., 
1999). We also observe changes in Timps expression upon TGF-β-induced EMT, 
specifically an increase in Timp3 and a decrease in Timp1 (Figure 35). MMP 
activity is controlled by TIMPs under physiological conditions having this 
regulation an important role in normal degradation of ECM to maintain liver 
homeostasis. However, alterations in MMPs-TIMPs balance have been linked to 
chronic liver pathologies, where MMPs and TIMPs play anti- and/or pro-fibrotic 
roles. MMP9 has been involved in the early stage of liver fibrosis, specifically 
promoting TGF-β release; but on the other hand, MMP9 can promote HSCs 
apoptosis in the presence of low TIMP1 levels (Duarte et al., 2015). Evidence 
endow TIMPs overexpression a pro-fibrotic action. Concretely, an enhancement 
in CCl4-induced hepatic fibrosis was demonstrated by TIMP1 overexpression 
(Yoshiji et al., 2000). So, the changes in the expression of Mmps and Timps in 
TβT-OC after EMT might be a reflection of what occurs in a context of liver injury 
and fibrosis and might indicate an anti-fibrotic profile whose relevance in a 
regenerative process remains open for further investigation. 
Interestingly, our group has demonstrated that HGF/Met through PI3K and 
p38MAPK activation induces a complex and specific migratory response in oval 
cells that involves MMPs (Suarez-Causado et al., 2015). Based on these results, 
and on the reduction of the invasive capacity of TβT-OC by inhibiting Met 
(Figure 46); we hypothesize that the autocrine HGF/Met loop operating in TβT-
OC could be in part responsible for Mmps induction and therefore, for the 
invasive phenotype. Nonetheless, additional experiments are required to 
establish a direct relationship between Mmps induction and HGF/Met axis in 
TβT-OC.  
In terms of cell growth, although EMT does no result in an increased growth 
capacity in the presence of serum, it enhances oval cell proliferation and 
resistance to pro-apoptotic stimuli in the absence of serum (Figure 33). A link 
between EMT and apoptosis resistance has been previously proposed by other 
authors (Robson et al., 2006; Valdes et al., 2002). We prove here that autocrine 
HGF/Met significantly contributes to TβT-OC growth and survival properties, as 
it does to cell invasive capacity (Figure 46). But, it is worth mentioning that 
HGF/Met autocrine signaling might not be the only autocrine pathway active in 
TβT-OC, since we have shown upregulation of other signaling ligands (Figure 
32). 
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Interestingly, although HGF autocrine signaling plays a relevant role in TβT-
OC properties, exogenous HGF has lost its ability to increase proliferation and 
invasion over cell intrinsic capacities (Figure 48), as it does in oval cells (del 
Castillo et al., 2008b; Suarez-Causado et al., 2015). Additionally, we see a 
weaker activation of some key downstream targets under HGF stimulation 
(Figure 48). One possible explanation could be that the autocrine HGF/Met 
signaling leads to maximum proliferative and invasive capacities. This is in line 
with the observation that a higher HGF expression in TβT-OC does not result in a 
higher activation of Met receptor.  
So far, this study has allowed us to elucidate the biological consequences of 
a partial EMT induction by TGF-β in oval cells in vitro. Next step is to clarify the 
consequences for oval cell fate in vivo, in a context of liver damage. Although 
some authors defend EMT could be responsible for the pro-fibrotic action of 
HPCs/oval cells (Wang et al., 2009), we found that transplantation of TβT-OC 
reduce liver fibrosis grade and improve liver function in CCl4-treated mice more 
efficiently than oval cells which have not underwent EMT process (Figure 38, 39 
and 40). In other words, our work support that EMT-induced traits improve 
and/or accelerate the regenerative potential of oval cells, thus facilitating the 
restoration of liver function upon injury. It is worth emphasizing that in our 
experimental model, oval cells, independently of the EMT, did not enhance liver 
fibrosis either, but rather contributed to ameliorate it, although differences did 
not reach significance, perhaps due to sample size limitations. This would be in 
agreement with different works published in the literature supporting a pro-
regenerative role for HPCs/oval cells (Awan et al., 2017; Espanol-Suner et al., 
2012; Lu et al., 2015) . 
We have not yet provided a mechanism for the pro-regenerative/anti-
fibrotic effect of TβT-OC. However, based on results from GFP 
immunohistochemistry at 1 week after transplantation, we hypothesize that an 
improved engraftment or enhanced cell survival and/or proliferation could 
certainly make a difference and enhance the effects of the transplanted cells on 
the injured liver (Figure 37). Based on our in vitro findings it is feasible to 
hypothesize that the improved regenerating capacity is the result of a 
combination of cell advantageous traits. Thus, increased Mmps expression and 
greater invasive capacity could contribute to enhance oval cell regenerative 
activity, since MMPs are known to be important for such activity (Van Hul et al., 
2009; Vestentoft et al., 2013). Additionally, data pointing to a switch to a more 
mature hepatic phenotype in TβT-OC (Figure 30 and 31) may suggest that TβT-
OC have an enhanced hepatocyte differentiating capacity in vivo, which would 
result in an enhanced capacity to restore liver functionality. Although further 
research is needed to demonstrate this hypothesis, we have preliminary data 
that indirectly support it. Cyp7a1, a known transcriptional target of HNF4α and a 
common marker of hepatocyte maturation and functionality (Asahina et al., 
2004; Cai et al., 2007), shows the highest levels in livers from TβT-OC-
transplanted mice (Figure 41). Certainly, Cyp7a1 expression could come from 
endogenous hepatocytes or from newly-formed OC- and TβT-OC-derived 
hepatocytes. In any event, data are overall consistent with an improved liver 
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function and decreased damage in livers from TβT-OC-transplanted mice. 
Finally, the highest levels of HGF in TβT-OC transplanted mice suggest a 
participation of this growth factor in this process (Figure 41). This finding is in 
line with a higher HGF expression in TβT-OC (Figure 45) in vitro. Thus, upon 
transplantation, TβT-OC could release HGF in the liver driving autocrine and 
paracrine actions on oval cells and other liver cell populations, respectively. The 
pro-regenerative and anti-fibrotic effects of HGF in the liver are well-known. 
Among others, HGF could promote survival and maturation in transplanted 
HPCs/oval cells and hepatocytes and inhibit the growth of activated HSCs (del 
Castillo et al., 2008b; Huh et al., 2004; Ishikawa et al., 2012; Kim et al., 2005; Li 
et al., 2008). 
Our work points to a fundamental activity of HGF/Met to allow oval cell 
expansion after EMT. In the absence of Met activity (Met-/- oval cells or 
pharmacological inhibition of Met), oval cells submitted to chronic treatment 
with TGF-β enter into senescence, as demonstrated by phenotypical changes, 
the presence of β-Gal activity and an increase in the expression of cell cycle 
inhibitors (Figure 42, 43 and 44). In other words, HGF/Met signaling pathway is 
essential to bypass senescence and to allow oval cell survival and expansion 
during TGF-β-induced EMT.  
It has already been reported that senescence and EMT, two processes 
initially considered independent, could be mechanistically linked. Indeed, there 
are numerous examples in the literature that show how Twist and Zeb1, two 
EMT-TF, impact on cell cycle machinery and suppress cellular senescence. For 
example, mouse embryonic fibroblasts from Zeb1-null mice show diminished 
replicative capacity in culture and undergo replicative senescence associated 
with Cdkn2b (p15) and Cdkn1 (p21) (Liu et al., 2008). Twist is responsible for the 
sustained proliferation of immortalized prostate epithelial cells through p14ARF 
down-regulation, which consequently suppresses cellular senescence caused by 
genomic damage (Kwok et al., 2007). Likewise, silencing of Twist in oncogene-
driven tumors results in growth inhibition and activation of oncogene-induced 
senescence program and in some cases apoptosis (Burns et al., 2013; Tran et al., 
2012). Twist 1 and 2 block the suppressor proteins pRB and p53, cooperating 
with oncoproteins such as H-Ras to induce a full EMT and cell invasion (Ansieau 
et al., 2008). Our data is in line with these findings and support the concept that 
overcoming senescence is a critical step for cell expansion upon EMT induction, 
highlighting a role for HGF/Met in this process. 
But what are the mechanisms underlying the senescence process in our cell 
model? TGF-β induces senescence in tumor cells and other cell types (Lyu et al., 
2018; Wu et al., 2009). TGF-β also induces ROS production in different cells 
(Krstic et al., 2015), including oval cells. The source of ROS in oval cells involves 
the NADPH oxidase, Nox4 although we can not discard the mitochondria as an 
additional source of ROS (Almale et al., 2019; Martinez-Palacian et al., 2013). 
Oxidative stress drives senescence and interestingly, TGF-β is able to induce 
senescence via increase of ROS in bone marrow mesenchymal cells and HCC 
cells (Senturk et al., 2010; Wu et al., 2014). In agreement with these findings, 
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here we show that during the establishment of TβT-OC very high levels of Nox4 
mRNA and intracellular ROS are observed in oval cells lacking Met tyrosine 
kinase activity (Figure 49). Awaiting further experiments mechanistically 
connecting the oxidative stress with the induction of senescence, these results 
suggest that TGF-β induces senescence in oval cells by an oxidative stress-
dependent way. 
In an effort to understand how the HGF/Met axis exerts its anti-senescent 
role in oval cells, we found that oval cells lacking Met tyrosine kinase activity 
have lower levels of Twist (Figure 50). Indeed, HGF upregulates Twist in oval 
cells (Figure 51). It has been already demonstrated that HGF/Met can induce 
Twist expression. Thus, HGF-driven Twist upregulation results in cell motility in 
canine mammary cell line and HGF triggers EMT in melanoma cells by inducing 
Twist (Koefinger et al., 2011; Yoshida et al., 2014). However, our results appear 
to contradict the established idea of Twist as an EMT-inducing TF since HGF/Met 
signaling in TβT-OC help maintain epithelial properties while upregulating Twist 
(Figure 47). In this regard, studies in bone metastatic and parental breast 
carcinoma cells revealed that induction of a MET process by HGF involves E-
cadherin upregulation via activation of a Twist program. Notably, a coordinated 
action of HGF and TGF-β is also reported in this context (Bendinelli P, 2015). So, 
the scenario is far more complex than initially thought. The fact that Twist 
knockdown in TβT-OC leads to increase in Nox4 and cell cycle inhibitors 
expression (Figure 52) supports the hypothesis that HGF/Met through 
upregulation of Twist would contain TGF-β-induced oxidative stress, which 
would in turn overcome cell senescence and allow cell survival and expansion. 
In this regard, it is well established that Met exerts a powerful antioxidant 
activity in hepatocytes and oval cells (Gomez-Quiroz et al., 2008; Martinez-
Palacian et al., 2013). Less is known about Twist antioxidant activity, which is 
mainly linked to its anti-apoptotic effects (Floc'h et al., 2013). It is worth noting 
that we provide here the first evidence of a role for Twist in HGF/Met-driven 
antioxidant activity. In conclusion, our data provide evidence that the balance 
between HGF and TGF-β signaling pathways might be critical for oval cell fate 
and outcome of liver regeneration. We propose a scenario where HGF/Met 
signaling restrains TGF-β effects. This allows maintaining a controlled oxidative 
stress and apoptotic response thereby promoting the expansion of oval cells 
and overall improving the regenerative potential of oval cells. 
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2. Interaction between HGF and TGF-β in 
HCC. A pro-survival role for the HGF/Met 
axis 
 
In the second part of this thesis, we run a small preliminary study on the 
relevance of the crosstalk between HGF/Met and TGF-β in hepatocellular 
carcinoma. 
Through a collaboration with Dr. Maina we had access to a mouse model 
recently generated in his laboratory that demonstrate that a subtle increase in 
wild type Met expression is sufficient to drive liver carcinogenesis. Using this 
model we aimed to answer the question of whether TGF-β could have any role 
in the development and/or progression of Met overexpression-driven HCC.  
 
Although there are not many studies in the literature that relate TGF-β and 
HGF/Met pathways during tumor development and more specifically HCC, we 
have found some direct or indirect evidence of this interaction. TGF-β 
suppresses tumor emergence in certain epithelial tissues by inhibiting 
fibroblast-mediated production of growth factors involved in the regulation of 
cell survival, proliferation and motility, such as HGF (Massague, 2008). β-catenin 
in hepatocytes aggravates HCC development driven by an oncogenic β-catenin 
in combination with Met due to, among others events, an upregulation of pro-
tumorigenic cytokines such as TGF-β (Liang et al., 2018) Co-expression of 
transgenic Met and c-Myc leads to the emergence of HCC. In this scenario, TβRII 
expression was down-regulated in tumors indicating that an impairment of TGF-
β1-induced growth inhibition is required for an acceleration of 
hepatocarcinogenesis (Amicone et al., 2002). In our work, we provide 
preliminary results of the activation of TGF-β canonical signaling pathway in HCC 
from Alb-R26Met mice (Figure 53). This result goes in opposite direction to that 
of Amicone et al, although the consequences of Smad activation in Alb-R26Met 
HCCs are not yet clear. Several opposing hypotheses can be drawn. Activation of 
TGF-β signaling could cooperate with HGF/Met signaling for tumor 
development, or alternatively, could be trying to restrain or inhibit HGF/Met 
pro-tumorigenic action. Indeed, our results show that HCC cells are able to 
respond to TGF-β, as demonstrated by phosphorylation of SMAD, but 
interestingly, the response is different depending on Met levels (Figure 54). High 
levels of Met and its constitutive activation (demonstrated by phosphorylation 
of MET and its signaling adaptor GAB1) in HCC cells attenuates TGF-β signal, that 
is, decreases the levels of phosphorylated SMAD2 (Figure 54) and Smad-
dependent transcriptional activity (Figure 55). This is not the first evidence of 
the ability of HGF to block TGF-β-induced biological responses at the 
transcriptional level. In fact, TGF-β-induced EMT in kidney epithelial cells and 
TGF-β profibrotic action in mesangial cells were inhibited by HGF through 
upregulation or stabilization of Smad transcriptional co-repressors SnoN or TGIF, 
respectively (Dai, 2004; Yang et al., 2005). However, it should be pointed out 
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that chemical inhibition of Met is not able to modulate significantly the 
transcriptional response elicited by TGF-β (Figure 55). There are several 
potential explanations that include (i) a non-optimal experimental design, (ii) 
differences are not Met-dependent, (iii) HCC cells have turned on additional 
pathways and eventually became independent on the upstream driver, in this 
case Met activity, a known phenomenon in carcinogenesis (Qi et al., 2011; Singh 
et al., 2017).In the same direction, combined treatment with HGF and TGF-β do 
not seem to affect in a significant manner the TGF-β-triggered transcriptional 
response (Figure 55). So, somehow, cells are not responsive to modulation of 
the HGF/Met pathway, at least in terms of Smad-mediated transcriptional 
activity. This is an interesting finding that should be further analyzed.  
From the other side, TGF-β is able to decrease or inhibit MET 
phosphorylation only in HCC cells with lower levels of Met (Figure 54), an 
additional evidence of the dose-dependent counteracting effect of Met on TGF-
β. However, the activation of the GAB1 adaptor protein is not modified by TGF-β 
suggesting that in this case, the TGF-β action occurs at a different time point or 
that the interaction between TGF-β and HGF is independent of GAB1. Negative 
control of the HGF/Met pathway by TGF-β has been described in glioblastoma 
cells where TGF-β inhibits Met phosphorylation and as a result, inhibits 
stemness (Papa et al., 2017). Additionally, authors propose ERK1/2 pathway as 
the major mediator of the crosstalk between TGF-β and HGF. Remarkably, we 
observe a stronger activation of ERKs under combined treatment with HGF and 
TGF-β in both cell lines, although this phenomenon seems more robust in cells 
with lower levels of Met (Figure 54). Results do not reach statistical significance 
probably due to the limited number of experiments performed, but for now, 
results provide a potentially interesting candidate for the mechanism mediating 
the functional crosstalk between TGF-β and HGF in this model of Met-driven 
HCC that should be further evaluated.  
Could the interplay TGF-β/HGF contribute somehow to tumor cell 
properties? The expression and/or activation of survival signaling pathways in 
HCC have been described to confer resistance to apoptosis. That is the case for 
EGFR signaling (Sancho et al., 2009) and Met signaling. Regarding the latest, it 
was shown that HGF through the activation of PI3K/AKT suppresses Fas-induced 
cell death in HCC cells (Suzuki et al., 2000). In the same line, our results evidence 
a proliferative and survival role for Met that counteracts the TGF-β growth 
inhibitory and pro-apoptotic activity. Thus, HCC cells with higher levels of Met 
show enhanced proliferative capacity and decreased sensitivity to TGF-β-
induced apoptosis (Figures 56 and 57). We demonstrate Met dependence of cell 
proliferative and survival properties as Met inhibition results in sharp decrease 
in cell number and a strong increase in caspase-3 activity in both cell lines 
(Figure 58). Furthermore, in low-Met, but not high-Met HCC cells, co-treatment 
with HGF decreases the apoptotic response triggered by TGF-β (Figure 58) 
evidencing that the former cells are still able to respond to paracrine HGF. 
Besides, the lack of effect of HGF on cell number (Figure 58), suggests that 
HGF/Met signaling mainly drives survival. Nonetheless, if HGF/Met is able to 
block TGF-β-induced growth inhibition in this model of Met-driven HCC needs to 
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be clarified. Literature in this respect is also not fully clarifying since early works 
showed that HGF does not induce but rather inhibits proliferation in HCC 
(Tajima, 1991). Inhibitory effect on HCC development was also seen in HGF/TGF-
α double transgenic mice with respect to TGF-α transgenic mice (Shiota et al., 
1992). However, more recent findings demonstrate that treatment of HCC cell 
lines with PHA665752 Met inhibitor inhibits cell proliferation and induces 
apoptosis (You et al., 2011). Likewise, suppressing the Met/Ras/Raf/ERK 
signaling pathway (Cheng et al., 2018). 
In summary, preliminary results presented here provide evidence that TGF-
β signaling pathway is able to interfere with HGF/Met and viceversa. More in 
detail, Met exerts a negative regulation on TGF-β signaling, that leads to 
blockage of its apoptotic activity. TGF-β is also able to decrease Met activation, 
but this regulatory activity is lost when Met is constitutively active. This opens 
the door to future studies to analyze the implications of these and other 
potential effects in tumor development and progression.  
3. General discussion  
 
There are numerous studies about the key roles of HGF and TGF-β signaling 
pathways in liver pathophysiology, liver regeneration and hepatocarcinogenesis. 
However, much less is known about how these two signaling axes could 
interfere or interact with each other to control oval cell behavior during a 
regenerative process and its relevance in the development and progression of 
liver tumors.  
On the one hand, in the present study, we deeply characterize the TGF-β-
induced EMT in oval cells, process that leads to the acquisition of in vitro 
invasion, survival and proliferation advantages, but rather than promoting 
stemness it induces a more mature hepatic phenotype. The consequence of all 
these changes is an enhancement in oval cell regenerative capacity in vivo. 
Interestingly, HGF/Met signaling pathway has an essential role during EMT 
induction, counteracting TGF-β oxidative activity and allowing oval cells to 
overcome the senescence process activated during chronic treatment with TGF-
β, and therefore, promoting oval cell expansion. Moreover, we reveal a role for 
Twist as a downstream mediator of Met-mediated antioxidant activity. 
HGF/Met signaling pathway also contributes to the induction and/or 
maintenance of the phenotypic and functional properties of oval cells after 
EMT.  
On the other hand, we show preliminary results of an activation of the TGF-
β pathway in livers with moderate Met overexpression and in subsequently 
developed tumors, which suggest a role of TGF-β in the development of the 
disease as well as a potential interaction between HGF and TGF-β signaling 
pathways in this context. Indeed, studies in HCC lines derived from these tumors 
show negative feedback loops of reciprocal regulation between HGF/Met and 
TGF-β. Although analysis of the functional relevance of such cross-regulation in 
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vivo is still pending, we provide evidence that Met activity in HCC cells is critical 
for cell survival and protection against TGF-β-induced apoptosis. 
This work contributes to improve our understanding of the mechanisms that 
regulate oval cell biology and fate in a liver regeneration process, which could 
be useful for the development of new therapies for CLDs. Besides, it opens new 
paths in the study of liver cancer pathogenic mechanisms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
  
 
  
10. Conclusions 
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1. Chronic treatment of oval cells with TGF-β leads to a stable and partial 
EMT phenotype. 
 
2. TGF-β-induced EMT in oval cells does not increase stemness but rather 
promotes differentiation along the hepatic lineage, while conferring 
proliferation, survival and invasion advantages in vitro. 
 
3. Oval cells chronically treated with TGF-β attenuate CCl4-induced liver 
damage and fibrosis upon transplantation. 
 
4. HGF/Met signaling activation is required to overcome the oxidative stress-
induced senescence and allow oval cell expansion after TGF-β-induced 
EMT. 
 
5. Twist is a downstream target of HGF/Met in oval cells that mediates the 
antioxidant activity driven by HGF/Met signaling and prevents cell 
senescence. 
 
6. HGF/Met signaling modulates TGF-β-induced EMT phenotype in oval cells 
contributing to cell proliferation, survival and invasive advantages while 
counterbalancing the mesenchymal phenotypic switching. 
 
7. HCC cell lines derived from Alb-R26Met mice show negative regulatory 
circuits between HGF and TGF-β signaling pathways. Thus, HCC cells with 
high levels of Met show an attenuation of TGF-β-triggered Smad signaling, 
whereas TGF-β is able to decrease Met phosphorylation but only in HCC 
cells with low levels of Met. 
 
8. HCC cell lines derived from Alb-R26Met mice show dependence on Met 
signaling for cell survival and protection against TGF-β. 
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c-Met Signaling Is Essential for Mouse Adult Liver
Progenitor Cells Expansion After Transforming
Growth Factor-β-Induced Epithelial–Mesenchymal
Transition and Regulates Cell Phenotypic Switch
LAURA ALMALÉ,a MARÍA GARCÍA-ALVARO,a ADORACIÓN MARTÍNEZ-PALACIÁN,a
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ABSTRACT
Adult hepatic progenitor cells (HPCs)/oval cells are bipotential progenitors that participate in
liver repair responses upon chronic injury. Recent ﬁndings highlight HPCs plasticity and impor-
tance of the HPCs niche signals to determine their fate during the regenerative process, favoring
either ﬁbrogenesis or damage resolution. Transforming growth factor-β (TGF-β) and hepatocyte
growth factor (HGF) are among the key signals involved in liver regeneration and as component
of HPCs niche regulates HPCs biology. Here, we characterize the TGF-β-triggered epithelial–
mesenchymal transition (EMT) response in oval cells, its effects on cell fate in vivo, and the regu-
latory effect of the HGF/c-Met signaling. Our data show that chronic treatment with TGF-β
triggers a partial EMT in oval cells based on coexpression of epithelial and mesenchymal
markers. The phenotypic and functional proﬁling indicates that TGF-β-induced EMT is not associ-
ated with stemness but rather represents a step forward along hepatic lineage. This phenotypic
transition confers advantageous traits to HPCs including survival, migratory/invasive and meta-
bolic beneﬁt, overall enhancing the regenerative potential of oval cells upon transplantation into
a carbon tetrachloride-damaged liver. We further uncover a key contribution of the HGF/c-Met
pathway to modulate the TGF-β-mediated EMT response. It allows oval cells expansion after
EMT by controlling oxidative stress and apoptosis, likely via Twist regulation, and it counterbal-
ances EMT by maintaining epithelial properties. Our work provides evidence that a coordinated
and balanced action of TGF-β and HGF are critical for achievement of the optimal regenerative
potential of HPCs, opening new therapeutic perspectives. STEM CELLS 2019;00:1–11
SIGNIFICANCE STATEMENT
The ﬁndings from this study support that a balanced action of transforming growth factor-β and
hepatocyte growth factor could determine liver progenitor’s fate and the outcome of liver
regeneration, and open possibilities for targeted therapies oriented at improving the regenera-
tive capacity of these cells in chronic liver diseases.
INTRODUCTION
Adult hepatic progenitor cells (HPCs), known in
rodent as oval cells, expand in situations of chronic
liver damage or diseases in which hepatocyte pro-
liferation and function are impaired and thus be-
coming a critical asset to orchestrate liver repair
response [1, 2]. The progenitor-associated liver re-
generation and supporting signals are still not well
characterized. A good understanding of the regula-
tion of HPCs is crucial not only because their
regenerative potential makes them interesting
therapeutic targets in liver pathologies, but also
because increasing evidence points to a role of
oval cells in progression of liver ﬁbrosis [3, 4], leav-
ing the question on the role of oval cells in the con-
text of chronic liver disease (CLD) open.
Transforming growth factor-β (TGF-β) is a
central regulator in CLD contributing to seem-
ingly all stages of disease [5, 6]. Once TGF-β is
activated upon damage, it triggers crucial cellu-
lar events that drive disease progression. Thus,
it promotes hepatic stellate cell (HSC) trans-
differentiation into myoﬁbroblast, the main
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